



41

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A8564

Zeev ALTBOUM, et al.

Appln. No.: 09/839,894

Group Art Unit: 1648

Confirmation No.: 4293

Examiner: Lucas, Z.

Filed: April 20, 2001

For: ISOLATION AND CHARACTERIZATION OF THE CSA OPERON (ETEC-CS4 PILI)
AND METHODS OF USING SAME

SUPPLEMENT TO AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed herewith are the curriculum vitae of Dr. Myron Levine and Dr. Eileen Barry, both of which executed the Declaration Under 37 C.F.R. §1.132 submitted with the Amendment Under 37 C.F.R. §1.111 on April 20, 2004. Applicants neglected to include the curriculum vitae with the Amendment Under 37 C.F.R. §1.111 filed on April 20, 2004.

Respectfully submitted,

Drew Hissong
Registration No. 44,765

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: April 21, 2004



CURRICULUM VITAE

Eileen M. Barry, Ph.D.
Assistant Professor of Medicine

March 23, 2004

Personal Information

Center for Vaccine Development
University of Maryland School of Medicine
685 West Baltimore Street
HSF 480
Baltimore, Maryland 21201

Phone: 410-706-3702
Fax: 410-706-6205
E-mail: ebarry@medicine.umaryland.edu

Education

1985	B.A. (Biology) University of Delaware, Newark, De. (French minor)
1991	Ph.D. (Microbiology and Immunology) Medical College of Virginia, Virginia Commonwealth University, Richmond, Va. Advisor: Alison A. Weiss, Ph.D.

Post Graduate Training

1992-1994	Postdoctoral Fellow, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Md. Advisor: J. Glenn Morris, Jr., M.D.
1994-1996	Postdoctoral Fellow, Center for Vaccine Development University of Maryland School of Medicine, Baltimore, Md. Advisor: Myron M. Levine, M.D., D.T.P.H.

Employment History

Industry

1985-1986	Toxicology Research Technician, Mobil Oil Corp., Pennington, N.J
-----------	---

Academic

1996-Present	Assistant Professor of Medicine, Center for Vaccine Development, University of Maryland, Baltimore.
1998-Present	Chief, <i>Shigella</i> /ETEC Vaccine Section Center for Vaccine Development

Professional Memberships

American Society for Microbiology, 1987-present
American Association for the Advancement of Science, 1997-present
American Chemical Society, 2001

Administrative Service

Institutional Service

2002 Center for Vaccine Development Frontiers in Vaccinology Speaker
 Search Committee
2003 BSL4/NBL Facility Proposal Committee (A. Azad, PI)
2003-present HSFII/BSL3 Oversight Committee
2003 Center for Vaccine Development Plasmid Manufacture RFP
 Evaluation Committee

Mentoring Committees:

Doctoral thesis committee, Cara Fiore, 1998-2001
Doctoral thesis committee, Thames Pickett, 1999
Doctoral thesis committee, Laurel Courtemanch Burall, 2001 - present
Doctoral thesis committee, Laura Quinn, 2001 – present
Doctoral thesis committee, Jennifer Smart, 2003 - present

International and National Service

Study Section Member

1999-2004 Military Infectious Disease Research Program, American Institute of
 Biological Sciences
2000 NIH, NIAID Special Emphasis Panel: Innovative Research in Human
 Mucosal Immunity
2004 NIAID Special Emphasis Panel: Biodefense and Emerging Infectious
 Disease Research Opportunities

Temporary Adviser, World Health Organization: Future Directions of Research
on ETEC Vaccines for Children in Developing Countries, September 8-9, 2003

Panel Member: Joint Medical Technology Workshop, Military Infectious Disease:
Diarrhea and other Bacterial Diseases. December, 2003.

Editorial Tasks

Ad Hoc Reviewer:

Microbial Pathogenesis
Infection and Immunity
Journal of Immunology
Journal of Bacteriology
Nature Biotechnology
Clinical and Experimental Immunology
Expert Opinion on Biological Therapy

Local Service

Community Science Activities

Judge, Baltimore County Science Fair, Baltimore Chapter ASM, 1997

Teacher, SMART Program, (Science Math and Related Technologies) Howard County, Maryland 1997

Judge, Graduate Student Day, University Of Maryland Baltimore, and Baltimore County Campuses 1998

Girl Scouts of Maryland Science Day, 2002

Teaching Service

Medical Microbiology I, Medical College of Virginia, one lecture per year, 1990, 1991 (10 graduate students; 1.0 hrs./yr.)

Molecular Pathogenesis, University of Maryland, Baltimore, one lecture per year, 1994, "*Yersinia*" (8 graduate students, 1.5 hrs.)

PREV 789 Vaccinology

1998, "NonTarget Effects" (10 graduate students and fellows/yr, 1.0 hrs./yr)

2001, 2003 "DNA Vaccines" (10 graduate students and fellows/yr, 1.0 hrs./yr)

2003 Co- Course Master

MMIC 701 Principles of Bacterial Pathogenesis

2001-2004 "Evasion of Host Immune Responses"

(7 graduate students/yr, 1.5 hrs./yr)

2003, "*Bordetella*" (7 graduate students/yr, 1.5 hrs./yr)

MSPR 520 Host Defenses and Infectious Diseases I, II, III, 6 labs/year

2001-2003 (40 medical students/yr; 12 hrs./yr.)

MSPR 520 Host Defenses and Infectious Diseases Small Group

2002-2003 Molecular Koch's Postulates

(20 medical students/yr; 1.0 hrs./yr.)

MEDT 490 Pathogenic Microbiology, Division of Medical Research Technology

2002-2004 "Enterics I" (18 DMRT students/yr; 1.5 hrs./yr)

2002-2004 "Enterics II" (18 DMRT students/yr; 1.5 hrs./yr)

2002-2004 "*Haemophilus* and Fastidious Bacteria"

(18 DMRT students/yr; 1.5 hrs./yr)

MEDT 454 Applied Cellular and Molecular Biology

2002, 2003 "Special Topics: STM, RIVET, IVET" (8 DMRT students; 1.5 hrs/yr)

BSCI-424 Pathogenic Microbiology (College Park)

2003, "*Streptococci*" (140 undergraduate students; 1.0 hrs/yr)

Laboratory Trainees

Morteza Loghmani, Medical Technology Student, 1997

Richard Anderson, Ph.D. Post Doctoral Fellow, 1998

Zeev Altboum, Ph.D. Visiting Fellow, 1998-2000

Hilary Koprowski II, M.S. Research Associate, 1998-1999

Fernando Ruiz, Visiting Graduate Student, 1998-1999

Daniela Jodorkovsky, Summer Student, 1999

Tom Nijenhuis, M.D. Visiting Fellow, 1999-2000

Navara Malayaman, M.S. Research Assistant, 1999-2000

Romina Magno, M.S. Research Assistant, 2000

Peter Thomas, M.S. Research Assistant, 2000-2001

Araceli Santiago, Ph.D. Postdoctoral fellow, 2001-present
Christofer Vindurampulle, Ph.D. Research Fellow, 2002-present
ManKi Song, Ph.D., Research Fellow, 2002-present
Anthony Herrera, Medical Technology Student, 2003-present

Publications

Refereed Journals

1. Barry, E.M., A.A. Weiss, I.E. Ehrmann, M.C. Gray, E.L. Hewlett, and T.S. Goodwin. 1991. *Bordetella pertussis* Adenylate Cyclase Toxin and Hemolytic Activities Require a Second Gene, *cyaC*, for Activation. J. Bacteriol. 173:720-726.
2. Ehrmann, I.E., A.A. Weiss, T.S. Goodwin, M.C. Gray, E.M. Barry, and E.L. Hewlett. 1992. Enzymatic Activity of Adenylate Cyclase Toxin from *Bordetella pertussis* is not Required for Hemolysis. FEBS 304:51-56.
3. Hewlett, E.L., M.C. Gray, I.E. Ehrmann, N.J. Maloney, A.S. Otero, L. Gray, M. Allietta, G. Szabo, A.A. Weiss, and E.M. Barry. 1993. Characterization of Adenylate Cyclase Toxin from a Mutant of *Bordetella pertussis* Deficient in the Activator Gene *cyaC*. J. Biological Chem. 268:7842-7848.
4. Levine, M.M., C. Tacket, J. Galen, E. Barry, F. Noriega, S. Chatfield, M. Sztein, and G. Dougan. 1995. Progress in Vaccines Against Typhoid Fever. Southeast Asian Journal of Tropical Medicine and Public Health. 26:264-271.
5. Levine, M.M., J. Galen, E.M. Barry, F. Noriega, S. Chatfield, M. Sztein, G. Dougan, and C. Tacket. 1996. Attenuated *Salmonella* as Live Oral Vaccines against Typhoid Fever and as Live Vectors. Journal of Biotechnology 44:193-196.
6. Sulkvelidze, A., K. Dalakishvili, E.M. Barry, R. Robins-Browne, and J.G. Morris. 1996. Analysis of Clinical and Environmental *Yersinia* Isolates in the Republic of Georgia. Journal of Clinical Microbiology 34:2325-2327.
7. Barry, E.M., O. Gomez-Duarte, S. Chatfield, R. Rappuoli, J. Galen, G. Losonsky and M.M. Levine. 1996. Expression and Antigenicity of Pertussis Toxin S1 Subunit-Tetanus Toxin Fragment C Fusions in the *S. typhi* Vaccine Strain CVD 908. Infect. and Immun. 64:4172-4181.
8. Franco, A.A., J.A. Johnson, E.M. Barry, P. Yeh, R. Maurer, and J.G. Morris. 1996. Cloning and Characterization of *dnaE*, Encoding the Catalytic Subunit of Replicative DNA Polymerase III, from *Vibrio cholerae* Strain C6706. Gene 175:281-281.
9. Kotloff, K. L., F. Noriega, T. Samandari, M. Sztein, G. Losonsky, J. Nataro, W. Picking, E. M. Barry, and M. M. Levine. 2000. *Shigella flexneri* 2a strain CVD 1207 with Specific Deletions in *virG*, *sen*, *set*, and *guaBA* is Highly Attenuated in Humans. Infect. and Immun. 68:1034-1039.
10. Koprowski II, H., M. M. Levine, R. Anderson, G. Losonsky, M. Pizza, and E. M.

Barry. 2000. Attenuated *Shigella flexneri* 2a Vaccine Strain CVD 1204 Expressing Colonization factor Antigen I (CFA/I) and Mutant Human Heat Labile Toxin of Enterotoxigenic *Escherichia coli*. Infect. and Immun. 68:4884-4892.

11. Wang, J. Y., F. Noriega, J. Galen, E. M. Barry, and M. M. Levine. 2000. Constitutive Expression of the Vi Polysaccharide Capsular Antigen in Attenuated *Salmonella enterica* Serovar Typhi Oral Vaccine Strain CVD 909. Infect. and Immun. 68:4647-4652.

12. Altboum, Z., E.M. Barry, G. Losonsky, and M.M. Levine. 2001. Attenuated *Shigella flexneri* 2a Δ guaBA strain CVD 1204-expressing ETEC CS2 and CS3 fimbriae as a live mucosal vaccine against *Shigella* and enterotoxigenic *Escherichia coli* infection. Infect. And Immun. 69:3150-3158.

13. Ruiz-Perez, F., R. Leon-Kempis, A. Santiago-Machuca, G. Ortega-Pierres, E. M. Barry, M.M. Levine, and G. Gonzalez-Bonilla. 2002. Expression of the *Plasmodium falciparum* Immunodominant Epitope (NANP)₄ on the Surface of *Salmonella enterica* using the Autotransporter MisL. Infect and Immun. 70:3611-3620.

14. Barry, E.M., Z. Altboum, G. Losonsky, and M.M. Levine. 2003. Immune Responses Elicited Against Multiple Enterotoxigenic *Escherichia coli* Fimbriae and Mutant LT expressed in Attenuated *Shigella* Vaccine Strains. Vaccine. 21:333-340

15. Altboum, Z, Myron M. Levine, James E. Galen, and Eileen M. Barry. 2003. Characterization and Immunogenicity of Coli Surface Antigen 4 (CS4) from Enterotoxigenic *E. coli* when it is Expressed in *Shigella flexneri* Live Vector Strain. Submitted Infect. Immun. Infect. and Immun. 71:1352-1360.

16. Pasetti, M. F., E. M. Barry, G. Losonsky, M. Singh, S. M. Medina-Moreno, J. M. Polo, J. Ulmer, H. Robinson, M. B. Sztein, and M.M. Levine. 2003. Attenuated *Salmonella enterica* serovar Typhi and *Shigella flexneri* 2a Strains Mucosally Deliver DNA Vaccines Encoding Measles Virus Hemagglutinin, Inducing Specific immune responses and Protection in Cotton Rats. J. Virol. 77: 5209-5217

17. Vindurampulle, C.J., L. Cuberos, E.M. Barry, M.F. Pasetti, and M.M. Levine. 2004. Recombinant *Salmonella enterica* serovar Typhi in a prime-boost strategy. Vaccine, in press.

Non-refereed Journals

1. Barry, E.M., A.A. Weiss, M.C. Gray, E.L. Hewlett, I.E. Ehrmann, and M.S. Goodwin. 1990. Mutational Analysis of the Adenylate Cyclase Toxin of *Bordetella pertussis*. p. 260-265. In C.R. Manclark (ed.). Proceedings of the Sixth International Symposium on Pertussis. Department of Health and Human Services, United States Public Health Service, Bethesda, Maryland. DHHS Publication No. (FDA) 90-1164.

2. Hewlett, E.L., I.E. Ehrmann, N.J. Maloney, P.R. Fregman, E.M. Barry, A.A. Weiss, and M.C. Gray. 1991. Adenylate Cyclase Toxin from *Bordetella pertussis*: Characterization of Toxin-Catalyzed Intoxication and Hemolysis. In B. Witholt et al. (eds). Bacterial Protein Toxins, Zbl. Bakt. Suppl. 23, Gustav Fischer, Stuttgart, Jen,

New York, 1992, pp 241-248.

Book Chapters:

1. Levine, M.M., C.O. Tackett, J.E. Galen, E.M. Barry, S.N. Chatfield, G. Dougan, F. Noriega, and M.B. Sztein. 1997. Progress in Development of New Attenuated Strains of *Salmonella typhi* as Live Oral vaccines. In: New Generation Vaccines, Second Edition. M.M. Levine, G.C. Woodrow, J.B. Kaper, and G.S. Cobon Eds., Marcel Dekker Inc., New York, N.Y. pp. 437-446.
2. Levine, M.M., and E.M. Barry. 1997. Inadvertant Nontarget Effects of Live Vaccines. In: New Generation Vaccines, Second Edition. M.M. Levine, G.C. Woodrow, J.B. Kaper, and G.S. Cobon Eds., Marcel Dekker Inc., New York, N.Y. pp. 1179-1183.

Book chapters, continued

3. Levine, M. M., E.M. Barry, J.P. Nataro, and J.B. Kaper. 1998. The Molecular Epidemiology of 19th Century Cholera. In: Digging for Pathogens. Balaban Publishers, Rehovot, Israel. pp. 265-276.
4. Levine, M.M., J. Galen, E.M. Barry, C. Tacket, K. Kotloff, O. Gomez, M. Pasetti, T. Pickett, and M. Sztein. 2000. Live Vectors: Have They Delivered? In: "Fighting Infection". Blackwell Science, London, pp. 72-86.
5. Levine, M.M., J.E. Galen, E.M. Barry, M.F. Pasetti, C.O. Tacket, and M.B. Sztein. 2002. Attenuated *Salmonella* and *Shigella* Live Vectors. In: Vaccine Delivery Strategies. G. Dietrich and W. Goebel Eds. Horizon Scientific Press, Norfolk, U.K, pp. 185-210.
6. Nataro, J.P. and E.M. Barry. Diarrheal Disease Vaccines. 2004. In: "Vaccines 4th Edition". S.A. Plotkin and W. Orenstein Eds. Elsevier Science. Philadelphia, PA. pp. 1209-1217.
7. Barry, E.M. and M.M. Levine. Multivalent *Shigella*-Enterotoxigenic *Escherichia coli* Vaccine. In: New Generation Vaccines, Third Edition. M.M. Levine, J.B. Kaper, R. Rappuoli, M.A. Liu, and M.F. Good Eds., Marcel Dekker Inc., New York, N.Y. In press.
8. Levine, M.M., J.E. Galen, C.O. Tacjet, E.M. Barry, M. Pasetti, and M. Sztein. Attenuated Strains of *Salmonella enterica* serovar Typhi as Live, Oral Vaccines Against Typhoid fever. In: New Generation Vaccines, Third Edition. M.M. Levine, J.B. Kaper, R. Rappuoli, M.A. Liu, and M.F. Good Eds., Marcel Dekker Inc., New York, N.Y. In press.
9. Galen, J.E., M.F. Pasetti, M.B. Sztein, E.M. Barry, and M.M. Levine. Attenuated *Salmonella* and *Shigella* as Live Vectors Carrying either Prokaryotic or Eukaryotic Expression Systems. In: New Generation Vaccines, Third Edition. M.M. Levine, J.B. Kaper, R. Rappuoli, M.A. Liu, and M.F. Good Eds., Marcel Dekker Inc., New York, N.Y. In press.

Abstracts:

1. Barry, E.M., and A.A. Weiss. 1989. Genetic Analysis of the Adenylate Cyclase Toxin/Hemolysin Operon of *Bordetella pertussis*. American Society for Microbiology, Annual Meeting, New Orleans, LA.
2. Barry, E.M., A.A. Weiss, M.S. Goodwin, E.L. Hewlett, M.C. Gray, and I.E. Ehrmann. 1990. Mutational Analysis of the Adenylate Cyclase Toxin/Hemolysin of *Bordetella pertussis*. Gordon Research Conference, Microbial Toxins and Pathogenesis.
3. Barry, E.M., and A.A. Weiss. 1992. Regulation and Expression of the *Bordetella pertussis* Adenylate Cyclase Toxin Genes. American Society for Microbiology, Annual Meeting, New Orleans, LA.
4. Hewlett, E.L., M.C. Gray, A. Otero, I.E. Ehrmann, N.J. Maloney, G. Szabo, A.A. Weiss, and E.M. Barry. 1992. Characterization of Adenylate Cyclase Toxin from BPDE386, a Mutant Defective in *cyaC*. American Society for Microbiology, Annual Meeting, New Orleans, LA.
5. Hewlett, E.L., M. Gray, A.A. Weiss, and E.M. Barry. 1993. Adenylate Cyclase Toxin Produces an Ion-Permeable Pore in a Phospholipid Bilayer. American Society for Microbiology, Annual Meeting, Atlanta, GA.
6. Barry, E.M., A. Quek, R.M. Robins-Browne, and J.G. Morris, Jr. 1993. Analysis of *Yersinia enterocolitica ypkA* Expression Using a Luciferase Reporter System. 17th Annual Mid-Atlantic Extrachromosomal Elements and Molecular Genetics Meeting. Virginia Beach, VA.
7. Sulakvelidze, A., E.M. Barry, K. Dalakishvili, and J.G. Morris, Jr. 1994. Distribution of *Yersinia enterocolitica* Isolates in the Republic of Georgia; Uncommon Serotypes and Study of Markers. American Society for Microbiology, Annual Meeting, Las Vegas, NE.
8. Barry, E.M., J. Galen, S. Chatfield, R. Rappuoli, and M.M. Levine. 1995. Stable Expression of *B. pertussis* Antigens in the *S. typhi* Live Oral Vaccine Strain CVD 908. Keystone Symposia on Mucosal Immunity: New Strategies for Protection Against Viral and Bacterial Pathogens, Keystone, CO.
9. Franco, A., E.M. Barry, and J.G. Morris, Jr. 1995. Cloning and Sequence Analysis of *Vibrio cholerae dnaE*. American Society for Microbiology, Annual Meeting, Washington, D.C.
10. Barry, E.M., O. Gomez, S. Chatfield, R. Rappuoli, J. Galen, and M.M. Levine. 1995. Stable Expression of Pertussis Toxin S1 Subunit - Fragment C Fusions in the *S. typhi* Vaccine Strain CVD 908. American Society for Microbiology, Annual Meeting, Washington, D.C.
11. Barry, E.M., C. Guzman, J. Galen, K. Timmis, and M.M. Levine. 1996. Expression of *B. pertussis* Antigens in the *S. typhi* Vaccine Strain CVD 908. American Society for Microbiology, Annual Meeting, New Orleans, LA.

12. Barry, E.M., M. Pizza, R. Rappuoli, and M.M. Levine. 1997. Co-Expression of LTK63 and DTP Antigens in *S. typhi* Vaccine Strain CVD 908htrA. American Society for Microbiology, Annual Meeting, Miami Beach, FL.
13. Xiang, Z., E. Barry, C. Guzman, K. Timmis, and M.M. Levine. 1997. Immunization of Mice with Multiple DTP Antigens Delivered in *S. typhi* Vaccine Strain CVD 908htrA. American Society for Microbiology, Annual Meeting, Miami Beach, FL.
14. Barry, E.M., and M.M. Levine. 1998. Immune Responses to the *Bordetella pertussis* Antigens Pertactin and Pertussis Toxin Expressed in *S. typhi* Vaccine Strains. American Society for Microbiology, Annual Meeting, Atlanta, GA.
15. Barry, E.M., F. Ruiz, J.S. Sampson, E.W. Ades, G.M. Carlone, and M.M. Levine. 1999. Expression of PsaA from *S. pneumoniae* in *S. typhi* Vaccine Strain CVD 908htrA. American Society for Microbiology, Annual Meeting, Chicago, IL.
16. Z. Altboum, J. Galen, E.M. Barry, and M.M. Levine. 1999. Construction of a Bivalent *Shigella*-ETEC Vaccine Expressing CS2 and CS3 Pili. American Society for Microbiology, Annual Meeting, Chicago, IL.
17. H. Koprowski II, R.J. Anderson, J. Galen, E.M. Barry, and M.M. Levine. 1999. Construction and Analysis of a *Shigella flexneri* 2a/CFA/I Vaccine. American Society for Microbiology, Annual Meeting, Chicago, IL.
18. E.M. Barry, F. Ruiz, J.C. Paton, E.W. Aides, J. Sampson, G. Carlone, and M.M. Levine. 2000. Immunogenicity of the Pneumococcal Antigens PsaA and Pneumolysin Expressed in *S. typhi* Vaccine Strain CVD 908htrA. American Society for Microbiology, Annual Meeting, Los Angeles, CA.
19. Altboum, Z., E.M. Barry, J.E. Galen, and M.M. Levine. 2000. Construction of a Bivalent *Shigella*-ETEC Vaccine Expressing CS4 Pili. American Society for Microbiology, Annual Meeting, Los Angeles, CA.
20. E.M. Barry, Z. Altboum, and M.M. Levine. 2001. Construction of a Multivalent *Shigella*/ETEC Hybrid Vaccine. American Society for Microbiology, Annual Meeting, Orlando, FL.
21. E.M. Barry, A.E. Santiago, J. Sampson, E. Aides, G. Carlone, J. Paton, D. Briles, and M.M. Levine. 2002. Multiple Pneumococcal Antigens Expressed in Attenuated *S. typhi* Vaccine Strains. 3rd International Symposium on Pneumococci and Pneumococcal Diseases. Anchorage, Alaska.
22. Santiago, A.E., M.M. Levine, and E.M. Barry. 2002. Expression of the *S. pneumoniae* antigens PsaA, Ply, and PspA in *Salmonella enterica* Serovar Typhi Vaccine Strain CVD 908htrA. American Society for Microbiology, Annual Meeting, Salt Lake City, Utah.
23. Santiago, A.E., M.M. Levine, and E.M. Barry. 2003. Expression of the *S. pneumoniae* PspA Antigen in *Salmonella enterica* serovar Typhi Vaccine Strain CVD 908htrA and Evaluation in a Mouse Model. American Society for Microbiology, Annual

Meeting, Washington, D.C.

Major Invited Speeches

1. New Frontiers in the Development of Vaccines Against Enterotoxigenic and Enterohemorrhagic *E. coli* Infections: "Live Oral Strategies". December 4-5 1998, Research Institute, International Medical Center of Japan. World Health Organization, sponsor. Tokyo, Japan.
2. Society for Industrial Microbiology Annual Meeting: Recombinant Vaccine Delivery Session, July 7, 2000. "The Use of Attenuated *Salmonella* and *Shigella* Vaccine Strains to Deliver Heterologous Antigens". San Diego, California.
3. Merck Research Laboratories Guest lecturer, February 13, 2001: "Live Attenuated *Salmonella* and *Shigella* as Delivery Vehicles for Heterologous Antigens". Rahway, New Jersey.
4. American Chemical Society National Meeting, Advances in Vaccine Development Session, April 2, 2001: "The Use of Attenuated *Shigella* Vaccine Strains to deliver Heterologous Antigens and DNA Vaccines". San Diego, California.
5. Second International Conference on Vaccines for Enteric Diseases, Invited Speaker, September 12, 2001. "Co-Expression of ETEC Fimbriae and Mutant LT in Attenuated *Shigella*". Tampere, Finland.
6. Future Directions of research on ETEC for Children in Developing Countries, September 9, 2003: "Multivalent *Shigella*/ETEC Vaccine". World Health Organization, sponsor. Montreux, Switzerland.

Proffered Communications

Center for Vaccine Development, University of Maryland, Baltimore, Faculty Seminar, October 24, 2001. "Multivalent ETEC Antigen Expression in Attenuated *Shigella* Vaccine Strains". Baltimore, Maryland.

11/3/03

CURRICULUM VITAE

Name	Myron Max Levine, M.D., D.T.P.H., F.A.A.P., F.A.C.P.M.
Date of Birth	February 11, 1944
Place of Birth	Riverdale, New York
Citizenship	U.S.A.
Social Status	Married (Suzanne), three children (Orin, Rachel, Rebecca)
Preliminary Education	Evander Childs High School, Bronx, New York 1959
Degrees	B.S. City College of New York 1963 M.D. Medical College of Virginia 1967 D.T.P.H. (with Distinction) London School of Hygiene and Tropical Medicine 1974
Student Fellowships	Louisiana State University - N.I.H. Fellow in Tropical Medicine, June-September 1966 I.C.M.R.T., San Jose, Costa Rica Supervisor: Antonio Pena-Chavarria, M.D. H.E.W. Fellow in Pediatric Clinical Research, Jinnah Children's Hospital, Karachi, West Pakistan March - June, 1967 Supervisor: Kathryn Bain, M.D.
Internship & Residency Training	Bronx Municipal Hospital Center, Albert Einstein College of Medicine, Bronx, New York Internship (Pediatric)-July 1967-June 1968 Assistant Pediatric Resident-July 1968-June 1969 Senior Pediatric Resident-July 1969-June 1970 Supervisors: Henry Barnett, M.D., Lewis Fraad, M.D.
Post-Doctoral Fellowship Training	Fellow in Pediatric Infectious Diseases, Division of Pediatric Infectious Diseases and Immunology, Department of Pediatrics, Albert Einstein College of Medicine, January - June 1970 Supervisor: John B. Robbins, M.D. Fellow, Division of Infectious Diseases, University of Maryland School of Medicine, August 1970 - July 1972 Supervisors: Richard B. Hornick, M.D.; Herbert L. DuPont.
Professional Societies	Fellow of the American Academy of Pediatrics Fellow of the American College of Preventive Medicine Fellow of the Infectious Diseases Society of America (elected 1976) American Society of Tropical Medicine & Hygiene

American Epidemiological Society (elected 1982)
Elected President 2000-2001

Royal Society of Tropical Medicine & Hygiene

American Society for Microbiology

Society for Epidemiologic Research

Society for Intestinal Microbial Ecology and Disease

Baltimore City Medical Society-Subcommittee on
International Health, 1976; Chairman, Public Health
Committee, 1977-1981

Medical and Chirurgical Faculty of Maryland-Chairman,
Subcommittee on Infectious Diseases, 1977-1978.
American Society for Clinical Investigation (elected 1986)

Sociedad Latinoamericana de Infectologia Pediatrica (corresponding member
inducted October, 1991)

Association for American Physicians (elected 1993)

American Academy of Microbiology (1995)

Member, Institute of Medicine,
National Academy of Sciences, elected October, 1995

Professional Boards

Pediatric Boards, Part I (Written) 1970

Pediatric Boards, Part II (Oral) 1972

Preventive Medicine Boards 1975

Exchangeships

Student AMA exchange student to the Hebrew University
Medical School, Jerusalem, Israel, June-September, 1964

Exchange student to Department of Dermatology,
L'Hôpital Saint-Louis, Paris, France,
June - September, 1965 - Sponsored by the Parisian
Society of Medical Students.

Fraternities and Honor Societies

Alpha Omega Alpha Medical Honor Society

Sigma Zeta Science Honor Society

Phi Delta Epsilon Medical Fraternity,
President Alpha Mu Chapter, 1965-66
Secretary 1964-1965

Scholarships

Aaron Brown Memorial Scholarship Award 1966

Sabbatical Activity	Fellow of the Sackler Institute of Advanced Studies, Tel Aviv University, Israel, September, 1987 to February, 1988.
Medical Licensure	National Boards New York State License Virginia Boards Virginia License Maryland License (current)
International Committees	Steering Committee on Diarrhoeal Disease Vaccines, Programme for Vaccine Development, World Health Organization, 1992-1994. Steering Committee on Diarrhoeal Disease Vaccines, Global Programme for Vaccines, World Health Organization, 1995. Member, Task Force on Vaccines, International Association of Biological Standardization, 1995- Member International Advisory Committee, Oxford Vaccine Group, 1995 Ad Hoc member, WHO Steering Committee Meeting on Vaccines against <i>Leishmania</i> , March, 1997 Member, Steering Committee on New Vaccination Approaches, Global Programme for Vaccines and Immunization, World Health Organization, 1997 Chairman, Working Group on Mucosal Vaccines, Steering Committee on New Vaccination Approaches, Global Programme for Vaccines and Immunization, World Health Organization, December, 1997-1999 Member, World Bank/World Health Organization/UNICEF/Industry/Rockefeller Foundation Working Group on Vaccine Development and Immunization, July 1998-March, 1999 Member, Working Group of the Global Coalition for Vaccines and Immunization April 1999- July 15, 1999 Member, Working Group of the Global Alliance for Vaccines and Immunization (GAVI), July 16, 1999 – June 20, 2002 Co-Chair, Task Force on Research and Development, GAVI, June 2000-present Member, WHO Product Development Group for Aerosol Measles Vaccine, August 2002- Member, International Advisory Board, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, 2003 – Cholera and Other Bacterial Enteric Infections Panel of the U.S.-Japan Cooperative Medical Science Program, 2003-2007.
National Committees, etc.	Recombinant DNA Advisory Committee, National Institutes of Health

July 1980-September 1984

Member Organizing Committee, NIH National Consensus
Conference on Travelers' Diarrhea - May 1984

National Research Council,
National Academy of Sciences
Steering Committee for the Study of the U.S.
Capacity to Address Tropical Disease Problems
August, 1984

Member, Technical Advisory Group for the AID-sponsored
Applied Diarrheal Diseases Research Project of the
Harvard Institute for International Development,
1986 - 1988

Member, Technical Advisory Group for the
U.S.-Aid-sponsored DiaTech Project, 1986 - 1990

Nominating Committee, American Epidemiological Society, 1991

Data and Safety Monitoring Board, AIDS/HIV trials Conducted by the U.S.
Department of Defense, 1991-1993

National Vaccine Advisory Committee, 1995-1999
Chair, Future Vaccines Sub-committee, 1997-1999

Member, Blue Ribbon Panel that evaluated the NIAID research plan for malaria
vaccine development, June, 1997

NIAID Strategic Plan Task Force, 1999

Data and Safety Monitoring Board, Cytomegalovirus (HCMV) protocol evaluated
by DMID, 2000-present

Department of Defense Blue Ribbon Panel on Analysis of Alternatives for
Biological Defense Vaccine Production Capability, 2000-present

Institute of Medicine, National Academy of Sciences
E. coli O157:H7 Risk Assessment Committee, 2001-2002

Institute of Medicine, Anti-Infectives Planning Committee to initiate a study on
bioterror agents and orphan vaccines, January 2002

NIAID Blue Ribbon Panel on Bioterrorism and its Implications for Biomedical
Research on Category B & C Agents, 2002

University Committees

University of Maryland Task Force on High Technology/Biotechnology,
1983Scientific Advisory Committee, Medical Biotechnology Center, 1993-5
Scientific Advisory Committee, Institute for Human Virology, 1997-

Medical School Committees

Student Research Day Committee 1982-84
Medical Biotechnology Task Force, 1984
Chairman, Subcommittee on Molecular Biology, 1984

Search Committee for a Chairperson for the Department of Microbiology, 1986 - 1987
Objectives Subcommittee, Institutional Self-Study Committee, 1998-1999
Research Subcommittee of SOM Strategic Plan 2000-2005
Steering Committee, 2000

Departmental Committees

Department of Medicine Research Committee, 1984 - 1988
Department of Medicine Promotions Committee, 1985 – 1992
Committee Chairman, 1985-1991

Primary Faculty Appointments

University of Maryland School of Medicine:
Department of Medicine:
Division of Infectious Diseases,
Assistant Professor July 1972 - June 1975
Associate Professor, July 1975 - June 1981
Research Professor, July 1981 - June 1982
Professor - July 1982
Head, Division of Geographic Medicine, January, 1984

Department of Pediatrics:
Instructor - July 1971-June 1972
Assistant Professor - July 1972-June 1982
Associate Professor - July 1982
Professor - July 1983
Acting Head, Division of Infectious Diseases - July 1984 - September 1985
Head, Division of Infectious Diseases and
Tropical Pediatrics - October, 1985 to present

Secondary and External Faculty Appointments

Department of Epidemiology and Preventive Medicine:
Professor

Department of Microbiology and Immunology:
Professor

Senior Associate, Department of Epidemiology,
Johns Hopkins University School of Hygiene and Public Health, 1985 to present

Visiting Professor
Facultad de Medicina,
Universidad Peruana Cayetano Heredia
Lima, Peru 1980 - present

Visiting Professor
Faculty of Tropical Medicine
Mahidol University
Bangkok, Thailand, 2001-

Other Appointments

Director, Center for Vaccine Development,
University of Maryland School of Medicine,
July 1974 - present

Acting Co-Director, Medical Biotechnology Center,

University of Maryland, 1987 - 1990

Editorial Boards

Editorial Board, **Journal of Infectious Diseases** 1986 - 1988
Editor, **Epidemiological Reviews**, 1985 - 1997
Board of Editors, **American Journal of Epidemiology**, 1997 - present
Editorial Board, 15th ed. of **Control of Communicable Diseases**, APHA, 1990
Editorial Board, 16th ed. of **Control of Communicable Diseases**, APHA, 1994
Editorial Board, **Infection and Immunity**, 1998 - 2000
International Editorial Board, **Public Health Reviews**, 1991 - present
Advisory Editor, **Molecular Medical Microbiology**, 1993
International Advisory Board, **GUT**, 1994 - 1998
International Advisory Board, **Annals of Tropical Medicine & Parasitology**, 1996
Editorial Board, **Vaccine**, 2000 - present

Military Service

U.S. Public Health Service Commissioned Corps, Asst.
Epidemic Surgeon Intelligence Service Officer,
Bacterial Diseases Branch, Epidemiology Program
Center for Disease Control, Atlanta, Georgia
Supervisors: Eugene J. Gangarosa, M.D., Phillip Brachman, M.D.

Active Duty Assignment - Medical Epidemiologist
assigned to the Shigella Vaccine Development Program,
Division of Infectious Diseases, University of
Maryland School of Medicine, Baltimore, Maryland
July 1970 - September 1973
Inactive Reserve - 1981 - 1997

**Special Lectures, Named
Visiting Professorships**

Howard Florey Memorial Lecturer and Visiting Professor, University of Adelaide,
South Australia, September, 1987.

Bazeley Oration, Australian Society for Microbiology, Sydney, 1992.

Felton Bequest Visiting Professor, Royal Children's Hospital,
Melbourne, Australia, October, 1994.

Lederle-Praxis Visiting Professor of Vaccinology, Oxford University, December,
1994

Bradford Dixon Memorial Lecture, The University of Alabama at Birmingham and
The Children's Hospital, Birmingham, Alabama, May, 2001.

Division Y (Public Health) Divisional Lecture, American Society for Microbiology
103rd General Meeting, Washington, D.C., May 21, 2003

Teaching Awards

The Colonel George W. Hunter III Award for Excellence as Senior Lecturer in
Tropical Medicine at the Walter Reed Army Institute of Research Tropical
Medicine Course, 1995.

Other Honors

Life Sciences Achievement Award of the University of Maryland at Baltimore
Presented October 17, 1995

Albert B. Sabin Gold Medal Award of the Albert B. Sabin Vaccine Institute for contributions in the field of vaccinology. Presented June 3, 1998

State of Maryland Governor's Citation "in recognition of contributions made in the medical profession". Presented November 9, 1999 at the Silver Anniversary celebration of the Center for Vaccine Development.

In conjunction with the Silver Anniversary celebration of the Center for Vaccine Development, Baltimore City Mayor Kurt L. Schmoke proclaimed November 9, 1999 as "Dr. Myron M. Levine Day" in recognition of contributions made in the field of vaccinology.

"Highly Cited Researcher in Immunology" awarded by Institute for Science Information (ISI)/Thomson Scientific as one of the top 100 most highly cited, influential researchers in the field of immunology. November 2000.

Voted by the editors of Baltimore Magazine as "Baltimorean of the Year." This honor was bestowed upon ten individuals in recognition of their contribution to improving the way of life in Baltimore in 2001. Featured in the January, 2002 issue.

Issued Patents

Kaper James B., Levine Myron M. US patent # 4,935,364 and # 5,135,862 "Method of isolating restriction fragment deletions in *Vibrio cholerae* and products thereof".

South African patent # 91/4286 (March 25, 1992).

EPO patent # 0119031 "Virulent *Vibrio cholerae* and methods for its production.

Baudry B, Levine MM. US patent # 5189151 (February 23, 1993). Highly specific DNA probe for enteroaggregative *Escherichia coli*.

Fasano A, Levine MM, Noriega F, Nataro JP. US patent #08/160317 Isolated DNA molecule encoding ShET2 of *Shigella flexneri* 2a.

Fasano A, Levine MM, Noriega F, Nataro JP. US patent #08/351147 Isolated DNA molecule encoding ShET1 of *Shigella flexneri* 2a.

Noriega F, Levine MM. US patent #08/629,600 Δ Gua mutants of *Shigella* spp. and vaccines containing the same.

Language Proficiency

	<u>Speak</u>	<u>Read</u>	<u>Write</u>
French	well	well	well
Spanish	well	well	well
Hebrew	poor	fair	poor

Recent Grant Support (partial listing)

R01 AI 40297 (Levine)	7/1/00-6/30/05
NIH	\$250,000 per year
Bacterial live vector-based vaccine against malaria.	

Generation of various constructs of attenuated *Salmonella typhi* carrying genes encoding putative protective antigens of *P. falciparum* genes to probe various components of the human immunological response to vaccination.

N01-AI-25461 (Levine) 6/1/02-5/31/07
NIH \$3,043,414 per year
Evaluation of control measures against infectious diseases other than AIDS.
Clinical testing of vaccines and related products in pediatric and geriatric populations.

T32 AI07524 (Levine) 7/1/02-6/30/07
NIH \$241,922 per year
Fellowship training program in vaccinology
T32 postdoctoral fellowship training grant

D43 TW 00907 (Levine) 9/20/97-1/31/04
NIH \$269,784 per year
International training and research in emerging infectious diseases
Training grant in Republic of Georgia and Chile.

R01-AI29471 (Levine) 4/1/98-3/31/04
NIH \$129,440 per year
Recombinant and live oral *Salmonella typhi* hybrid vaccines
Development of oral DPT vaccines.

Measles vaccine (Levine) 9/01/00-8/31/05
Bill and Melinda Gates Foundation \$4,095,000 per year
"Development of a "stealth" mucosal measles vaccine that can immunize young infants (2-6 months of age) in developing countries, despite the presence of maternal antibodies".

U54 AI57168 (Levine) 9/4/03 - 2/29/08
NIH \$3,365,168
Defense against biowarfare and emerging infection agents
Development and testing of vaccines, diagnostics, and therapeutics against agents of biowarfare.

U19 AI056578 (Nataro) 9/30/03 - 6/30/08
NIH \$645,385
Live bacterial vector vaccines against agents of bioterror
Development and pre-clinical testing of biodefense vaccines

FIELD EXPERIENCES (Partial Listing)

1. Safety testing of *Shigella flexneri* 2 and *Shigella sonnei* oral attenuated vaccines in institutionalized children, 1970.
2. Principal Investigator, U.S. Public Health Service *Shigella sonnei* Vaccine Field Trial, Fort Myers, Florida 1972-1973.
3. Principal Investigator, U.S. Public Health Service *Shigella flexneri* 2 Vaccine Field Trial, Staten Island, New York, 1971-1973.
4. Pan American Health Organization Consultant Epidemiologist to the Ministry of Health of the Dominican Republic to assist in the investigation and control of epidemic poliomyelitis. June-July 1971.
5. Conduction of a rectal swab and sero-survey to determine the prevalence of enteroviruses and enteroviral antibodies in the Republic of Haiti. July 1971.

6. Pan American Health Organization Consultant to Guatemala to discuss Epidemic Shiga Dysentery. August 1971.
7. World Health Organization Temporary Advisor to Morocco to evaluate diarrheal and enteric diseases. June 1972.
8. Site Inspector to report on the status of the U.S. PL 480-funded *Shigella* field trials of Dr. David Mel in Yugoslavia. July 1972.
9. Preliminary inspection of prospective field sites in South and Central America for the conduction of an oral typhoid vaccine field trial. April-June 1973.
10. Pan American Health Organization Consultant for the evaluation of endemicity of typhoid fever in Peru. August 1973.
11. World Health Organization Consultant Epidemiologist to the Smallpox Eradication Program during August, September and October 1975. Service as District Coordinator of Rajshahi District, Bangladesh during this period.
12. World Health Organization/Pan American Health Organization Advisor to Guatemala November 1975, to participate in a symposium and teaching seminar on enteric diseases, "Seminario sobre Nuevas Tendencias para el Diagnostico y Tratamiento del Sindrome Diarreico."
13. Director and Coordinator, "Swine Influenza Vaccine Testing Program," Maryland 1976.
14. Guest of the Ministry of Health, Cuba, to observe the Infant Diarrhea Control Program. September, 1977.
15. Pan American Health Organization Temporary Advisor on Diarrheal Diseases and Oral Fluid Therapy. Dominican Republic, Guatemala, Costa Rica, Panama, and Nicaragua, November, 1977.
16. Pan American Health Organization Advisor to Costa Rica, December 1977 to design, initiate and coordinate an investigation of the efficacy of glucose/electrolyte and rehydration therapy in infantile diarrhea due to rotavirus.
17. Pan American Health Organization Advisor to Costa Rica, July, 1978 to participate as Technical Consultant and Course Manager in Expanded Program on Immunization Course.
18. Pan American Health Organization Temporary Advisor to Surinam to discuss enteric diseases.
19. Pan American Health Organization consultant to Chile to study the epidemiology of endemic typhoid fever and design control measures.
20. Pan American Health Organization Temporary Advisor to Peru to assist as course manager in the Expanded Program on Immunization Course, January 1979.
21. Consultant to the World Health Organization Program on Diarrheal Diseases, Geneva, February 1979. Development of teaching aids and manuals to assist senior health officials to establish diarrhea disease control program.
22. Consultant to the Agency for International Development and the Academy for Educational Development project on use of mass media communication methods to combat diarrheal disease. Tanzania and Cameroon, April 1979.
23. Consultant to the Agency for International Development and the Academy for Educational Development project on use of mass media communication methods to combat diarrheal disease. Honduras and Ecuador, May 1979.
24. Temporary Advisor to Pan American Health Organization to assist in provincial level courses on treatment and control of diarrheal diseases, Amatlan and Huehuetenango, Guatemala, September 1979.
25. Consultant to the Academy for Educational Development project on use of mass media communication methods to combat diarrheal disease. Honduras, September 1979.

26. Temporary Advisor to Pan American Health Organization for the Regional Seminar on Diarrheal Disease Control. Lima Peru, October 1979.
27. U.S. Agency for International Development Consultant to the Government of Honduras to design a five year Diarrheal Disease Control Program, December 1979.
28. Pan American Health Organization consultant to Honduras to initiate oral therapy studies at Hospital Materno Infantil, February 1980.
29. Pan American Health Organization consultant to Peru to teach a course on diarrheal diseases, February 1980.
30. World Health Organization Consultant to Rwanda and Burundi, July 1980, to advise the ministries of health in organizing national diarrheal disease control programs for those countries with oral rehydration activities as the keystone.
31. Consultant to the Ministry of Health, Santiago, Chile on the control of endemic typhoid fever. Approximately two months annually since 1980 are spent supervising activities in Chile where the Center for Vaccine Development maintains a field unit in collaboration with the Ministry of Health.
32. U.S. Agency for International Development consultant to Bangladesh, December, 1982, to review the status of epidemiologic activities at the International Center for Diarrheal Disease Research, Bangladesh.
33. Supervised a large-scale controlled field trial of Ty21a oral typhoid vaccine involving 150,000 schoolchildren in Area Occidente, Santiago, Chile. Vaccination occurred in August and September, 1983. Surveillance for typhoid fever in the cohort was maintained for seven years.
34. Agency for International Development (PRITECH) consultant to Kenya to review the status of oral rehydration activities, 1984.
35. Consultant to the Egyptian Diarrheal Disease Control Project, July 1984.
36. Invited consultant to the Lanzhou Institute of Biological Products, Lanzhou, People's Republic of China, to discuss vaccines against enteric infections, November 1984.
37. U.S. Agency for International Development Consultant to the Vaccine Assistance Program, Delhi, India, to explore the possibility of field trials of new typhoid vaccines. May, 1986.
38. U.S. Agency for International Development Consultant to the International Center for Diarrheal Disease Research, Bangladesh, to evaluate the status of research at the Center. May, 1986.
39. U.S. Agency for International Development Consultant to Mahidol University Vaccine Trial Centre, Bangkok, Thailand, to explore the possibility of Phase 1 and 2 trials of malaria vaccine candidates. June, 1986.
40. Initiation of longitudinal field studies of the etiology and prevention of pediatric diarrhea in Santa Julia, Santiago, Chile in collaboration with the Ministry of Health and the Microbiology Unit of the University of Chile, November, 1986 - present.
41. Co-designed and participated in an AID-supported study of malaria in Yanomami Indians living along the Orinoco River in the Amazon region of Venezuela, 1987.
42. Initiation of collaborative studies of the etiology of persistent diarrhea in children with Dr. M.K. Bhan of the Department of Paediatrics, All-India Institute of Medical Sciences, New Delhi, India June 1987 - present.
43. Consultant to the Department of Preventive Medicine, Israel Defence Forces on the control of diarrheal diseases in soldiers, August, 1987 to present.

44. Initiation of Phase 2 studies of live oral cholera vaccine CVD 103-HgR in Thai university students and in Thai military personnel, Bangkok, Thailand, 1988.
45. Designed and provided overall coordination of Phase 2 pediatric studies of the safety and immunogenicity of CVD 103-HgR live oral cholera vaccine in Indonesian children, Jakarta, Indonesia, 1989-1992.
46. Consultant to the Institute of Epidemiology and Microbiology of the Chinese Academy of Preventive Medicine, Beijing China on enteric vaccine development, September, 1990.
47. Consultant to the Minister of Health, Chile on control of cholera, May, 1991.
48. Ad Hoc invited member, Chilean Cholera Commission, May, 1991.
49. Consultant to Centre Muraz, Bobo Doullasso, Burkina Faso, to explore possible collaborative studies on diarrheal diseases. 1991.
50. Consultant to the Sociedad Colombiana de Medicina Tropical y Parasitologia on the subject of cholera (inspection of two cholera affected areas of Colombia), October, 1991.
51. World Health Organization (Western Pacific Regional Office) Consultant in Vaccine Development to the People's Republic of China, November, 1991.
52. World Health Organization Consultant to the Program for Vaccine Development, 1992-1994.
53. Member of the U.S. Army Data Monitoring Safety Board for HIV Vaccine Field Trials, 1992 to present.
54. Consultant to the Ministry of Health and the Fundación Centro de Estudios Infectologicos, Argentina, February, 1993, to investigate epidemic cholera in Northern Argentina and to review activities of the the National Cholera Control Commission.
55. Evaluation of potential field sites in Mali to conduct phase 2 trial of CVD 103-HgR live oral cholera vaccine in HIV +/- adults. Mali, Africa. February, 1996.
56. Member of Vaccine Action Program and U. S. Malaria Mission. Mumbai and Rajasthan, India. February, 1997.
57. Member of a WHO field site team assessing the feasibility of using leishmanization to assess the efficacy of new *Leishmania* vaccines. Samarkand, Uzbekistan, September, 1997.
58. Participant "Consultative Meeting on Vaccine Development and Immunization Implementation", Harare, Zimbabwe, December 4, 1998.
59. Organizer, "Consultative Meeting on Vaccine Development and Immunization Implementation", Santiago, Chile, January 15 & 16, 1999.
60. Organizer, "Consultative Meeting on Vaccine Development and Immunization Implementation", New Delhi, India, February 9, 1999.
61. Member, initial GAVI mission to China, December, 2000.
62. Member of the CVD team that established, in conjunction with the Minstry of Health of Mali, a clinical bacteriology laboratory in the Gabriel Tour9 Hospital in Bamako, Mali, February, 2002 .
63. WHO consultant participating in the preparation of a field manual for the diagnosis, treatment and prevention of typhoid fever, Hanoi Vietnam, March, 2002.

64. WHO consultant to SEARO, Delhi, India for consultation on aerosol measles vaccine production and licensure track, September, 2002.
65. WHO consultant to SEARO, Delhi, and to the Serum Institute of India for consultation on aerosol measles vaccine production and licensure track, March, 2003.

**ABSTRACTS AND PRESENTATIONS AT NATIONAL
AND INTERNATIONAL MEETINGS (PARTIAL LISTING)**

1. Levine MM, DuPont HL, Hornick RB. Immunity in shigellosis. *Clinical Research*, XVIII:689, 1970 (abstract).
2. Levine MM, DuPont HL, Libonati JP, Gangarosa EJ, Snyder MJ, Hornick RB. An immunologic approach to the control of epidemic shiga dysentery. *Clinical Research* XIX:461, 1971 (abstract).
3. Levine MM, Gangarosa EJ. Oral attenuated streptomycin-dependent (SmD) shigella vaccines: *In vivo* stability and transmissibility. *Ped. Res.* 7:736, 1973 (abstract).
4. Levine MM, Hattwick M, Risi J. Poliovirus in the Caribbean. *Ped. Res.* 7:736, 1973 (abstract).
5. Levine MM and Hornick RB. Lactulose therapy in shigella carrier state and acute dysentery. 14th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Sept. 1974 (abstract).
6. Levine MM, Hornick RB, Snyder MH, DuPont HL, Woodward WE, Gilman RH. Streptomycin-dependent oral typhoid vaccine. Abstract of paper presented at 15th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 26, 1975. Washington DC (abstract #371).
7. Levine MM, Gilman RH, Grados O, Solis R. Diagnostic value of Widal test in areas endemic for typhoid fever. Abstract of paper presented at 15th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, September 24, 1975 (abstract #132).
8. Levine MM, Caplan ES, Cash RA, Snyder MJ. Diarrhea due to *Escherichia coli* that produce only heat-stable enterotoxin. Presented at the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois, October 27-29, 1976.
9. Levine MM. Legal and ethical problems in epidemiologic research -- informed consent (abstract) *Am. J. Epidemiol.* 104:350, 1976.
10. Levine MM, Nalin DR, Hoover DL, Bergquist EHJ, and Hornick RB. Immunity to enterotoxigenic *Escherichia coli*. Presented at 17th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York City, October 14, 1977.
11. Levine MM, Nalin DR, Craig JP, Hoover D, Bergquist EJ, Waterman D, Holley HP, Jr, Libonati JP, Hornick RB, Pierce NF. Immunity to Cholera. 13th Joint Conference on Cholera U.S.-Japan Cooperative Medical Science Program. Atlanta, September, 1977.
12. Levine MM. Immunity to Cholera in Man. Royal Society of Tropical Medicine and Hygiene Symposium on Cholera. London, England, May 4, 1978.
13. Levine MM. Immunity to Cholera as Evaluated in Volunteers. Nobel Symposium on Cholera. Sweden, August, 1978.
14. Levine MM. Oral Rehydration of Infant Diarrhea. Presented at Diarrhea Research Symposium at the Caribbean Epidemiology Center. October 18, 1978.
15. Levine MM, Daya V. Hemagglutination, Pili and Diarrheagenic Potential of *Escherichia coli* Strains in Man. 18th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, October, 1978.
16. Levine MM. Infant Diarrhea in the Less-Developed World: Epidemiology and Control. Am Publ Hlth Assoc Annual Meeting, New York, Nov. 8, 1979.
17. Levine MM. Adhesion of Enterotoxigenic *Escherichia coli* in Humans and Animals. Presented at Ciba Foundation Symposium on Adhesion and Microorganism Pathogenicity. London, May, 1980.

18. Levine MM, Black RE, Clements ML, Nalin DR, Cisneros L, Finkelstein RA. Volunteer Studies in Development of Vaccines against Cholera and Enterotoxigenic *Escherichia coli*: A Review. Presented at Nobel Conference 3: Acute Enteric Infections in Children. New Prospects for Treatment and Prevention. Stockholm, Sweden, September 22-26, 1980.
19. Levine MM, Clements ML, Black RE, Hughes TP, Cleaves Tome F. Oral Rehydration with Simple Sugar/Salt Solutions as an Alternative in Rural Areas when Glucose/Electrolyte Solutions are Unavailable. Presented at Nobel Conference 3: Acute Enteric Infections in Children. New Prospects for Treatment and Prevention. Stockholm, Sweden, September 22-26, 1980.
20. Levine MM, Black RE, Clements ML, Young CR, Finkelstein RA, Honda T, Murphy JR. Clinical and Immunologic Response in Man Following Ingestion of Naturally-Occurring and Laboratory-Derived Attenuated *Vibrio cholerae*. Presented at the 16th Joint Conference U.S.-Japan Cooperative Medical Science Program Cholera Panel. Gifu, Japan, October 6-8, 1980.
21. Levine MM. Immunity to Enterotoxigenic *Escherichia coli* in Man Stimulated by Prior Infection or Purified Pili Vaccine. Presented at the Workshop on Bacterial Attachment. Stockholm, Sweden, January 23, 1981.
22. Levine MM. Shigella Infections and Vaccines: Experiences from Volunteer and Controlled Field Studies. International Conference on Shigellosis. Cox's Bazaar, Bangladesh, June 18, 1981.
23. Levine MM, Black RE, Clements ML, Young CR, Honda T, Finkelstein R. Texas Star-SR: Attenuated *Vibrio cholerae* Oral Vaccine Candidate. Presented at the 17th Joint Conference on Cholera, U.S.-Japan Cooperative Medical Science Program. Baltimore, October 26-28, 1981.
24. Levine MM, Black RE, Clements ML, Young CR, Lanata C, Sears S, Honda T, Finkelstein R. Texas Star-SR: Attenuated *Vibrio cholerae* oral vaccine candidate. Symposium on Enteric Infections in Man and Animals: Standardization of Immunological Procedures. Dublin, Sept. 6-8, 1982.
25. Levine MM, Black RE, Clements ML, Young CR, Boedeker EC, Cheney C, Brinton CC, Jr. Immunoprophylaxis of Enterotoxigenic *Escherichia coli* Infections in Man by Vaccines that Stimulate Anti-Pili Immunity. Symposium on Enteric Infections in Man and Animals: Standardization of Immunological Procedures. Dublin, Sept. 6-8, 1982.
26. Levine MM, Black RE, Clements ML, Kaper JB. Present Status of Cholera Vaccines. Biochemical Society, Cambridge, England, June 29 - July 1, 1983.
27. Levine MM, Kaper JB, Black RE, Clements ML, Morris JG. New Insights into the Pathogenesis of Cholera and its Prevention. 19th Joint Conference on Cholera. U.S.-Japan Cooperative Medical Science Program, Bethesda, Md. October 17-19, 1983.
28. Levine MM, Black RE, Clements M, Boedeker E, Young C, Rowe B. Stimulation of Intestinal Secretory IgA Antibody to Colonization Factor Fimbriae of Enterotoxigenic *Escherichia coli* by Both Killed Antigen and Live Oral Vaccines. Intestinal Immunity Workshop. XI. International Congress of Tropical Medicine and Malaria. Calgary, Alberta, September 16-22, 1984.
29. Levine MM. Landmarks on the Road Toward a Live Oral Attenuated Cholera Vaccine. Robert Koch Memorial Symposium on Cholera. Kashiwara City, Japan, November 5, 1984.
30. Levine MM. Epidemiologic Patterns of Endemic Typhoid Fever and Usefulness of Seroepidemiology. International Workshop on Typhoid Fever, Washington, DC November 29 and 30, 1984.
31. Levine MM. New Approaches to Immunization Against Cholera. Symposium on Cholera. Am. Soc. Trop. Med. and Hygiene, 33rd Annual Meeting. Baltimore, December 2-6, 1984.

32. Levine MM. Antibiotic Treatment for Infectious Diarrheas. NIH National Consensus Conference on Travelers' Diarrhea. Bethesda, January 24-26, 1985.
33. Levine MM. Dehydration, Metabolic and Nutritional Consequences of Infant Diarrhea and Oral Rehydration. International Seminar on Infectious Diarrhoea in the Young. Strategies for Control in Humans and Animals. Geelong, Australia, February 10-15, 1985.
34. Levine MM. Vaccines against Bacterial Enteric Infections of Man. Strategies for Control in Humans and Animals. Geelong, Australia, February 10-15, 1985.
35. Levine MM, Black RE, Ferreccio C, Clements ML, Lanata C, Rooney J, Germanier R, Chilean Typhoid Committee. The Efficacy of Attenuated *Salmonella typhi* oral vaccine strain Ty21a evaluated in controlled field trials. Development of Vaccines and Drugs against Diarrhea. 11th Nobel Conference, Stockholm, June 3-6, 1985.
36. Levine MM, Losonsky G, Herrington D, Kaper JB, Tacket CO, Rennels MB, Morris JG. Pediatric Diarrhea: The Challenge of Prevention. Thrasher International Conference on Pediatric Enteric Infections. Salt Lake City, June 13-15, 1985.
37. Levine MM, Morris JG, Losonsky G, Boedeker E, Rowe B. Fimbriae (Pili) Adhesins as Vaccines. Federation of European Microbiology Societies Symposium on Molecular Biology of Pathogenic Microorganisms. Lulea, Sweden, June 17-20, 1985.
38. Levine MM. Pathogenesis of Bacterial Enteric Infection. Keynote Speaker, Third International Workshop on Campylobacter Infections. Ottawa, July 8-10, 1985.
39. Levine MM. Stimulation of Mucosal Immunity against Enterotoxigenic *Escherichia coli*. Conference on Immunity and Infection at Mucosal Surfaces. Hamilton, Montant, August 26-28, 1985.
40. Levine MM. The Pathogenesis of Bacterial Diarrheas: A Basis for Rational Therapy. Canadian Society of Clinical Investigation. Vancouver, Canada, September 12, 1985.
41. Levine MM, Herrington D. The Current Status of Phase I and II Clinical Trials of the Anti-Sporozoite *Plasmodium falciparum* Vaccines. Agency for International Development Americas Conference on Malaria Vaccines. Ft. Lauderdale, October 9-12, 1985.
42. Levine MM. Status of Vaccines against Enteric Infections. Typhoid Vaccines. Interscience Conference on Antimicrobial Agents and Chemotherapy. Minneapolis, September 29 - October 2, 1985.
43. Levine MM, Kaper JB, Morris JG, Herrington D, Losonsky G, Tall B, Hall R. Reactogenicity, Colonizing Capacity and Immunogenicity of Further Attenuated, Genetically-Engineered *Vibrio cholerae* 01 Vaccine Strains. 21st U.S.-Japan Joint Conference on Cholera. Bethesda, October 21-23, 1985.
44. Levine MM. *Escherichia coli* qui Causent les Maladies Diarrheiques. Congres Africain de Maladies Infectieuses. Kigali, Rwanda, January 21-23, 1986.
45. Levine MM. Patogenia e Inmunidad de las Infecciones Intestinales. International Seminar on Diarrheal Diseases and Oral Rehydration. Mexico City, April 2-4, 1986.
46. Levine MM. New Vaccines under Development. Federation of Societies for Experimental Biology. St. Louis, April 13, 1986.
47. Levine MM. Immunity to Shigellosis. World Health Organization Meeting on Development of Vaccines against Shigellosis. Calcutta, May 19-22, 1986.

48. Levine MM. *Salmonella typhi* Vaccine. International Symposium on Vaccine Development and Utilization. Sponsored by the U.S. Agency for International Development and the Pan American Health Organization. Washington, D.C., June 9 and 10, 1986.
49. Levine MM. Vaccines against Bacterial Enteric Infections. International Congress of Pediatrics, Honolulu, July 9, 1986.
50. Levine MM. New Approaches to Antibacterial Vaccines. Vaccines against Enteric Infections. IXth International Congress of Infections and Parasitic Diseases. Munich, July 20-26, 1986.
51. Levine MM. Keynote Speaker, 24th Annual Meeting of the Infectious Diseases Society of America. *Escherichia coli* that cause Diarrhea. New Orleans, October 3, 1986.
52. Levine MM. Clinical and field trials to assess the efficacy of vaccines against bacterial enteric infections. Sclavo International Symposium. November 17-19, 1986.
53. Levine MM, Jian-Guo J, Kaper JB, Lior H, Prado V, Tall B, Nataro J, Karch H, Wachsmuth K. International Symposium and Workshop on Verocytotoxin-Producing Infections. A DNA Probe to Identify Enterohemorrhagic *Escherichia coli* of O157:H7 and other Serotypes that Cause Hemorrhagic Colitis and Hemolytic Uremic Syndrome. Toronto, July 12-15, 1987.
54. Levine MM. Vaccines against typhoid fever. The Annual Howard Florey Memorial Lecture, University of Adelaide, September, 1987.
55. Levine MM. Prospects for a Vaccine against AIDS. Annual meeting of the Chilean Infectious Diseases Society, October, 1987.
56. Levine MM. Identification of diarrheagenic *Escherichia coli* by DNA probes. Fifth International Symposium on Rapid methods and Automation in Microbiology and Immunology. Florence, Italy, November 6, 1987.
57. Levine MM. Diarrheal diseases in young children in the developing world: magnitude of the problem and prospects for prevention by vaccines and other interventions. Sackler Visiting Scholar Lecture, Sackler Institute of Advanced Studies, Tel Aviv University Medical School, November 8, 1987.
58. Levine MM. Update on vaccines against bacterial infections in pediatrics. International Congress of Pediatrics, Bangkok, Thailand, November 11, 1987.
59. Levine MM. Progress in vaccines against typhoid fever. International Conference on Advanced Knowledge on Vaccines for Tropical Diseases of Public Health Importance. Bangkok, Thailand, February 1, 1988.
60. Levine MM. New developments in vaccines against typhoid fever. Tel Hashomer Hospital, Tel Aviv, Israel, November 26, 1987.
61. Levine MM. The pathogenesis and epidemiology of *Escherichia coli* that cause diarrhea. Colloquium Lecture, Tel Aviv University School of Medicine, December 9, 1987.
62. Levine MM. New developments in vaccines against cholera. International Conference on Advanced Knowledge on Vaccines for Tropical Diseases of Public Health Importance. Bangkok, Thailand, February 2, 1988.
63. Levine MM. Progress in vaccines against typhoid fever. International Conference on Advanced Knowledge on Vaccines for Tropical Diseases of Public Health Importance. Bangkok, Thailand, February 2, 1988.
64. Levine MM. The application of biotechnology to vaccine development. Keynote talk at the Annual Meeting of the Israeli Society of Microbiology, Tel Aviv, Israel, February 8, 1988.

65. Levine MM. The role of clinical trials in vaccine development. Joint Israel Defence Forces - United States Army Conference on Vaccines of Military Importance. Kfar Maccabiah, Ramat Gan, Israel, March 21-23, 1988.
66. Levine MM. New diagnostic tools in gastrointestinal microbiology. International Meeting on Recent Progress in Pediatric Gastroenterology and Nutrition. Naples, June 2-3, 1988.
67. Levine MM. Pathogenesis of diarrhoeal diseases caused by *Escherichia coli*. International Symposium on Infections in Developing Countries. Johannesburg, South Africa, August 31, 1988.
68. Levine MM. New developments in malaria vaccines. International Symposium on Infections in Developing Countries. Johannesburg, South Africa, September 1, 1988.
69. Levine MM. *Escherichia coli* que causan la diarrhea: patogenia y propiedades de virulencia. Keynote speaker, Annual meeting of the Argentinian Society of Microbiology, Mar de Plata, Argentina, November 21-22, 1988.
70. Levine MM. Prospects for oral enteric vaccines. XIII International Symposium on Intestinal Microecology. Sardinia, Italy, September 11-14, 1988.
71. Levine MM. Oral vaccines against typhoid fever: results of recent controlled field trials. Symposium on oral vaccines, American Society for Microbiology Annual Meeting, Miami Beach, May 9, 1988.
72. Levine MM. The pathogenic mechanisms in *Escherichia coli* diarrhea. Dallas Infectious Diseases Dinner Seminar, Dallas, Texas, January, 1989.
73. Levine MM. Typhoid vaccines. Armed Forces Epidemiological Board, Washington, D.C., February 16, 1989.
74. Levine MM. Enterotoxigenic *Escherichia coli*. A new diarrheal agent. Federation of European Microbiological Societies Workshop on Microbial Surface Components and Toxins in Relation to Pathogenesis. Ramat Rachel, Israel, May 15-19, 1989.
75. Levine MM. The epidemiology of diarrhea due to *Escherichia coli* in children less than five years of age. Second Annual Joint Israel Defence Force - U.S. Army Medical Research and Development Command Conference on Vaccines. Tel Hashomer Hospital, Tel Aviv, May 30-31, 1989.
76. Levine MM. Attenuated *Salmonella typhi* live oral vaccine strains expressing foreign antigens: a summary of clinical experience. World Health Organization Meeting on the Potential Use of Live Vectors for Vaccines: the Biological Requirements and the Medical Constraints. Geneva, Switzerland June 19-22, 1989.
77. Levine MM. Shigellosis. 26th Annual Semana Pediatrica, Hospital Nacional de Ninos. San Jose, Costa Rica, September 18-22, 1989.
78. Levine MM. Attenuated *Salmonella* as carrier vaccine strains for the expression of foreign antigens. U.S. - India Joint Vaccine Working Group Meeting. New Delhi, India, October 23-26, 1989.
79. Levine MM. Progress in the development of live oral vaccines to prevent cholera. International Center for Diarrhoeal Diseases Research, Bangladesh. Dhaka, Bangladesh, October 28, 1989.
80. Levine MM. *Salmonella* vectors for immunization. Seminar given at the Walter and Eliza Hall Institute for Immunology, Melbourne, Australia, November 8, 1989.
81. Levine MM. The Center for Vaccine Development. Invited lecture given at the Commonwealth Serum Laboratories, Melbourne, Australia, November 10, 1989.
82. Levine MM. Vaccines against enteric infections. Annual Meeting of the Australian Society for Infectious Diseases, Melbourne, Australia, November 13, 1989.

83. Levine MM. The pathogenesis of bacterial enteric infections. 2nd Annual Course in Infectious, Parasitic and Tropical Diseases, Armed Forces Institute of Pathology. Bethesda, Maryland November 30, 1989.
84. Levine MM. Field trials of efficacy of live oral typhoid vaccine, Ty21a. American Epidemiological Society, Baltimore, March 1990.
85. Levine MM. Prevention of enteric infections using vaccines and oral immunoglobulin preparations. International Symposium on the Management of Acute Diarrhea. Stuart, Florida, May 17-19, 1990.
86. Levine MM. The design of clinical trials. First European Course on Hospitalology. Annecy, France, June 1, 1990.
87. Levine MM. Clinical and field trials with attenuated *Salmonella typhi* as live oral vaccines and as "carrier" vaccines. International Symposium on Oral Immunization using Recombinant Bacteria. Munich, June 4-8, 1990.
88. Levine MM. A large-scale field trial comparing the efficacy of Ty21a, live oral typhoid vaccine in liquid versus enteric-coated capsule formulations. Annual Joint Meeting on Vaccines of the U.S. Army Medical Research and Development Command and the Israel Defence Force. Gaithersburg, Maryland June 18-20, 1990.
89. Levine MM. *Salmonella* vaccines. International symposium on New Antimicrobial Strategies, Brocket Hall, England, July 1-3, 1990.
90. Levine MM. Vaccines against typhoid fever. Department of Chemical Immunology Seminar, the Weizmann Institute of Science, Rehovoth, Israel, July 13, 1990.
91. Levine MM. Attenuated *Salmonella typhi* as a live oral vaccine and as a carrier to express foreign antigens. Life Science Transfer Technology Seminar, Kyoto, September 19, 1990.
92. Levine MM. *Escherichia coli* that cause diarrhea in the tropics. International Union of Microbiological Societies, Osaka, Japan, September, 19, 1990.
93. Levine MM, Fasano A, Savarino S, Robertson D, Maneval D. Enterotoxins elaborated by enteroinvasive and enteroaggregative *Escherichia coli*. 26th Joint Conference of the U.S.- Japan Cooperative Medical Science Program on Cholera and Related Diarrheal Diseases. Kyoto, September 24-26, 1990.
94. Levine MM. Typhoid vaccines. Council on Industrial Health. Johns Hopkins University, Baltimore, MD, October 3, 1990.
95. Levine MM. The new generation of typhoid vaccines: prospects for the protection of international travelers and children in endemic areas. Centers for Infectious Diseases Grand Rounds. Centers for Diseases Control, Atlanta, Georgia, October 10, 1990.
96. Levine MM. Vaccines against diarrheal infections. Symposium on diarrheal diseases at the Annual Meeting of the American Society of Tropical Medicine and Hygiene. New Orleans, November 6, 1990.
97. Levine MM. *Salmonella typhi* and foreign epitopes. Philippe Laudat International Conference on Immune Responses to Proteins with Recombinant Epitopes: Perspectives for Vaccines. Bischenberg, France, November 12-15, 1990.
98. Levine MM. Advances en el desarrollo de vacunas contra la fiebre tifoidea. 5th Congreso Panamericano de Infectologia, Lima, Peru, April 7-10, 1991.
99. Levine MM. Cholera: epidemiologia y control de la enfermedad. 5th Congreso Panamericano de Infectologia, Lima, Peru, April 7-10, 1991.

100. Microbiologia, inmunologia y patogenia del colera. Congreso Paraguayo de Pediatría, October 11, 1991, Asuncion, Paraguay.
101. Fisiologia de la rehidratacion oral. Congreso Paraguayo de Pediatría, October 11, 1991, Asuncion, Paraguay.
102. Vacunas del futuro. Sociedad Colombiana de Medicina Tropical y Parasitologia, Bogota, Colombia, October 13, 19, 1991.
103. La epidemiologia global del colera. Sociedad Colombiana de Medicina Tropical y Parasitologia, Bogota, Colombia, October 13, 1991.
104. *Escherichia coli* that cause diarrhea. Annual Meeting of the Brazilian Pediatric Society, Porto Alegre, Brazil, October 17, 1991.
105. Vaccines against *Haemophilus influenzae* type b. Annual Meeting of the Brazilian Pediatric Society, Porto Alegre, Brazil, October 17, 1991.
106. New vaccines against typhoid fever and cholera. Congreso Latinoamericano de Infectologia Pediatrica, Santiago, Chile October 23, 1991.
107. Perspectives on diarrhea caused by *Escherichia coli*. Congreso Latinoamericano de Infectologia Pediatrica, Santiago, Chile October 23, 1991.
108. Cholera - Worldwide epidemiology and prevention. Annual Meeting of the Israel Society for Microbiology, Beer Sheva, Israel February 11, 1992.
109. Current trends in *S. typhi* vaccines. Society for General Microbiology, 122nd Meeting, University of Wales College of Cardiff March 23-26, 1992.
110. Cholera. Biomedical Research Advancement: Saturday Scholars (BRASS) Program, National Institutes of Health, April 4, 1992.
111. A progress report on the safety, immunogenicity and efficacy of CVD 103-HgR, a one dose, genetically engineered live oral cholera vaccine. First International Symposium on Cholera in the Americas, Mexico City, April 20-21, 1992.
112. The problem of cholera in the world. International Symposium on Cholera in Latin America, Buenos Aires, Argentina, April 29, 1992.
113. Vaccine development. International Symposium on Cholera in Latin America, Buenos Aires, Argentina, April 29, 1992.
114. Cholera: Keynote address for the Cholera session. Vaccines for Enteric Diseases, Cambridge, England, April 13-15, 1992.
115. Attenuated *Salmonella typhi* as live oral vaccines to prevent typhoid fever and as carrier vaccines to express foreign antigens. NATO Advanced Research Workshop on the Biology of *Salmonella*, Portofino, Italy, May 10-15, 1992.
116. Production, laboratory evaluation, and clinical trial of vaccines against cholera. International Symposium on Cholera in the American Continents, Sao Paulo, Brazil, May 21-23, 1992.
117. Old and new cholera vaccines: A 100 year perspective. The American Society for Microbiology 1992 General Meeting, New Orleans, Louisiana, May 27, 1992.
118. A new generation of cholera vaccines. The Bazeley Oration, The Australian Society for Microbiology 1992 Annual Meeting, Sydney, Australia, July 16, 1992.

119. Cholera. Brazilian Society of Immunology Annual Meeting, August 26, 1992.
120. Enteric Fever: *Salmonella typhi*. Eastern Pennsylvania Branch, American Society for Microbiology, Philadelphia, PA, November 12, 1992.
121. Attenuated *Salmonella typhi* live vector vaccines expressing foreign antigens: Versatility to meet public health demands. University of California at San Francisco. February 9, 1993.
122. Attenuated *Salmonella typhi* live vector vaccines expressing foreign antigens. The Mount Sinai Medical Center, New York, February 23, 1993.
123. The recent cholera epidemic in Latin America. Baltimore Tropical Medicine Dinner Club. Baltimore, Maryland. March 17, 1993.
124. Vaccines to prevent enteric infections in travelers. Presented at the 3rd Conference on International Travel Medicine, Paris, France, April 26, 1993.
125. CVD 103-HgR, live oral cholera vaccine. Presented at the International Workshop on New Approaches to Bacterial Vaccines. Munich, Germany, April 28-29, 1993.
125. Vacuna oral contra el colera. Congreso de la Sociedad Panameiricana de Infectologia, Viña del Mar, Chile, May 27, 1993.
126. Vacunas contra enfermedades entericas. Congreso de la Sociedad Panameiricana de Infectologia, Viña del Mar, Chile, May 27, 1993.
127. Vaccines against cholera and enterotoxigenic *E. coli*. The 18th International Congress of Chemotherapy. Stockholm, Sweden. June 27-July 2, 1993.
128. Modern approaches to the development of vaccines against bacterial enteric infections. Canadian Society of Microbiology/Society for Industrial Microbiology Annual Meeting. Symposium on Vaccination Strategies for Bacterial Pathogens, keynote address. Toronto, Ontario, August 3, 1993.
129. *Shigella*, *Salmonella* and other enteric vaccines. Ross Conference on Strategies for Pediatric Vaccines: conventional and molecular approaches. San Diego, CA, September 19-22, 1993.
130. The emergence of diarrheal diseases including cholera. Colloquium on Changes in Human Ecology and Behavior: Infectious Diseases. National Academy of Sciences, Washington, D.C., September 27-28, 1993.
131. Cholera Vaccines and Typhoid Vaccines. Invited talks given at the Mexican Infectious Diseases Society XVIII Annual Meeting, Mexico City, November 21-24, 1993.
132. Recent Advances in Vaccine Development. Invited talk delivered at the XI Biennial Conference of the Pakistan Pediatric Association, Lahore, Pakistan, February 2-5, 1994.
133. Experiences with *Haemophilus influenzae* type b capsular polysaccharide-tetanus protein conjugate vaccine in Chilean infants. Special lecture of the Korean pediatric Society, Seoul, Korea, March 30, 1994.
134. Bacterial enteric vaccines. Mucosal Immunology Symposium, FASEB, Anaheim, CA, April 28, 1994.
135. Cholera Vaccines. Invited lecture presented at the 2nd Simposio Internacional de Infectologia Pediatrica, Cordoba, Argentina, May 9, 1994.

136. Mucosal immunization -- The perspective of the vaccinologist versus the immunologist. Invited talk at the inaugural meeting of the International Society for Vaccines. Las Vegas, May 22-23, 1994.
137. Live oral cholera vaccines - A status report. 7th Asian Conference on Diarrheal Diseases. Dhaka, Bangladesh, September 17, 1994.
138. Attenuated strains of *Vibrio cholerae*, *Salmonella typhi* and *Shigella* as live oral vaccines and as live vectors. Keystone Conference on Mucosal Immunization. January, 1995.
139. The epidemiology of typhoid fever. WHO meeting on Vaccines against Bacterial Infections, Madrid, March 1-2, 1995.
140. Large-scale post-licensure effectiveness trial of PRP-T conjugate vaccine in preventing invasive *Haemophilus influenzae* type b infections in Chilean infants. Annual Meeting of the American Epidemiological Society, Tampa, Florida March 23, 1995.
141. Attenuated *Salmonella* as live oral vaccines against typhoid fever and as live vectors. New Approaches to Vaccine Development, Vienna April 12, 1995.
142. Enteric vaccines -- the next five years. Keynote talk at the 8th International Workshop on *Campylobacters*, *Helicobacters* and Related Organisms. Winchester, United Kingdom, July 12, 1995.
143. Characteristics of newly licensed typhoid vaccines (Ty21a, Vi polysaccharide), candidate Vi conjugate vaccines and new generation attenuated vaccine strains. U.S.-India Vaccine Program, New Delhi, July 17, 1995.
144. Immunizations for diarrheal diseases. International Congress of Chemotherapy, Montreal, July 20, 1996.
145. The epidemiology of enteropathogenic *Escherichia coli* (EPEC) infections in Chile. International Symposium on EPEC, Sao Paulo, Brazil, August 28, 1995.
146. Prospects for a vaccine against EPEC. International Symposium on EPEC, Sao Paulo, Brazil, August 28, 1995.
147. Engineered live oral cholera vaccines. State of the Art Minilecture, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 18, 1995
148. Development of a live oral cholera vaccine; a paradigm. NIH Meeting on Planning and Implementing Clinical Trials for Parasitic Diseases, Bethesda, MD, September 19, 1995.
149. Live attenuated vaccines against bacterial enteric infections. Year of Louis Pasteur Symposium, Paris, September 26, 1995.
150. Vaccines against diarrheal disease, dysentery and enteric fever. Presented at Nestlé Nutrition Workshop Series 38 :Diarrheal Disease@. Islamabad, Pakistan, October 23, 1995.
151. New developments in cholera vaccines. Congress of the African Society of Microbiology. Bamako, Africa. February 2, 1996.
152. A consideration of the host factors that modulate susceptibility to cholera and the immune response to engineered live oral cholera vaccines. ICTDR Meeting, Bethesda, MD, April 23, 1996.
152. Mucosal routes of vaccination. Edward Jenner Bi-centennial Celebration, Royal College of Physicians, London. May 15, 1996.
153. Attenuated *Salmonella typhi* and *Shigella flexneri* as live vector vaccines: Expression of foreign antigens and elicitation of relevant immune responses. Munich, Germany. May 28, 1996.

154. New vaccines against cholera and typhoid fever. International Society for Infectious Diseases, Hong Kong, June 12, 1996.
155. Engineered vibrio cholerae and shigella strains as live oral vaccines and as live vectors to deliver foreign antigens by mucosal immunization. 10th International Biotechnology Symposium. Sydney, Australia. August 26, 1996.
156. The vaccine development paradigm: Illustrative examples in the development of vaccines against tropical diseases. American Society of Tropical Medicine and Hygiene, Baltimore, MD, December 2, 1996.
157. Development of enteric vaccines. Asia Pan Pacific Society for Paediatric Gastroenterology and Nutrition, Jakarta, Indonesia, December 16, 1996.
158. Quantitating invasive Hib disease in Santiago, Chile. Revelation of an important public health problem. First International Symposium on Hib in Asia, Bali, Indonesia, December 17, 1996.
159. Cholera vaccine for travelers: Indications and options. Presented at the Fifth International Conference on Travel Medicine, Geneva, SW, March 24, 1997.
160. Bacterial live vector vaccines. Presented at 2nd National Symposium on Basic Aspects of Vaccines, Walter Reed Army Institute of Research, Bethesda, MD, April 30, 1997.
161. Salmonella vaccines as carriers of foreign antigens. American Gastroenterological Association. Washington, DC. May 13, 1997.
162. The molecular epidemiology of 19th century cholera: What was the serogroup and biotype of Vibrio cholerae responsible for the early cholera pandemics? First International Symposium The Archaeology of Emerging Diseases, Tel Aviv, Israel, May 20, 1997.
163. Artificial challenge studies. Presented at International Association of Biologic Standardization Meeting on Clinical Trials in Paris, France, May 28, 1997.
164. Phase 1 and 2 clinical trials of candidate malaria vaccines. Presented at the Second Global Meeting on Parasitic Diseases with a focus on Malaria, Hyderabad, India. August 18, 1997.
165. New strategies of bacterial vaccines against enteric infections. Presented at the Deutschen Gesellschaft für Hygiene und Mikrobiologie in Jena Germany. October 7, 1997.
166. Developments in prevention: The way forward. Presented at the Strategies for Vaccine Protection in Developing Countries, Universidad Nacional Autonoma de Mexico, Mexico City. October 17, 1997.
167. Emerging infections: fundamental concepts and models to explain a phenomenon of global importance. Presented at the Congreso Chileno de Infectología, Valdivia, Chile, December 2, 1997.
168. Mucosal vaccines. Presented at the Congreso Chileno de Infectología, Valdivia, Chile, December 3, 1997.
169. Recent research on vaccines and prevention of typhoid fever. Presented at the Third Asia-Pacific Symposium on typhoid fever and other salmonellosis, Denpasar, Bali, Indonesia December 8-10, 1997.
170. New typhoid vaccine development. Presented at Workshop on Typhoid Fever, National Institute of Health, Seoul, Korea, December 16, 1997.
171. *Salmonella* as a live vector. Presented at the WHO/NIAID Workshop on Vaccines administered via Mucosal Surfaces, February 9-11, 1998.

172. Vaccines delivered via mucosal surface. Presented at the International Workshop on Vaccine Development, Rio de Janeiro, April 14-16, 1998.
173. Mucosal Immunization. Presented at the 8th International Congress on Infectious Diseases meeting, Boston, May 15-18, 1998
174. Prospects for improving disease control through simplifying vaccination: Oral/mucosal vaccines and combinations. Presented at the Consultative Group Meeting of the Children's Vaccine Initiative in Geneva, Switzerland, November 9-10, 1998.
175. Live oral vaccines against enteric pathogens. Presented at the Centennial celebration of the Swiss Serum and Vaccine Institute, Berne, Switzerland, November 6, 1998.
176. Rotavirus Vaccines. Presented at the Infectious Diseases in Children conference, New York, November 21-22, 1998.
177. Status of typhoid vaccines. Presented at the V International Congress of Tropical Pediatrics, Jaipur, India, February 10-15, 1999.
178. Oral and Nasal Immunization. Presented at A New Approaches to Bacterial Vaccine Development, Munich, Germany, May 19-22, 1999.
179. Update on Edible Vaccines. Presented at meeting on An Overview on Vaccine Research in WHO and UNAIDS@, Montreux, Switzerland, June 16-18, 1999.
180. Vacunas contra Enfermedades Entericas. Presented at the 8th Congreso de la Sociedad Latinoamericana de Infectología Pediátrica. Asunción, Paraguay, August 8-11, 1999.
181. Enfermedades Emergentes. Presented at the 8th Congreso de la Sociedad Latinoamericana de Infectología Pediátrica. Asunción, Paraguay, August 8-11, 1999.
182. Development of new vaccines against diarrheal pathogens -- a hope for developing countries? Presented at the International Congress on Cooperative Research with Developing Countries. Basel, Switzerland, August 19-21, 1999.
183. How to test vaccines in the field -- Are there alternatives? Presented at the International Congress on Cooperative Research with Developing Countries. Basel, Switzerland, August 19-21, 1999.
184. Organizing Vaccine Trials. Presented at the 1st Global Conference on Vaccines and Immunisation into the next millennium. Manchester, UK, September 6-9, 1999.
185. Evaluaciones de la eficacia y la efectividad (impacto epidemiológico) de las vacunas. Second Congress of the Sociedad Española de Medicina Tropical y Salud Internacional. Sitges (Barcelona), January 27-29, 2000.
186. Current status of new generation vaccines: Live oral; Live oral Shigella vaccines; and Live oral Cholera vaccines (CVD candidates). Three talks presented at the DOMI Program Meeting, WHO headquarters, Geneva, Switzerland. February 7-8, 2000.
187. Live oral vaccines to prevent enteric infections in travelers. Presented at the Oral Vaccination Symposium at I. Matzkel "Droeth" Ltd., Tel Aviv, Israel. March 23, 2000.
188. Live attenuated vectors: have they delivered? Presented at the Millennium Joint Meeting of the Society for General Bacteriology and the Society for Applied Microbiology, April 10-14, 2000.
189. Global efforts in vaccination. From the laboratory to the field. Presented at the Wellcome Trust conference on Bacteriology in the Tropics. Cambridgeshire, UK, May 14-17, 2000.

190. The global burden of diarrheal diseases: A perspective. Presented at the XV International Congress for Tropical medicine and Malaria. Cartagena, Bogota, Colombia, August 20-25, 2000.
191. Progress in non-parenteral delivery of vaccines. Infectious Disease Society of America. New Orleans, LA, September 7-10, 2000.
192. Ethical Considerations in Mass Vaccination Campaigns. Presented at the Berzelius Symposium, Vaccines are beneficial! What are the risks? Stockholm, February 8-10, 2001.
193. Vaccines against enteric infections: Public health rationale, vaccinology strategies, successes, disappointments and surprises. Presented at the Institute Butantan Symposium on vaccines against enteric infections. Sao Paulo, Brazil, February 19-22, 2001.
194. Realizing the promise of new vaccine technologies: Pitfalls, perseverance, disappointments and successes. Presented at the World Vaccine Congress. Montreal, Canada, April 3-5, 2001.
195. Vaccine triumphs and tribulations in the USA and globally. Presented at the Practical Day of Pediatrics, University of Alabama-Birmingham, May 16-17, 2001.
196. "Oral Vaccines", and, "Attenuated *Salmonella typhi* and *Shigella* as live vectors to deliver foreign protein antigens or DNA vaccines to the mammalian immune system". Both lectures presented at the American Society for Microbiology. Orlando, Florida, May 20-24, 2001.
197. Review of issues too be considered in Phase 3 trials: Lessons from various clinical trials. Presented at the Second Advanced Vaccinology Course. Merieux Foundation, Annecy, France, May 23, 2001.
198. Issues in clinical trials. Presented at the Global Vaccine Research Forum. Montreux, Switzerland, June 10-12, 2001.
199. Cholera Vaccines – Overview. Presented at the Vaccines for Enteric Diseases VED 2001. Tampere, Finland, September 12-14, 2001.
200. Widespread Vaccination Against Gastrointestinal Pathogens in DCC - Is it Worthwhile? Pediatric Infectious Disease Conference. Monterey, California, October 28-30, 2001.
201. Vaccines against bioterror agents: Overcoming the challenges to development, testing, stockpiling and implementation. Presented at the University of Maryland, Baltimore, Health Policy Seminar, November 16, 2001.
202. Overview of the Research and Development Activities of the Global Alliance for Vaccines and Immunization. Presented at the NFID's Fifth Annual Conference on Vaccine Research. Baltimore, Maryland, May 6-8, 2002.
202. Memory at the Mucosal Level. Presented at the NIFID's Fifth Annual Conference on Vaccine Research. Baltimore, Maryland, May 6-8, 2002.
203. Attenuated *Shigella* and *Salmonella Typhi* Live Vectors to Deliver DNA Vaccines via Mucosal Administration. Presented at the 4th International Meeting, New Approaches to Bacterial Vaccine Development. Munich, Germany, May 26-29, 2002.
204. Typhoid Fever: Lessons from the Past and Challenges for the Future. Typhoid Symposium. American Society of Tropical Medicine and Hygiene, Annual Meeting, November 12, 2002, Denver.
205. The Future: Typhoid and Cholera Vaccines. Presentation at the Centennial Celebration of the Pan American Health Organization, November 25, 2002, Washington, D.C.

206. Typhoid. Presentation at the International Vaccine Institute's Inaugural Symposium, New Frontiers in Vaccinology Research, June 26, 2003, Seoul, Korea.

JOURNAL ARTICLES

1. Clyde DF, Miller RM, Schwartz AR, Levine MM. The treatment of falciparum malaria with sulfalene and trimethoprim. *Am J Trop Med Hyg* 20:804-811, 1971.
2. Levine MM, DuPont HL, Gangarosa EJ, Hornick RB, Snyder MJ, Libonati JP, Glaser K, Formal SB. Shigellosis in custodial institutions. II. Clinical, immunologic, and bacteriologic response of institutionalized children to oral attenuated *Shigella* vaccines. *Am J Epidemiol* 96:40-49, 1972.
3. Levine MM, DuPont HL, Formal SB, Hornick RB, Takeuchi A, Gangarosa EJ, Snyder MJ, Libonati JP. Pathogenesis of *Shigella dysenteriae*-1 (Shiga) dysentery. *J Infect Dis* 127:261-270, 1973.
4. Levine MM, DuPont HL, Khodabandelou M, Hornick RB. Long-term *Shigella*-carrier state. *New Eng J Med* 288:1169-1171, 1973.
5. Wald ER, Levine MM, Togo Y. Concomitant Varicella and staphylococcal Scalded Skin Syndrome. *J Pediatr* 83:1017-1019, 1973.
6. Levine MM, Rice PA, Gangarosa EJ, Morris GK, Snyder MJ, Formal SB, Wells JG, Gemski P, Jr., Hammond J. An outbreak of Sonnei shigellosis in a population receiving oral attenuated *Shigella* vaccines. *Am J Epidemiol* 99:30-36, 1974.
7. Levine MM, Gangarosa EJ, Werner M, Morris GK. Shigellosis in custodial institutions. III. Prospective clinical and bacteriologic surveillance of children vaccinated with oral attenuated *Shigella* vaccine. *J Pediatr* 84:803-806, 1974.
8. Levine MM, Togo Y, Wald ER. Practicability of influenza surveillance by virus culture of children. *Am J Epidemiol* 100:272-276, 1974.
9. Levine MM, Edsall G, Bruce-Chwatt LJ. Live virus vaccines in pregnancy: risks and recommendations. *Lancet* II:34-38, 1974.
10. Levine MM, Gangarosa EJ, Barrow WB, Norris GK, Wells JG, Weiss CF. Shigellosis in custodial institutions. IV. *In Vivo* stability and transmissibility of oral attenuated streptomycin-dependent *Shigella* vaccines. *J Infect Dis* 131:704-707, 1975.
11. Levine MM, Hornick RB, DuPont HL. Lactulose in the therapy of acute *Shigella* dysentery and *Shigella*-carrier state. *Antimicrob Agents Chemother* 8:581-584, 1975.
12. Gilman RH, Termini M, Levine MM, Mendosa PH, Calderone E, Vasquez V, Martinez E, Snyder MJ, Hornick RB. Comparison of trimethoprim-sulfamethoxazole and amoxicillin in chloramphenicol-resistant and sensitive typhoid fever. *J Infect Dis* 132:630-635, 1975.
13. Gilman RH, Termini M, Levine MM, Mendoza PH, Hornick RB. Relative efficacy of blood, urine, rectal swab, bone marrow, and rose-spot cultures for recovery of *Salmonella typhi* in typhoid fever. *Lancet* I:1211-1215, 1975.
14. Levine MM. Use of live virus vaccines in pregnant women in the tropics. *Tropical Doctor* 5:83-85, 1975.
15. Levine MM, Ashman R, Heald FP. Anaerobic (putrid) lung abscess in adolescence. *Am J Dis Child* 130:77-81, 1976.
16. Wald ER, Levine MM. Frequency of detection of *Haemophilus Influenzae* type B capsular polysaccharide in infants and children with pneumonia. *Pediatrics* 57:266-267, 1976.

17. Keusch GT, Jacewicz M, Levine MM, Hornick RB, Kochwa S. Pathogenesis of Shigella Diarrhea. Serum anti-toxin antibody response produced by toxigenic and "non-toxigenic" *S. dysenteriae* I. J Clin Invest 57: 194-202, 1976.
18. Levine MM, DuPont HL, Hornick RB, Snyder MJ, Woodward WE, Gilman RH, Libonati JP. Attenuated Streptomycin-dependent *Salmonella typhi* oral vaccine: potential deleterious effects of lyophilization. J Infect Dis 133:424-429, 1976.
19. Levine MM, Gangarosa EJ, Barrow WB, Weiss CF. Shigellosis in custodial institutions. V. Effect of intervention with streptomycin-dependent *Shigella sonnei* vaccine in an institution with endemic disease. Am J Epidemiol 104:88-92, 1976.
20. Richman DD, Murphy BR, Chanock RM, Gwaltney JM, Douglas RG, Betts RF, Blacklow NR, Rose FB, Parrino TA, Levine MM, Caplan ES. Temperature-sensitive mutants of influenza A Virus. XII. Safety, antigenicity, transmissibility, and efficacy of influenza A/Udorn/72-ts-I(E) recombinant temperature-sensitive viruses in adult volunteers. J Infect Dis 134:585-594, 1976.
21. Hornick RB, DuPont HL, Levine MM, Gilman RH, Woodward WE, Snyder MJ, Woodward TE. Efficacy of a live oral typhoid vaccine in human volunteers. Develop Biol Standard 33:89-92, 1976.
22. Miller RM, Garbus J, Schwartz A, DuPont H, Levine MM, Clyde DF, Hornick RB. A modified leukocyte nitroblue tetrazolium test in acute bacterial infection. Am J Clin Path 66:905-910, 1976.
23. Richman D, Murphy B, Rusten H, Blacklow N, Levine M, Caplan E, Chanock RM. Temperature-sensitive mutants of influenza virus, XIV. Evaluation of influenza A/Georgia/10/74-ts-I(E) recombinant viruses in human adults. J Infect Dis 136:256-262, 1977.
24. Gilman RH, Hornick RB, Woodward WE, DuPont HL, Snyder MJ, Levine MM, Libonati JP. Immunity in typhoid fever: evaluation of Ty2la - an epimerase-less mutant of *S. typhi* as a live oral vaccine. J Infect Dis 136:717-723, 1977.
25. Levine MM, Caplan ES, Waterman D, Cash RA, Hornick RB, Snyder MJ. Diarrhea due to *Escherichia coli* that produce only heat-stable enterotoxin. Infect Immun 17:78-82, 1977.
26. Levine MM, Hughes T, Simon P, O'Donnell S, Grauel S, Levine SG. Monovalent inactivated A/New Jersey/8/76 (HswINI) vaccine studies in healthy children age 3-5 years. J Infect Dis (Suppl) 136:S571-S574, 1977.
27. Caplan ES, Hughes TP, O'Donnell S, Levine MM, Hornick RB. Evaluation of the reactogenicity and immunogenicity of parenteral monovalent A/Victoria/3/75 (H3N2) influenza vaccine in healthy adults. J Infect Dis (Suppl) 136:S484-S490, 1977.
28. Levine MM. Parasitology for the U.S. practitioner. Medical Digest 23:11-21, 1977.
29. Levine MM, Woodward WE, Formal SB, Gemski P, Jr., DuPont HL, Hornick RB, Snyder MJ. Studies with a new generation of oral attenuated *Shigella* vaccine: *Escherichia coli* bearing *Shigella* surface antigens. J Infect Dis 136:577-582, 1977.
30. Wald ER, Levine MM. *Haemophilus Influenzae* type b pneumonia. Arch Dis Child 53:316-318, 1978.
31. Levine MM, Grados O, Gilman RH, Woodward WE, Solis-Plaza R, Waldman W. Diagnostic value of the Widal test in areas endemic for typhoid fever. Am J Trop Med Hyg 27:795-800, 1978.
32. Murphy BR, Markoff LJ, Hosier NT, Rusten HM, Chanock RM, Kendal AP, Douglas RG, Betts RF, Cate TR Jr, Couch RB, Levine MM, Waterman DH, Holley HP, Jr. Temperature-sensitive mutants of influenza A virus: evaluation of A/Victoria/3/75-ts-I(E) recombinant viruses in volunteers. Infect Immun 20:665-670, 1978.

33. Levine MM, Hughes TP, Young CR, O'Donnell S, Craig JP, Holley P, Bergquist E. Antigenicity of purified glutaraldehyde-treated cholera toxoid administered orally. *Infect Immun* 21:158-162, 1978.
34. Levine MM, Bergquist EJ, Nalin DR, Waterman DH, Hornick RB, Young CR, Sotman S, Rowe B. *Escherichia coli* strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. *Lancet* I:1119-1122, 1978.
35. Nalin DR, Levine MM, Young CR, Bergquist EJ, MacLaughlin J. Concentrating *Escherichia coli* culture supernates increases detection of heat-stable enterotoxin in the infant mouse assay. *J Clin Microbiol* 8:700-703, 1978.
36. Nalin DR, Levine MM, Mata L, DeCespedes C, Vargas W, Lizano C, Loria AR, Simhon A. Comparison of sucrose with glucose in oral therapy of infant diarrhoea. *Lancet* II:277-279, 1978.
37. Nalin CR, Levine MM, Rhead J, Bergquist E, Rennels M, Hughes T, O'Donnell S, Hornick RB. Cannabis, hypochlorhydria, and cholera. *Lancet* II:859-861, 1978.
38. Nalin DR, Levine RJ, Levine MM, Hoover D, Bergquist E, McLaughlin J, Libonati J, Alam J, Hornick RB. Cholera, non-*Vibrio cholerae*, and stomach acid. *Lancet* II:856-859, 1978.
39. Nalin DR, Levine MM, Mata L, DeCespedes C, Vargas W, Lizano C, Loria AR, Simhon A, Mohs E. Oral rehydration and maintenance of children with bacterial and rotavirus diarrheas. *Bull Wld Hlth Org* 57:453-459, 1979.
40. Greenberg HB, Levine MM, Merson MH, Sack RB, Sack DA, Valdesuso JR, Nalin DR, Hoover D, Chanock RM, Kapikian AZ. Solid phase microtiter radioimmunoassay blocking test for detection of antibodies to *Escherichia coli* heat-labile enterotoxin. *J Clin Microbiol* 9:60-64, 1979.
41. Nalin DR, Levine MM, Hornick RB, Bergquist EJ, Hoover D, Holley HP, Jr., Waterman DH, Van Blerk J, Matheny S, Sotman S, Rennels M. The Problem of emesis during oral glucose-electrolytes therapy given from the onset of severe cholera. *Trans Roy Soc Trop Med Hyg* 73:10-14, 1979.
42. Levine MM, Nalin DR, Craig JP, Hoover D, Bergquist EJ, Waterman D, Holley HP, Jr., Hornick RB, Pierce NF, Libonati JP. Immunity to cholera in man: relative role of antibacterial versus antitoxic immunity. *Trans Roy Soc Trop Med Hyg* 73:3-9, 1979.
43. Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB, Young CR. Immunity to enterotoxigenic *Escherichia coli*. *Infect Immun* 23:729-736, 1979.
44. Murphy BR, Chanock RM, Levine MM, Van Blerk GA, Bergquist EJ, Douglas RG, Betts RF, Couch RB, Cate TR, Jr. Temperature-sensitive mutants of influenza A virus: evaluation of the A/Victoria/75-ts-1A2 temperature sensitive recombinant virus in seronegative adult volunteers. *Infect Immun* 23:249-252, 1979.
45. Murphy BR, Holley HP, Jr., Bergquist EJ, Levine MM, Spring SB, Maassab HF, Kendal AP, Chanock RM. Cold-adapted variants of influenza A virus: evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain. *Infect Immun* 23:253-259, 1979.
46. Levine MM. Shigella and salmonella diarrhoeal disease. *Tropical Doctor* 9:4-9, 1979.
47. Levine MM, Barua D, Nalin DR, Rennels MB, Hornick RB, Sotman S, Van Blerk G, Hughes TP, O'Donnell S. Genetic susceptibility to cholera. *Ann Human Biol* 6:369-374, 1979.

48. Douglas RG Jr., Markoff LJ, Murphy BR, Chanock RM, Betts RF, Levine MM, Van Blerk GA, Sotman SB, Nalin DR. Evaluation of live Vic/75-ts-1 (E) influenza virus vaccines in adult volunteers: role of hemagglutinin immunity in protection against illness and infection caused by influenza A virus. *Infect Immun* 26:274-179, 1979.
49. Gunn RA, Kimball AM, Dutta SP, Matthew PP, Mahmood RA, Pollard RA, Feeley JC, Levine MM, Feldman RA. Bottle feeding as a risk factor for cholera in infants. *Lancet* II:730-732, 1979.
50. Levine MM, Edelman R. Acute diarrheal infections in infants. I. Epidemiology, treatment and immunoprophylaxis. *Hosp Pract* 14:89-100, 1979.
51. Nalin DR, Daya V, Reid A, Levine MM, Cisneros L. Absorption and growth of *V. cholerae* on chitin. *Infect Immun* 25:768-770, 1979.
52. Pizarro D, Posada G, Nalin DR, Mohs E, Levine MM. Evaluation of oral therapy for infant diarrhea in an emergency room setting: utilization of acute episode for instructing mothers in oral therapy method. *Bull Wld Hlth Org* 57:983-986, 1979.
53. Young CR, Levine MM, Craig JP, Robins-Browne R. Microtiter enzyme-linked immunosorbent assay (ELISA) for IgG cholera antitoxin in man. I. Method and correlation with rabbit skin vascular permeability factor technique. *Infect Immun* 27:492-496, 1980.
54. Murphy BR, Rennels MB, Douglas RG, Jr., Betts RF, Couch RB, Cate TR, Jr., Chanock RM, Kendall AP, Maassab HF, Suwanagool S, Sotman SB, Cisneros LA, Anthony WC, Nalin DR, Levine MM. Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. *Infect Immun* 29:348-355, 1980.
55. Levine MM, Rennels MB, Cisneros L, Hughes TP, Nalin DR, Young CR. Lack of person-to-person transmission of enterotoxigenic *Escherichia coli* despite intimate contact. *Am J Epidemiol* 113:347-355, 1980.
56. Huang TL, Levine MM, Daoud GS, Nalin DR, Nichols BL. Fecal steroids in diarrhea. III. Experimentally - induced travelers' diarrhea. *Am J Clin Nutr* 33:40-44, 1980.
57. Robins-Browne RM, Young CR, Levine MM, Craig JP. Microtiter enzyme-linked immunosorbent assay (ELISA) for IgG cholera antitoxin in man. II. Sensitivity and specificity. *Infect Immun* 27:497-500, 1980.
58. Edelman R, Levine MM. Acute diarrheal infections in infants. II. Bacterial and viral causes. *Hosp Pract*
59. Levine MM. Cholera in Louisiana: Old problem, new light. (Editorial). *N Eng J Med* 302:345-347, 1980.
60. Levine MM, Rennels MB, Daya V, Hughes TP. Hemagglutination and colonization factors in enterotoxigenic and enteropathogenic *Escherichia coli* that cause diarrhea. *J Infect Dis* 141:733-737, 1980.
61. Rennels MB, Levine MM, Daya V, Angle P, Young C. Selective vs. non-selective media and direct plating vs. enrichment technique in isolation of *Vibrio cholerae*: recommendations for clinical laboratories. *J Infect Dis* 142:328-331, 1980.
62. Pizarro D, Posada G, Levine MM, Mohs E. Oral rehydration of infants with acute diarrhoeal dehydration: a practical method. *J Trop Med Hyg* 83:241-245, 1980.
63. Levine MM, Hughes TP, Black RE, Clements ML, Matheny S, Siegel A, Cleaves F, Gutierrez C, Foote D, Smith W. Variability of sodium and sucrose levels of simple sugar/salt oral rehydration solutions prepared under optimal and field condition. *J Pediatr* 97:324-327, 1980.

64. Nalin DR, Harland E, Ramlal A, Swaby D, McDonald J, Gangarosa R, Levine M, Akierman A, Antoine M, Mackenzie K, Johnson B. Comparison of low and high sodium and potassium content in oral rehydration solutions. *J Pediatr* 97:848-853, 1980.
65. Murphy BR, Chanock RM, Douglas RG, Betts RF, Waterman DH, Holley HP Jr, Hoover DL, Suwanagool S, Nalin DR, Levine MM. Temperature-sensitive mutants of influenza A virus: evaluation of the A/Alaska/77-ts-1A2 temperature-sensitive recombinant virus in seronegative adult volunteers. *Arch Virol* 65:169-173, 1980.
66. Murphy BR, Markoff LJ, Chanock RM, Spring SB, Maassab HF, Kendal AP, Cox NJ, Levine MM, Douglas RG Jr, Betts RF, Couch RB, Cate TF Jr. Genetic approaches to attenuation of influenza A viruses for man. *Philos Trans R Soc Lond (Biol.)* 228:401-415, 1980.
67. Clements ML, Levine MM, Black RE, Robins-Browne RM, Cisneros LA, Drusano GL, Lanata CF, Saah AJ. Lactobacillus prophylaxis for diarrhea due to enterotoxigenic *Escherichia coli*. *Antimicrob Ag Chemother* 20:104-108, 1981.
68. Murphy BR, Chanock RM, Clements ML, Anthony WC, Saah AJ, Cisneros LA, Rennels MB, Miller EH, Black RE, Levine MM, Maassab HF, Cox NJ, Kendal AP. Evaluation of A/Alaska/6/77 (H3N2) cold-adapted recombinant viruses derived from the A/Ann Arbor/6/60 cold-adapted donor virus in adult seronegative volunteers. *Infect Immun* 32:693-697, 1980.
69. Robins-Browne RM, Levine MM. The fate of ingested Lactobacilli in the proximal small intestine. *Am J Clin Nutr* 34:514-519, 1981.
70. Robins-Browne R, Levine MM. Effect of chlorpromazine on intestinal secretion mediated by *Escherichia coli* heat-stable enterotoxin and 8-Br-Cyclic GMP in mice. *Gastroenterology* 80:321-326, 1981.
71. Huang C, Levine MM, Woodward WE, Gopalakrishna GS, Nalin DR, Hornick RB, Nichols BL. Biohydrogenation of cholesterol as an index of bacterial 7 - dehydroxylase activity. *Lipids* 16:670-675, 1981.
72. Levine MM, Clements ML, Black RE, Hughes TP, Blum D, Andino R, Corrales G. A practical, reliable method for preparing simple sugar/salt oral rehydration solutions. *J Trop Med Hyg* 84:73-76, 1981.
73. Clements ML, Levine MM, Cleaves F, Hughes TP, Caseres M, Aleman E, Black RE, Rust J. Comparison of simple sugar/salt versus glucose/electrolyte oral rehydration solutions in infant diarrhoea. *J Trop Med Hyg* 84:189-194, 1981.
74. Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR. The quality and duration of infection-derived immunity to cholera. *J Infect Dis* 143:818-820, 1981.
75. Levine MM, Young CR, Hughes TP, O'Donnell S, Black RE, Clements ML, Robins-Browne T, Lim YL. Duration of serum antitoxin response following *Vibrio cholerae* infection in North Americans: relevance for seroepidemiology. *Am J Epidemiol* 114:348-354, 1981.
76. Mendoza HR, Levine MM, Kapikian AZ, Martinez JD, Dominguez JA, Montero MM. Factores etiologicos de la diarrea aguda del lactante en la Republica Dominicana. *Arch Dom Pediat* 17:3-51, 1981.
77. Levine MM, Kaper JB. The significance of *Vibrio cholerae* in the United States. *Clin Microbiol Newsletter* 3:162-164, 1981.
78. Pizarro D, Posada G, Levine MM, Mohs E. Tratamiento oral de la deshidratación hipernatremica. *Act Med Cost* 24:341-346, 1981.
79. Snyder JD, Allegra DT, Levine MM, Craig JP, Feeley JC, DeWitt WE, Blake PA. Serologic studies of naturally acquired infection with *Vibrio cholerae* O Group 1 in the United States. *J Infect Dis* 143:182-187, 1981.

80. Candy DCA, Leuang TSM, Mak RHK, Harries JT, Marshall WC, Phillips AD, Robins-Browne R, Chadwick MV, Levine MM. A fimbrial antigen mediating adhesion and hemagglutination of *Escherichia coli* from children. *FEMS Microbiol Lett* 15:325-329, 1982.
81. Hobbins TE, Hughes TP, Rennels MB, Murphy BR, Levine MM. Bronchial reactivity in experimental influenza virus infections. *J Infect Dis* 146:468-471, 1982.
82. Levine MM. Oral therapy for diarrhoea: past, present and future. *J Trop Med Hyg* 84:185-187, 1982.
83. Clements ML, Levine MM, Young CR, Black RE, Lim YL, Robins-Browne RM, Craig JP. Magnitude, kinetics and duration of vibriocidal responses in North Americans following ingestion of *Vibrio cholerae*. *J Infect Dis* 145:465-473, 1982.
84. Black RE, Levine MM, Clements ML, Angle P, Robins-Browne R. Proliferation of enteropathogens in oral rehydration solutions prepared with river water from Honduras and Surinam. *J Trop Med Hyg* 84:195-197, 1982.
85. Levine MM. Bacillary dysentery - mechanism and treatment. *Med Clin N Amer* 66:623-638, 1982.
86. Levine MM, Black RE, Clements ML, Cisneros L, Saah A, Nalin DR, Gill MD, Craig JP, Young CR, Ristaino R. Pathogenicity of non-enterotoxigenic *Vibrio cholerae* El Tor isolated from sewage water in Brazil. *J Infect Dis* 145:296-299, 1982.
87. Levine MM, Black RE, Brinton CC Jr, Clements ML, Fusco P, Hughes TP, O'Donnell S, Robins-Browne R, Wood S, Young CR. Reactogenicity, immunogenicity and efficacy studies of *Escherichia coli* type 1 somatic pill parenteral vaccine in man. *Scand J Infect Dis Supplement* 33:83-95, 1982.
88. Black RE, Levine MM, Clements ML, Cisneros L, Daya V. Treatment of experimentally induced enterotoxigenic *Escherichia coli* diarrhea with trimethoprim, trimethoprim/sulfamethoxazole, or placebo. *Rev Infect Dis* 4:550-545, 1982.
89. Huang CTL, Levine MM, Daoud GS, Nalin DR, Nichols BL. Fecal steroids in diarrhea. IV. Cholera. *Lipids* 17:612-616, 1982.
90. Tolpin MD, Clements ML, Levine MM, Black RD, Saah AJ, Anthony WC, Cisneros L, Chanock RM, Murphy BR. Evaluation of a phenotypic revertant of the A/Alaska/77-ts-1A2 reassortant virus in hamsters and in seronegative adult volunteers: further evidence that the temperature-sensitive phenotype is responsible for attenuation of ts-1A2 reassortant viruses. *Infect Immun* 36:645-650, 1982.
91. Black RE, Levine MM, Young CR, Rooney J, Levine S, Clements ML, O'Donnell S, Hughes TP, Chilean Typhoid Committee, Germanier R. Immunogenicity of Ty21a attenuated *Salmonella typhi* given with sodium bicarbonate or in enteric-coated capsules. *Develop Biol Standard* 53:9-14, 1982.
92. Levine MM. Conceptos Tradicionales sobre Diarrea Aguda: Viejos y nuevos agentes y agentes equivocicos. *Gen (Revista de la Sociedad Venezolana de Gastroenterologia)*. 36:9-11, 1982.
93. Levine MM. Diarreas bacterianas producidas por toxinas. *Gen (Revista de la Sociedad Venezolana de Gastroenterologia)*. 36:39-40, 1982.
94. Levine M.M. Empleo de los antibioticos y otras drogas en el tratamiento de la diarrea aguda. *Gen (Revista de la Sociedad Venezolana de Gastroenterologia)*. 36:107-108, 1982.

95. Levine MM. Vacunas contra agentes bacterianos. Gen (Revista de la Sociedad Venezolana de Gastroenterologia). 36:121-122, 1982.
96. Wyatt RG, Kapikian AZ, Greenberg HA, Kalica AR, Flores J, Hoshino Y, Chanock RM, Levine MM. Development of vaccines against rotavirus disease. Prog Food Nutr Sci 7:189-192, 1982.
97. Robins-Browne RM, Levine MM, Rowe B, Gabriel EM. Failure to detect conventional enterotoxin in classical enteropathogenic (serotyped) *Escherichia coli* strains of proven pathogenicity. Infect Immun 38:798-801, 1982.
98. Levine MM, Black RE, Lanata C, Chilean Typhoid Committee. A precise estimation of chronic *Salmonella typhi* carriers in Santiago, Chile, an endemic area. J Infect Dis 146:724-726, 1982.
99. Kapikian AZ, Wyatt RG, Levine MM, Yolken RH, Van Kirk DH, Dolin R, Greenberg HB, Chanock RM. Oral administration of a human rotavirus to volunteers: induction of illness and correlates of resistance. J Infect Dis 147:95-106, 1983.
100. Clements ML, Levine MM, Ristaino P, Daya VE, Hughes TP. Exogenous Lactobacilli fed to man - their fate and ability to prevent diarrheal disease. Prog Food Nutr Sci 7:29-37, 1983.
101. Levine MM, Lanata C. Progresos en vacunas contra diarrea bacteriana. Adelantos Microbiol Enferm Infecc 2:67-117, 1983.
102. Levine MM, Ristaino P, Sack RB, Kaper JB, Orskov F, Orskov I. Colonization factor antigens I and II and type 1 somatic pili in enterotoxigenic *Escherichia coli*: relation to enterotoxin type. Infect Immun 39:889-897, 1983.
103. Clements ML, O'Donnell S, Levine MM, Chanock RM, Murphy BR. Dose response of A/Alaska/6/77 (H3N2) cold-adapted recombinant vaccine virus in adult volunteers - role of local antibody in resistance to infection with vaccine virus. Infect Immun 40:1044-1051, 1983.
104. Pizarro D, Posada G, Villavicencio N, Mohs E, Levine MM. Hypernatremic and hyponatremic diarrheal dehydration treated with oral glucose/electrolyte solution (90 mmol/l sodium). Am J Dis Child 137:730-734, 1983.
105. Baldini MM, Kaper JB, Levine MM, Candy DCA, Moon HW. Plasmid mediated adhesion in enteropathogenic *Escherichia coli*. J Ped Gastroenterol 2:534-538, 1983.
106. Levine MM. Vaccines to prevent travelers' diarrhea. Therapeutische Umschau 40:253-256, 1983.
107. Levine MM. Traveller's diarrhoea: prospects for successful immunoprophylaxis. Scand J Gastroenterol vol. 18 (supplement 84):121-134, 1983.
108. Ristaino P, Levine MM, Young CR. An improved GM₁-enzyme-linked immunosorbent assay for the detection of *Escherichia coli* heat-labile enterotoxin. J Clin Microbiol 18:808-815, 1983.
109. Levine MM, Kaper JB, Lockman H, Black RE, Clements ML. Recombinant DNA risk assessment studies in man: efficacy of poorly-mobilized plasmids in biologic containment. J Infect Dis 148:699-709, 1983.
110. Levine MM, Black RE, Clements ML, Young CR, Lanata C, Sears S, Honda T, Finkelstein R. Texas Star-SR: Attenuated *Vibrio cholerae* oral vaccine candidate. Develop Biol Standard 53:59-65, 1983.
111. Moon HW, Whipp SC, Argenzio RA, Levine MM, Gianella RA. Attaching and effacing activities of rabbit and human enteropathogenic *Escherichia coli* in pig and rabbit intestines. Infect Immun 41:1340-1351, 1983.
112. Lanata CF, Levine MM, Ristori C, Black RE, Jimenez L, Salcedo M, Garcia J, Sotomayor V. Vi Serology in the detection of chronic *Salmonella typhi* carriers in an endemic area. Lancet II:441-443, 1983.

113. Edelman RE, Levine MM. Summary of a workshop on enteropathogenic *Escherichia coli*. J Infect Dis 147:1108-1118, 1983.
114. Clements ML, Wisseman CL, Woodward TE Jr, Fiset P, Dumler JS, McNamee W, Black RE, Rooney J, Hughes TP, Levine MM. Reactogenicity, immunogenicity, and efficacy of a chick embryo cell-derived vaccine for Rocky Mountain Spotted Fever. J Infect Dis 148:922-930, 1983.
115. Clements ML, Dumler JS, Fiset P, Wisseman CL Jr, Levine MM. Serodiagnosis of Rocky Mountain Spotted Fever: comparison of IgM and IgG enzyme-linked immunosorbent assay and indirect fluorescent antibody test. J Infect Dis 148:876-880, 1983.
116. Levine MM, Kaper JB, Black RE, Clements ML. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev 47:510-550, 1983.
117. Taylor DN, Harris JR, Barrett TJ, Hargrett NT, Valdivieso C, Palomino C, Levine MM, Blake PA. Detection of urinary Vi antigen as a diagnostic test for typhoid fever. J Clin Microbiol 18:872-876, 1983.
118. Levine MM, Pizarro D. Advances in therapy of diarrheal dehydration. Adv Pediatr 31: , 1993.
119. Kapikian AZ, Wyatt RG, Levine MM, Black RE, Greenberg HB, Flores J, Kalica AR, Hoshino Y, Chanock R.M. Studies in volunteers in human rotaviruses. Develop Biol Standard 53:209-218, 1983.
120. Svennerholm A-M, Holmgren J, Black R, Levine M, Merson M. Serologic differentiation between antitoxin responses to infection with *Vibrio cholerae* and enterotoxin-producing *Escherichia coli*. J Infect Dis 147:514-522, 1983.
121. Kaper JB, Lockman H, Baldini MM, Levine MM. Recombinant nontoxigenic *Vibrio cholerae* strains as attenuated cholera vaccine candidates. Nature 308:655-658, 1984.
122. Levine MM, Black RE, Clements ML, Kaper JB. Present status of cholera vaccines. Biochem Soc Trans 12:200-202, 1984.
123. Levine MM, Black RE, Clements ML, Lanata C, Sears S, Honda T, Young CR, Finkelstein RA. Evaluation in man of attenuated *Vibrio cholerae* El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun 43:515-522, 1984.
124. Levine MM, Edelman R. Enteropathogenic *Escherichia coli* of classical serotypes associated with infant diarrhea-epidemiology and pathogenesis. Epidemiol Rev 6:31-51, 1984.
125. Pizarro D, Posada G, Levine MM. Hypernatremic diarrheal dehydration treated with "slow" (12 hour) oral rehydration therapy: a preliminary report. J Pediat 104:316-319, 1984.
126. Kaper JB, Lockman H, Baldini MM, Levine MM. Recombinant live oral cholera vaccine. Biotechnology 2:345-349, 1984.
127. Ferreccio C, Levine MM, Manterola A, Rodriguez G, Rivara I, Prentzel I, Black RE, Mancuso T, Bulas D. Benign bacteremia due to *Salmonella typhi* and *paratyphi* in children less than two years of age. J Pediat 104:899-901, 1984.
128. Sears SD, Ferreccio C, Levine MM, Cordano AM, Monreal J, Black RE, D'Ottone K, Rowe B, Chilean Typhoid Committee. Isolation of *Salmonella typhi* from irrigation water in Santiago, Chile using Moore swabs. J Infect Dis 149:640-642, 1984.

129. Booth IW, Levine MM, Harries JT. Oral rehydration therapy in acute diarrhoea in childhood. *J Pediat Gastro Nutr* 3:491-499, 1984.
130. Levine MM, Ristaino P, Marley G, Smyth C, Knutton S, Boedeker E, Black R, Young C, Clements ML, Cheney C, Patnaik R. Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic *Escherichia coli*: morphology, purification, and immune responses in humans. *Infect Immun* 44:409-420, 1984.
131. Sears SD, Richardson K, Young C, Parker CD, Levine MM. Evaluation of the human response to outer membrane proteins of *Vibrio cholerae*. *Infect Immun* 4:439-444, 1984.
132. O'Brien AD, Chen ME, Holmes RK, Kaper J, Levine MM. Environmental and human isolates of *Vibrio cholerae* and *Vibrio parahaemolyticus* produce a *Shigella dysenteriae* 1 (Shiga)-like cytotoxin. *Lancet* I:77-78, 1984.
133. Morris JG Jr, Ferreccio C, Garcia J, Lobos H, Black RE, Rodriguez H, Levine MM. Typhoid fever in Santiago, Chile: a study of household contacts of pediatric patients. *Am J Trop Med Hyg* 33:1198-1202, 1984.
134. Svennerholm AM, Levine MM, Holmgren J. Weak serum and intestinal antibody responses to *Vibrio cholerae* soluble hemagglutinin in cholera patients. *Infect Immun* 45:792-794, 1984.
135. Nataro JP, Scaletsky ICA, Kaper JB, Levine MM, Trabulsi LR. Plasmid-mediated factors conferring diffuse and localized adherence of enteropathogenic *Escherichia coli*. *Infect Immun* 48:378-383, 1985.
136. Murray BE, Levine MM, Cordano AM, D'Ottone K, Jayanetra P, Kopecko D, Pan-Urai R, Prenzel I. Possible reasons for the paucity of resistance plasmids in *Salmonella typhi*. *J Infect Dis* 151:551-555, 1985.
137. Levine MM, Young CR, Black RE, Takeda Y, Finkelstein RA. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of *Escherichia coli* and to cholera toxin: application in serodiagnosis and seroepidemiology. *J Clin Microbiol* 21:174-179, 1985.
138. Black RE, Cisneros L, Levine MM, Banfi A, Lobos H, Rodriguez H. A case-control study to identify risk factors for endemic typhoid fever in Santiago, Chile. *Bull Wld Hlth Org* 63:899-904, 1985.
139. Nataro JP, Baldini MM, Kaper JB, Black RE, Levine MM. Detection of an adherence factor of enteropathogenic *Escherichia coli* with a DNA probe. *J Infect Dis* 152:560-565, 1985.
140. Levine MM, Nataro JP, Baldini MM, Kaper JB, Black RE, Clements ML, O'Brien AD. The diarrheal response of humans to some classical serotype enteropathogenic *Escherichia coli* is dependent on a plasmid encoding an enteroadhesiveness factor. *J Infect Dis* 152:550-559, 1985.
141. Lanata CF, Kaper JB, Baldini MM, Black RE, Levine MM. Sensitivity and specificity of DNA probes for the detection of *E. coli* enterotoxins using the stool blot technique. *J Infect Dis* 152:1087-1090, 1985.
142. Levine MM. *Escherichia coli* infections. *N Eng J Med* 313:445-447, 1985.
143. Levine MM, Losonsky G, Herrington D, Kaper JB, Tacket C, Rennels MB, Morris JG. Pediatric diarrhea: the challenge of prevention. *J Pediat Infect Dis* 5(supplement):S29-S43, 1986.
144. Losonsky GA, Rennels MB, Kapikian AZ, Midthun K, Ferra PJ, Fortier DN, Hoffman KM, Baig A, Levine MM. Safety, infectivity, transmissibility and immunogenicity of Rhesus rotavirus vaccine (MMU 18006) in infants. *J Pediat Infect Dis* 5:25-29, 1986.
145. Harris JR, Holmbert SC, Parker RDR, Kay DE, Barrett TJ, Young CR, Levine MM, Blake PA. Impact of epidemic cholera in a previously uninfected island population: evaluation of a new seroepidemiologic method. *Am J Epidemiol* 123:424-30, 1986.

146. Levine MM. Antimicrobial therapy for infectious diarrhea. Rev Infect Dis 8(supplement):S207-S216, 1986.
147. Avendano A, Herrera P, Horwitz I, Duarte E, Prenzel I, Lanata C, Levine MM. Duodenal string cultures: practicality and sensitivity for diagnosing enteric fever in children. J Infect Dis 159:356-362, 1986.
148. Edelman RE, Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis 8:329-349, 1986.
149. Rennels MB, Levine MM. Classical bacterial diarrhea: perspectives and update -- *Salmonella*, *Shigella*, *Escherichia coli*, *Aeromonas* and *Plesiomonas*. J Pediat Infect Dis 5:(supplement):S91-S100, 1986.
150. Maher K, Morris JG Jr, Gotuzzo E, Benavente L, Black RE, Ward LR, Levine MM. Molecular techniques in the study of *Salmonella typhi* in epidemiologic studies in endemic areas: comparison with Vi phage typing. Am J Trop Med Hyg 35:831-835, 1986.
151. Tacket CO, Ferreccio C, Robbins JB, Tsai-C-M, Schulz D, Cadoz M, Goudeau A, Levine MM. Safety and immunogenicity of two *Salmonella typhi* Vi capsular polysaccharide vaccines. J Infect Dis 154:342-345, 1986.
152. Thompson MR, Jordan RL, Luttrell MA, Brandwein H, Kaper JB, Levine MM, Gianella RA. A blinded two laboratory comparative analysis of *E. coli* STa production using monoclonal antibody ELISA, radioimmunoassay, suckling mouse assay and gene probe analysis. J Clin Microbiol 24:753-758, 1986.
153. Rennels MB, Losonsky GA, Staciak JY, Hughes TP, Levine MM. A preliminary evaluation of the efficacy of Rhesus rotavirus vaccine strain MMU 18006 in young children. J Pediat Infect Dis 5:587-5588, 1986.
154. Sears SD, Ferreccio C, Levine MM. Sensitivity of Moore Sewer swabs for isolating *Salmonella typhi*. Appl Environ Microbiol 51:425-426, 1986.
155. Levine MM, Ferreccio C, Black RE, Chilean Typhoid Committee, Germanier R. New Vaccines against typhoid fever. World Pediatrics and Child Care 3:15-126, 1987.
156. Rennels MB, Losonsky GA, Shindledecker C, Hughes TP, Kapikian AZ, Levine MM, Clinical Study Group. Immunogenicity and reactogenicity of lowered doses of Rhesus rotavirus vaccine strain MMU 18006 in young children. J Pediat Infect Dis 6:260-264, 1987.
157. Pizarro DT, Posada GS, Levine MM, Nalin DR, Mohs EV. Comparison of efficacy of oral rehydration fluids administered at 37 C or 23 C. J Trop Pediat 33:48-51, 1987.
158. Karch H, Heeseman J, Laufs R, O'Brien AD, Tacket CO, Levine MM. A plasmid of enterohemorrhagic *Escherichia coli* 0157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells. Infect Immun 55:455-461, 1987.
159. Herrington DA, Tzipori S, Robins-Browne R, Tall BD, Levine MM. *Plesiomonas shigelloides* - In vitro and In vivo studies of pathogenicity. Infect Immun 55:979-985, 1987.
160. Black RE, Levine MM, Clements ML, Losonsky G, Herrington D, Berman S, Formal SB. Prevention of shigellosis by a *Salmonella typhi*-*shigella sonnei* bivalent vaccine. J Infect Dis 155:1260-1265, 1987.
161. Levine MM. *Escherichia coli* that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic and enteroadherent. J Infect Dis 155:377-389, 1987.
162. Levine MM, Herrington D, Murphy JR, Morris JG, Losonsky G, Tall B, Lindberg A, Svenson S, Baqar S, Edwards MF, Stocker B. Safety, infectivity, immunogenicity and in vivo stability of two attenuated auxotrophic mutant strains of *Salmonella typhi*, 541Ty and 543Ty, as live oral vaccines in man. J Clin Invest 79:888-902, 1987.

163. Levine MM, Ferreccio C, Black RE, Chilean Typhoid Committee, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. *Lancet* I:1049-1052, 1987.
164. Levine MM, Xu J-G, Kaper JB, Lior H, Prado V, Tall B, Nataro J, Karch H, Wachsmuth IK. A DNA probe to identify enterhemorrhagic *Escherichia coli* 0157:H7 and other serotypes that cause hemorrhagic colitis and hemolytic uremic syndrome. *J Infect Dis* 156:175-182, 1987.
165. Black RE, Levine MM, Clements ML, Hughes T, O'Donnell S. Association between O blood group and occurrence and severity of diarrhoea due to *Escherichia coli*. *Trans Royal Soc Trop Med Hyg* 81:120-123, 1987.
166. Black RE, Levine MM, Clements ML, Young CR, Svennerholm A, Holmgren J. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera Toxin. *Infect Immun* 55:1116-1120, 1987.
167. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, Baqar S, Felix AM, Heimer EP, Gillesen D, Nardin EH, Nussenzweig RS, Nussenzweig V, Hollingdale MR, and Levine MM. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against *Plasmodium falciparum* sporozoites. *Nature* 328:257-259, 1987.
168. Nash TE, Herrington DA, Losonsky GA, Levine MM. Experimental human infections with *Giardia lamblia*. *J Infect Dis* 156:974-984, 1987.
169. Nataro JP, Kaper JB, Robins-Browne R, Prado V, Vial PA, Levine MM. Patterns of adherence of diarrheagenic *Escherichia coli* to HEp-2 cells. *Pediatr Infect Dis J* 6:829-831, 1987.
170. Losonsky GA, Ferreccio C, Kotloff KL, Kaintuck S, Robbins JB, Levine MM. Development and evaluation of an enzyme-linked immunosorbent assay for Vi antibodies in the detection of chronic *Salmonella typhi* carriers. *J Clin Micro* 25:2266-2269, 1987.
171. Shaw RD, Fong KJ, Losonsky GA, Levine MM, Maldonado Y, Yolken R, Flores J, Kapikian AZ, Vo PT, Greenberg HB. Epitope-specific immune responses to rotavirus. *Gastroenterology* 93:941-950, 1987.
172. Gotuzzo E, Morris JGJr, Benavente L, Wood PK, Levine O, Black RE, Levine MM. Association between specific plasmids and relapse in typhoid fever. *J Clin Microb* 25:1779-1781, 1987.
173. Tzipori S, Karch H, Wachsmuth KI, Robins-Browne RM, O'Brien AD, Lior H, Cohen ML, Smithers J, Levine MM. Role of a 60-megadalton plasmid and Shiga-Like toxins in the pathogenesis of infection caused by enterohemorrhagic *Escherichia coli* 0157:H7 in gnotobiotic piglets. *Infect Immun* 55:3117-3125, 1987.
174. Murphy JR, Baqar S, Munoz C, Schlesinger L, Ferreccio C, Lindberg AA, Svenson S, Losonsky G, Koster F, Levine MM. Characteristics of humoral and cellular immunity to *Salmonella typhi* in residents of typhoid-endemic and typhoid-free regions. *J Infect Dis* 156:1005-1009, 1987.
175. Murphy JR, Baqar S, Losonsky GA, Tacket CO, Lindberg AA, Levine MM. Human immunogenicity of orally administered typhoid vaccines, Ty21a and 541Ty-543-Ty. *Microecology and Therapy* 17:107-116, 1987.
176. Nash TE, Herrington DA, Levine MM. Usefulness of an enzyme-linked immunosorbent assay for detection of *Giardia* antigen in feces. *J Clin Microbiol* 25:1169-1171, 1987.
177. Tacket CO, Maneval DR, Levine MM. Purification, morphology and genetics of a new fimbrial putative colonization factor of enterotoxigenic *Escherichia coli* O159:H4. *Infect Immun* 55:1063-1069, 1987.
178. Tacket CO, Losonsky G, Link H, Hoang Y, Guesry P, Hilpert H, Levine MM. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic *Escherichia coli*. *N Eng J Med* 318:1240-1243, 1988.

179. Levine MM, Kaper KB, Herrington DA, Losonsky GA, Morris JG, Clements ML, Black RE, Tall BD, Hall R. Volunteer studies of deletion mutants of *Vibrio cholerae* 01 prepared by recombinant techniques. *Infect Immun* 56:161-167, 1988.
180. Kaper JB, Levine MM. Progress towards a vaccine against enterotoxigenic *Escherichia coli*. *Vaccines* 6:197-199, 1988.
181. Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental *Campylobacter jejuni* infection in humans. *J Infect Dis* 157:472-479, 1988.
182. Hall RE, Vial PA, Kaper JB, Mekalanos JJ, Levine MM. Morphological studies on fimbriae expressed by *Vibrio cholerae* 01. *Microb Pathogen* 4:257-265, 1988.
183. Levine MM, Prado V, Robins-Browne R, Lior H, Kaper JB, Moseley SL, Gicquelais K, Nataro JP, Vial P, Tall B. DNA probes and HEp-2 cell adherence assay to detect diarrheagenic *Escherichia coli*. *J Infect Dis* 158:224-228, 1988.
184. Vial P, Robins-Browne R, Lior H, Prado V, Nataro J, Kaper J, Elsayed A, Maneval D, Levine MM. Characterization of enteroadherent-aggregative *Escherichia coli*: a newly-defined agent of diarrheal disease. *J Infect Dis* 158:70-79, 1988.
185. Herrington DA, Clyde DF, Murphy JR, Baqar S, Levine MM, do Rosario V, Hollindale MR. A model for *Plasmodium falciparum* sporozoite challenge and very early therapy of parasitaemia for efficacy studies of sporozoite vaccines. *Trop Geog Med* 40:124-127, 1988.
186. Herrington DA, Hall RH, Losonsky GA, Mekalanos JJ, Taylor RK, Levine MM. Toxin, toxin-coregulated pili, and the *toxR* regulon are essential for *Vibrio cholerae* pathogenesis in humans. *J Exp Med* 168: 1487-1492, 1988.
187. Levine MM, Herrington DA, Clyde D, Murphy J, Davis J, Nussenzweig R, Nardin E, Felix A, Heimer E, Gillesen D, Baqar S, Hollingdale M, Nussenzweig V. Malaria vaccines: experience with sporozoite vaccines against falciparum malaria. *SE Asian J Trop Med Publ Hlth* 19:360-374, 1988.
188. Levine MM, Kaper JB, Herrington DA, Losonsky GA, Tacket C, Tall B. The current status of cholera vaccine development and experience with cholera vaccine trials in volunteers. *SE Asian J Trop Med Pub Hlth* 19:401-415, 1988.
189. Levine MM, Tacket CO, Herrington DA, Losonsky GA, Murphy J, Ferreccio C. The current status of typhoid vaccine development and clinical trials with typhoid vaccines. *SE Asian J Trop Med Publ Hlth* 19:459-469, 1988.
190. Levine MM, Kaper JB, Herrington DA, Ketley J, Losonsky GA, Tacket CO, Tall, Cryz S. Safety, immunogenicity and efficacy in man of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. *Lancet* II:467-470, 1988.
191. Levine MM, Vial PA. *Escherichia coli* that cause diarrhea. *Indian J Pediatr* 55:183-190, 1988.
192. Losonsky GA, Rennels MB, Lim Y, Krall G, Kapikian AZ, Levine MM. Systemic and mucosal immune responses to rhesus rotavirus vaccine MMU 18006. *Pediatr Infect Dis J* 7:388-393, 1988.
193. Herrington D, Rennels MB, Levine MM. Vacunas y otras medidas de prevención de gastroenteritis viral y bacteriana. *Boletín Escuela de Medicina, P Universidad Católica de Chile* 18:45-50, 1988.
194. Finch MJ, Morris JG Jr, Kaviti J, Kagwanja W, Levine MM. Molecular epidemiology of antimicrobial-resistant cholera in Kenya and East Africa. *Am J Trop Med Hyg* 39:484-490, 1988.

195. Tacket CO, Levine MM, Robbins JB. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. *Vaccine* 6:307-308, 1988.
196. Cryz SC, Fürer E, Levine MM. Zur Wirkamset des oralen, attenuierten Lebendimpfstoffes *Salmonella typhi* Ty21a in kontrollierten Feldversuchen. *Schweiz Med Wschr* 118:467-470.
197. Ferreccio C, Morris JG Jr, Valdivieso C, Prenzel I, Sotomayor V, Drusano GL, Levine MM. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. *J Infect Dis* 157:1235-1239, 1989.
198. DiJohn D, Torres JR, Murillo J, Herrington DA, Wasserman SS, Cortesia MJ, Losonsky GA, Sturcker D, Levine MM. Effect of priming with carrier on response to conjugate vaccine. *Lancet*: 1415-1418, 1989.
199. Kotloff KL, Wasserman SS, Steciak JY, Tall BD, Losonsky GA, Nair P, Morris JG, Levine MM. Acute diarrhea in Baltimore children attending an outpatient clinic. *Pediatr Infect Dis J* 7:753-759, 1989.
200. DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. *J Infect Dis* 159:1126-1128, 1989.
201. Ferreccio C, Levine MM, Rodriguez H, Contreras R, Chilean Typhoid Committee. Comparative efficacy of two, three, or four doses of Ty21A live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. *J Infect Dis* 159:766-769, 1989.
202. Murphy JR, Wasserman SS, Baqar S, Schlesinger L, Ferreccio C, Lindberg AA, Levine MM. Immunity to *Salmonella typhi*: considerations relevant to measurement of cellular immunity in typhoid-endemic regions. *Clin Exp Immunol* 75:228-233, 1989.
203. Bhan MK, Raj P, Levine MM, Kaper JB, Bhandari N, Srivastava R, Kumar R, Sazawal S. Enteroggregative *Escherichia coli* associated with persistent diarrhea in a cohort of rural children in India. *J Infect Dis* 159:1061-1064, 1989.
204. Levine MM, Taylor DN, Ferreccio C. Typhoid vaccines come of age. *Pediatr Infect Dis J* 8:374-381, 1989.
205. Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R. Progress in vaccines against typhoid fever. *Rev Infect Dis* 2 (supplement 3):S552-S567, 1989.
206. Kotloff KL, Losonsky GA, Morris JG, Wasserman SS, Singh-Naz N, Levine MM. Enteric adenovirus infection and childhood diarrhea: an epidemiologic study in three clinical settings. *Pediatrics* 84:219-225, 1989.
207. Richardson K, Kaper JB, Levine MM. Human immune response to *Vibrio cholerae* whole cells and isolated outer membrane antigens. *Infect Immun* 57:495-501, 1989.
208. Sharma DP, Thomas C, Hall RH, Levine MM, Altridge SR. Significance of toxin-coregulated pili as protective antigens of *Vibrio cholerae* in the infant mouse model. *Vaccine* 7:451-456, 1989.
209. Davis JR, Murphy JR, Baqar S, Clyde DF, Herrington DA, Levine MM. Estimate of anti-*Plasmodium falciparum* sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP)₃. *Trans Royal Soc Trop Med and Hygiene* 83:748-750, 1989.
210. Bhan MK, Bhandari N, Sazawal S, Clemens J, Raj P, Levine MM, Kaper JB. Descriptive epidemiology of persistent diarrhoea among young children in rural northern India. *Bull Wild Hlth Org* 67:281-288, 1989.
211. Hall RH, Maneval DR, Collins JH, Theibert JL, Levine MM. Purification and analysis of colonization factor antigen I, coli surface antigen 1, and coli surface antigen 3 fimbriae from enterotoxigenic *Escherichia coli*. *J Bacteriol* 171:6372-6374, 1989.

212. Levine MM, Hone D. Prospects for oral enteric vaccines. *Microecology and Therapy*. 18:85-94, 1989.
213. Nardin E, Herrington D, Davis JR, Levine M, Stuber D, Takacs B, Caspers P, Barr P, Altszuler R, Clavijo P, Nussenzweig RS. A conserved epitope is recognized by CD4⁺ clones from a malaria immunized volunteer. *Science* 246:1603-1606, 1989.
214. Migasena S, Pitisuttitham P, Prayurahong B, Suntharasami P, Supanaranond W, Desakorn V, Vongsthongsri U, Tall B, Ketley J, Losonsky G, Cryz S, Kaper JB, Levine MM. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. *Infect Immun* 57:3261-3264, 1989.
215. Levine MM. Vaccines against enteric infections. *Lancet* 335:958-961, 1990.
216. Tacket CO, Forrest B, Morono R, Attridge SR, LaBrooy J, Tall BD, Reymann M, Rowley D, Levine MM. Safety, Immunogenicity, and efficacy against cholera challenge in man of a typhoid-cholera hybrid vaccine derived from *S. typhi* Ty21a. *Infect Immun* 58:1620-1627, 1990.
217. Baudry B, Savarino SJ, Vial PA, Kaper JB, Levine MM. A sensitive and specific DNA probe to identify enteroaggregative *Escherichia coli*, a recently-discovered diarrheal pathogen. *J Infect Dis* 161:1249-1251, 1990.
218. Tacket CO, Moseley SL, Kay BA, Losonsky GA, Levine MM. Challenge studies in volunteers using *Escherichia coli* strains with diffuse adherence to HEP-2 cells. *J Infect Dis* 162:550-552, 1990.
219. Van de Verg L, Herrington DA, Murphy JR, Wasserman SS, Formal SB, Levine MM. Specific IgA secreting cells in peripheral blood following oral immunization with bivalent *Salmonella typhi/Shigella sonnei* vaccine or infection with pathogenic *S. sonnei* in humans. *Infect Immun* 58:2002-2004, 1990.
220. Levine MM, Hone D, Heppner DG, Noriega F, Sriwathana B. Attenuated *Salmonella* as carriers for the expression of foreign antigens. *Microecology and Therapy* 19:23-32, 1990.
221. Rennels MB, Losonsky GA, Young AE, Levine MM. An efficacy trial of the rhesus rotavirus vaccine in Maryland. *Am J Dis Child* 144:601-604, 1990.
222. Herrington DA, Van De Verg L, Formal SB, Hale TL, Tall BD, Cryz SJ, Tramont EC, Levine MM. Studies in volunteers to evaluate candidate *Shigella* vaccines: further experience with a bivalent *Salmonella typhi-Shigella sonnei* vaccine and protection conferred by previous *Shigella sonnei* disease. *Vaccine* 8:353-357, 1990.
223. Cryz SJ, Levine MM, Kaper JB. Randomized double-blind placebo-controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in adult Swiss. *Vaccine* 8:577-580, 1990.
224. Ferreccio C, Levine MM, Solari V, Misraji A, Astroza EL, Berrios G, Pefaur C. Deteccion de portadores cronicos de *S. typhi*: metodo practico aplicado a manipuladores de alimentos del centro de Santiago. *Rev Med Chile* 118:33-37, 1990.
225. Gicquelais KG, Baldini MM, Martinez J, Maggi L, Martin WC, Prado V, Kaper JB, Levine MM. Practical and economical method for using biotinylated DNA probes with bacterial colony blots to identify diarrhea-causing *Escherichia coli*. *J Clin Micro* 28:2485-2490, 1990.
226. Fasano A, Kay BA, Russell RG, Maneval DR, Levine MM. Enterotoxin and cytotoxin production by Enteroinvasive *Escherichia coli*. *Infect Immun* 58:3717-3723, 1990.
227. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in a randomized controlled field trial. *Lancet* 336:891-894, 1990.
228. Levine MM, Edelman R. Future vaccines against enteric pathogens. *Infect Disease Clin N Amer* 4:105-121, 1990.

229. Servos S, Chatfield S, Hone D, Levine MM, Dimitriadis G, Pickard D, Dougan G, Fairweather N, Charles I. Molecular cloning and characterization of the *aro D* gene encoding 3-dehydroquinase from *Salmonella typhi*. J Gen Micro 137:147-152, 1990.
230. Levine MM, Hone D, Tacket C, Ferreccio C, Cryz S. Clinical and field trials with attenuated *Salmonella typhi* as live oral vaccines and as "carrier vaccines". Res Microbiol 141:807-816, 1990.
231. Vial PA, Mathewson JJ, DuPont HL, Guers L, Levine MM. Comparison of two assay methods for patterns of adherence to HEp-2 cells of *Escherichia coli* from patients with diarrhea. J Clin Microbiol 28:882-885, 1990.
232. Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, Germanier R, and the Chilean Typhoid Committee. Efficacy of one or two doses of Ty21a *Salmonella typhi* vaccine in enteric-coated capsules in a controlled field trial. Vaccine 8:81-84, 1990.
233. Ferreccio C, Ortiz E, Astroza L, Rivera C, Clemens J, Levine MM. A population-based retrospective assessment of the disease burden resulting from invasive *Haemophilus influenzae* in infants and young children Santiago, Chile. Pediatr Infect Dis J 9:488-494, 1990.
234. Ketley J, Kaper JB, Herrington DA, Losonsky G, Levine MM. Diminished immunogenicity of a recombination-deficient derivative of *Vibrio cholerae* vaccine strain CVD 103. Infect Immun 58:1481-1484, 1990.
235. Herrington DA, Clyde DF, Davis JR, Baqar S, Murphy JR, Cortese JF, Bank RS, Nardin E, DiJohn D, Nussenzweig RS, Nussenzweig V, Torres JR, Murillo J, Cortesia M, Sturchler D, Hollingdale MR, Levine MM. Human studies with a synthetic peptide sporozoite vaccine (NANP)³-TT and immunization with irradiated sporozoites. Bull Wld Hlth Org 68 (supplement):33-37, 1990.
236. Nardin EH, Nussenzweig RS, Altszuler R, Herrington D, Levine MM, Murphy J, Davis JR, Bathurst I, Barr P, Romero P, Zavala F. Cellular and humoral immune responses to a recombinant *P. falciparum* CS protein in sporozoite-immunized rodents and human volunteers. Bull Wld Hlth Org 68 (supplement):85-87, 1990.
237. Kaper JB, Levine MM. Recombinant attenuated *Vibrio cholerae* strains used as live oral vaccines. Res Microbiol 141:901-906, 1990.
238. Savarino SJ, Fasano A, Robertson DC, Levine MM. Enterotoxigenic *Escherichia coli* elaborate a heat-stable enterotoxin demonstrable in an in vitro rabbit intestinal model. J Clin Invest 87:1450-1455, 1991.
239. Edelman R, Levine MM. Enteric Vaccines. Maryland Med J 40:199-203, 1991.
240. Levine MM. Vaccines and milk immunoglobulin concentrates for prevention of infectious diarrhea. J Pediatr 118 supplement:S129-S136, 1991.
241. Tacket CO, Losonsky G, Taylor DN, Baron L, Kopeck D, Cryz S, Levine MM. Lack of immune response to the Vi component of a Vi-positive variant of the *Salmonella typhi* live oral vaccine strain Ty21a in volunteer studies. J Infect Dis 163:901-904, 1991.
242. Cohen D, Green M, Block C, Slepon R, Ambar R, Wasserman S, Levine MM. Reduction of transmission of shigellosis by control of houseflies (*Musca domestica*). Lancet 337:993-997, 1991.
243. Levine O, Levine MM. Are houseflies (*Musca domestica*) mechanical vectors for transmitting *Shigella* infection? Rev Infect Dis. 13:688-696, 1991.
244. Hone DM, Harris AM, Chatfield S, Dougan G, Levine MM. Construction of genetically-defined double *aro* mutants of *Salmonella typhi*. Vaccine 9:810-816, 1991.

245. Ferreccio C, Prado V, Ojeda A, Cayazzo M, Abrego P, Guers L, Levine MM. Epidemiologic patterns of acute diarrhea and endemic *Shigella* infections in a poor periurban setting in Santiago, Chile. *Am J Epidemiol*. 134:614-627, 1991.
246. Black RE, Levine MM. Intestinal protein loss in shigellosis. *Nutr Res* 11:1215-1220, 1991.
247. Hall R, Losonsky G, Silveira APD, Taylor RK, Mekalanos JJ, Levine MM. Toxin coregulated pili, an essential colonization factor of *Vibrio cholerae* O1, are not immunogenic in humans. *Infect Immun*. 59:2508-2512, 1991.
248. Lagos R, Avendano A, Horwitz I, Musser JM, Hoiseth SK, Maneval DM Jr, Jones J, Levine MM, Dattas JP, Prenzel I, Enriquez N, Topelberg S, Olivan F, Morris JG Jr. Molecular epidemiology of *Haemophilus influenzae* within families in Santiago, Chile. *J Infect Dis* 164:1149-1153, 1991.
249. Morris JG Jr, Prado V, Ferreccio C, Robins-Browne RM, Bordun A-M, Cayazzo M, Kay BA, Levine MM. *Yersinia enterocolitica* isolated from two cohorts of young children in Santiago, Chile: incidence and lack of correlation between illness and proposed virulence factors. *J Clin Microbiol* 29:2784-2788, 1991.
250. Herrington DA, Davis J, Nardin E, Beier M, Cortese J, Eddy H, Losonsky G, Hollingdale M, Sztein M, Levine M, Nussenzweig R, Clyde D, Edelman R. Successful immunization of humans with irradiated sporozoites: humoral and cellular responses of the protected individuals. *Am J Trop Med Hyg* 45:539-547, 1991.
251. Levine MM. South America: The return of cholera. *Lancet* 338:45-46, 1991.
252. Clemens JD, Ferreccio C, Levine MM, Horwitz I, Rao M, Edwards K, Fritzell B. Impact of *Haemophilus influenzae* type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. *J Am Med Ass* 267:673-678, 1992.
253. Ferreccio C, Clemens JD, Avendano A, Horwitz I, Flores C, Avila L, Cayazzo M, Fritzell B, Cadoz M, Levine MM. The clinical and immunologic response of Chilean infants to *Haemophilus influenzae* type b polysaccharide-tetanus protein conjugate vaccine co-administered in the same syringe with DTP at two, four and six months of age. *Pediatr Infect Dis J*. 10:764-771, 1992.
254. Davis JR, Cortese JF, Herrington DA, Murphy JR, Clyde DF, Thomas AW, Baqar S, Cochran MA, Thanassi J, Levine MM. *Plasmodium falciparum*: in vitro characterization and human infectivity of a cloned line. *Experiment Parasitol* 74:159-168, 1992.
255. Tacket CO, Hone DM, Curtiss R III, Kelly SM, Losonsky G, Guers L, Harris AM, Edelman R, Levine MM. Comparison of the safety and immunogenicity of Δ aroC Δ aroD and Δ cya Δ crp *Salmonella typhi* strains in adult volunteers. *Infect Immun* 60:536-541, 1992.
256. Tacket CO, Hone DM, Losonsky G, Guers L, Edelman R, Levine MM. Clinical acceptability and immunogenicity of CVD 908 *Salmonella typhi* vaccine strain. *Vaccine* 10:443-446, 1992.
257. Kotloff K, Herrington D, Hale TL, Newland JW, Van de Verg L, Cogan JP, Snoy PJ, Sadoff JC, Formal SB, Levine MM. Safety, immunogenicity, and efficacy in monkeys and humans of invasive *Escherichia coli* K-12 hybrid vaccine candidates expressing *Shigella flexneri* 2a somatic antigen. *Infect Immun* 60:2218-2224, 1992.
258. Van de Verg L, Herrington D, Boslego J, Lindberg AA, Levine MM. Age-specific prevalence of serum antibodies to the invasion plasmid and lipopolysaccharide antigens of *Shigella* in Chilean and North American populations. *J Infect Dis* 166:158-161, 1992.
259. Su-Arehawaratana PS, Singharaj P, Taylor DN, Hoge C, Trofa A, Kuvanont K, Migasena S, Pitisuttitham P, Lim Y-L, Losonsky G, Kaper JB, Wasserman SS, Cryz S, Echeverria P, Levine MM. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. *J Infect Dis* 165:1042-1048, 1992.

260. Nataro JP, Deng Y, Maneval DR, German KL, Martin WC, Levine MM. Aggregative adherence fimbriae I of enteroaggregative *Escherichia coli* mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes. *Infect Immun* 60:2297-2304, 1992.
261. Levine MM, McEwen J, Losonsky G, Reymann M, Harari L, Brown JE, Taylor DN, Donohoue-Rolfe A, Cohen D, Bennish, Lim Y-L, Arnon R. Antibodies to Shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shiga dysentery. *J Clin Microbiol* 30:1636-1641, 1992.
262. Hone DM, Tacket CO, Harris AM, Kay B, Losonsky G, Levine MM. Evaluation in volunteers of a candidate live oral attenuated *Salmonella typhi* vaccine. *J Clin Invest* 90:412-420, 1992.
263. Kotloff KL, Hermann JE, Blacklow NR, Hudson RW, Morris JG Jr, Levine MM. Medical importance of astrovirus as a cause of diarrhea in Baltimore children. *Pediatr Infect Dis J* 11:587-589, 1992.
264. Echeverria P, Serichantalerg O, Changchawalit S, Baudry B, Levine MM, Orskov F, Orskov I. Tissue culture adherent *Escherichia coli* in infantile diarrhea. *J Infect Dis* 165:141-143.
265. Harpaz R, Edelman R, Wasserman SS, Levine MM, Davis JR, Sztein MB. Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course following challenge. *J Clin Invest* 90:515-523, 1992.
266. Kotloff KL, Wasserman SS, O'Donnell SA, Losonsky GA, Cryz SJ, Levine MM. Safety and immunogenicity in North America of a single dose of live oral cholera vaccine CVD 103-HgR: Results of a randomized, placebo-controlled, double-blind cross-over trial. *Infect Immun* 60:4430-4432, 1992.
267. Tacket CO, Losonsky GA, Nataro JP, Cryz SJ, Edelman R, Kaper JB, Levine MM. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. *J Infect Dis* 166:837-841, 1992.
268. Franco A, Gonzalez C, Levine MM, Lagos R, Hall RH, Hoffman SL, Moechtar MA, Gotuzzo E, Levine MM, Hone DM, Morris JG Jr. Further evaluation of the clonal nature of molecular and clinical characteristics of strains from Indonesia and Peru. *J Clin Microbiol* 30:2187-2190, 1992.
269. Cordovez A, Prado V, Maggi L, Cordero J, Martinez J, Misraji A, Rios R, Soza G, Ojeda A, Levine MM. Enterohemorrhagic *Escherichia coli* associated with hemolytic-uremic syndrome in Chilean children. *J Clin Microbiol* 30:2153-2157, 1992.
270. Tacket CO, Losonsky G, Lubeck MD, Davis AR, Mizutani S, Horwith G, Hung P, Edelman R, Levine MM. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. *Vaccine* 10:673-676, 1992.
271. Finch MJ, Franco A, Gotuzzo E, Carrillo C, Benavente L, Wasserman SS, Levine MM, Morris JG. Plasmids in *Salmonella typhi* in Lima Peru, 1987-1988: epidemiology and lack of association with severity of illness or clinical complications. *Am J Trop Med Hyg* 47:390-396, 1992.
272. Cryz SJ Jr., Levine MM, Losonsky GA, Kaper JB, Althaus B. Safety and immunogenicity of a booster dose of *Vibrio cholerae* CVD 103-HgR live oral cholera vaccine in Swiss adults. *Infect Immun* 60:3916-3917, 1993.
273. Olanratmanee T, Levine MM, Losonsky GA, Thisyakorn U, Cryz SJ Jr. Safety and immunogenicity of *Salmonella typhi* Ty21a liquid formulation vaccine in 4- to 6-year-old Thai children. *J Infect Dis* 166:451-452, 1992.
274. Suharyono, Simanjuntak C, Witham N, Punjabi N, Heppner DG, Losonsky GA, Totosudirjo H, Rifai AR, Clemens J, Lim YL, Burr D, Wasserman SS, Kaper J, Sorenson K, Cryz S, Levine MM. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. *Lancet* 340:689-694, 1992.

275. Makowiak PA, Wasserman SS, Levine MM. A critical appraisal of 37°C (98.6°F), the upper limit of the normal body temperature and other legacies of Carl Reinhold August Wunderlich. *JAMA* 268:1578-1580, 1992.
276. Morris, JG Jr., Tacket CO, Levine MM. Oral carrier vaccines: New tricks in an old trade. *Gastroenterology* 103:699-702, 1992.
277. Herrington DA, Losonsky GA, Smith G, Volvovitz F, Cochran M, Jackson K, Hoffman SL, Gordon DM, Levine MM, Edelman RE. Safety and immunogenicity in volunteers of a recombinant *Plasmodium falciparum* circumsporozoite protein malaria vaccine produced in Lepidopteran cells. *Vaccine* 10:841-846, 1992.
278. Prado V, Ferreccio C, Levine MM, Morris JG, Marinkovic K, Cayazzo M, Reyes R. Perfil clinico y microbiologico de las infecciones entericas por *Yersinia enterocolitica* en ninos de Santiago, Chile. *Rev Chil Pediatr* 63:121-127, 1992.
279. Franco A, Gonzalez C, Levine OS, Lagos R, Hall RH, Hoffman SL, Moechtar MA, Gotuzzo E, Levine MM, Hone DM, Morris JG. Further consideration of the clonal nature of *Salmonella typhi*: Evaluation of molecular and clinical characteristics of strains from Indonesia and Peru. *J Clin Microbiol* 30:2187-2190, 1992.
280. Mackowiak PA, Wasserman SS, Levine MM. An analysis of the quantitative relationship between oral temperature and severity of illness in experimental shigellosis. *J Infect Dis* 166:1181-1182, 1992.
281. Chatfield SN, Fairweather N, Charles I, Pickard D, Levine MM, Hone D, Posada M, Strugnell RA, Dougan G. Construction of a genetically defined *Salmonella typhi* Ty2 aroA, aroC mutant for the engineering of a candidate live oral typhoid-tetanus vaccine. *Vaccine* 10:8-11, 1992.
282. Tzipori S, Montanaro J, Robins-Browne RM, Vial P, Gibson R, Levine MM. Studies with enteroaggregative *Escherichia coli* in the gnotobiotic piglet gastroenteritis model. *Infect Immun* 60:5302-5306, 1992.
283. Levine MM, Kaper JB. Live oral vaccines against cholera: An update. *Vaccines* 11:207-212 1993.
284. Cohen MB, Hawkins JA, Weckbach LS, Staneck JL, Levine MM, Heck JE. Colonization by enteroaggregative *Escherichia coli* in travelers with and without diarrhea. *J Clin Microbiol* 31:351-353, 1993.
285. Losonsky GA, Tacket CO, Wasserman SS, Kaper JB, Levine MM. Secondary *Vibrio cholerae* specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: Changes with time and lack of correlation and protection. *Infect Immun* 61:729-733, 1993.
286. Cryz SJ Jr, Vanprapar N, Thisyakorn U, Olanratamanee T, Losonsky G, Levine MM, Chearskul S. Safety and immunogenicity of *Salmonella typhi* Ty21a vaccine in young children. *Infect Immun* 61:1149-115, 1993.
287. Wolf MK, Taylor DN, Boedeker EC, Hyams KC, Maneval DR, Levine MM, Tamura K, Wilson RA, Echeverria P. Characterization of enterotoxigenic *Escherichia coli* isolated from US troops deployed to the Middle East. *J Clin Microbiol* 31:851-856, 1993.
288. Makowiak PA, Wasserman SS, Levine MM. Relationship between humoral immune responses and oral temperature during human shigellosis. *J Infect Dis* 167:1449-1452, 1993.
289. Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, Losonsky G, Lanata D, Wasserman S, Salazar E, Kaper J, Cryz S, Levine M. The safety, immunogenicity and excretion pattern of single-dose live oral cholera vaccine, CVD 103-HgR in Peruvian adults of high and low socioeconomic level. *Infect Immun* 61:3994-3997, 1993.
290. Weintraub A, Leontein K, Widmalm G, Vial PA, Levine MM, Lindberg AA. Structural studies of the O-antigenic polysaccharide of an enteroaggregative *Escherichia coli* strain. *Euro J Biochem* 213:859-864, 1993.

291. Savarino SJ, Fasano A, Watson J, Martin BM, Levine MM, Guandalini S, Guerry P. Enteraggregative *Escherichia coli* heat-stable enterotoxin 1 represents another subfamily of *E. coli* heat-stable toxin. PNAS 90:3093-3097, 1993.
292. Edelman R, Russell RG, Losonsky G, Tall BD, Tacket CO, Levine MM, Lewis DH. Immunization of rabbits with enterotoxigenic *E. coli* colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide). Vaccine 11:155-158, 1993.
293. Donnenberg, Tacket CO, James SP, Losonsky GA, Nataro JP, Wasserman SS, Kaper JB, Levine MM. The role of the *eaeA* gene in experimental enteropathogenic *Escherichia coli* infection. J Clin Invest 92:1412-1417, 1993.
294. Lagos R, Avendaño A, Horwitz I, Prado V, Ferreccio C, Sotomayor V, Losonsky G, Wasserman S, Cryz S, Kaper JB, Levine M. Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated *Vibrio cholerae* 01 strain: A double blind study in Chilean adults. Rev Méd Chile 121:857-863, 1993.
295. Avendaño A, Ferreccio C, Lagos R, Horwitz I, Cayazzo M, Fritzell B, Meschievitz C, Levine M. *Haemophilus influenzae* type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 12:638-643, 1993.
296. Simanjuntak CH, O'Hanley P, Punjabi NH, Noriega F, Pazzaglia G, Dykstra P, Kay B, Suharyono, Budiarto A, Rifai A, Wasserman SS, Losonsky GA, Kaper J, Cryz S, Levine MM. The safety, immunogenicity and transmissibility of single-dose live oral cholera vaccine CVD 103-HgR in 24 to 59 month old Indonesian children. J Infect Dis 168:1169-76, 1993.
297. Ketley JM, Michalski J, Galen J, Levine MM, Kaper JB. Construction of genetically-marked *Vibrio cholerae* 01 vaccine strains. FEMS Microbiol Lett 111:15-21, 1993.
298. Levine MM, Ferreccio C, Prado V, Cayazzo M, Abrego P, Martinez J, Maggi L, Baldinid MM, Martin W, Maneval D, Kay B, Guers L, Lior H, Wasserman SS, Nataro JP. Epidemiologic studies of *Escherichia coli* diarrheal infections in a low socioeconomic level periurban community in Santiago, Chile. Amer J Epi 138:849-869, 1993.
299. Pongsuk S, Sarosombath S, Ekpo P, Tangtherawattana, Levine MM. Production of monoclonal antibodies to Vi polysaccharide antigen of *Salmonella typhi*. Asian Pacific J Allergy and Immunology 11:53-56, 1993.
300. Mahle W and Levine MM. *salmonella typhi* infection in children younger than five years of age. pediatr Infect Dis J 12:627-631, 1993.
301. Kaper JB, Michalski J, Ketley JM, Levine MM. Potential for reacquisition of cholera enterotoxin genes by attenuated *Vibrio cholerae* vaccine strain CVD 103-HgR. Infect Immun 62:1480-1483, 1994.
302. Hone DM, Harris AM, Levine MM. Adaptive acid tolerance response by *Salmonella typhi* and candidate live oral typhoid vaccine strains. Vaccine 12:895-898, 1994.
303. Wasserman SS, Kotloff KL, Losonsky GA, Levine MM. Immunological response to oral cholera vaccination in a crossover study: a novel placebo effect. Am J Epidemiol 138: 988-993, 1993.
304. Tacket CO, Losonsky G, Nataro JP, Cryz SJ, Edelman R, Fasano A, Michalski J, Kaper JB, Levine MM. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a $\Delta ctxA \Delta zot \Delta ace$ derivative of El Tor Ogawa *Vibrio cholerae*. J Infect Dis 168:1536-1540, 1993.
305. Giron J, Levine MM, Kaper JB. Longus: a long pilus ultrastructure produced by enterotoxigenic *Escherichia coli*. Molec Microbiol 12:71-82, 1994.
306. Levine MM, Noriega F. Vaccines to prevent bacterial enteric infections in children. Pediatr Ann 22:719-725, 1993.

307. Levine MM, Noriega F. Current status of vaccine development for enteric diseases. *Semin Pediatr Infect Dis* 5:243-250, 1994.
308. Levine MM, Levine OS. Changes in human ecology and behaviour in relation to the emergence of diarrheal diseases, including cholera. *Proc Natl Acad Sci, USA* 91:2390-2394, 1994.
309. Gonzalez C, Hone D, Noriega F, Tacket CO, Davis JR, Losonsky G, Nataro JP, Hoffman S, Malik A, Nardin E, Sztein MB, Heppner DG, Fouts TR, Isibasi A, Levine MM. *Salmonella typhi* strain CVD 908 expressing the circumsporozoite protein of *Plasmodium falciparum*: strain construction, safety and immunogenicity. *J Infect Dis* 169:927-931, 1994.
310. Sztein MB, Wasserman SS, Tacket CO, Edelman R, Hone D, Lindberg AA, Levine MM. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of *Salmonella typhi*. *J Infect Dis* 170:1508-1517, 1994.
311. Wasserman SS, Losonsky GA, Noriega F, Tacket CO, Castañeda E, Levine MM. Kinetics of the vibriocidal antibody response to live oral cholera vaccine. *Vaccine* 12:1000-1003, 1994.
312. Kotloff KL, Losonsky GA, Nataro JP, Wasserman SS, Hale TL, Taylor DN, Newland JW, Sadoff JC, Formal SB, Levine MM. Evaluation of the safety, immunogenicity and efficacy in healthy adults of four doses of live oral hybrid *Escherichia coli-Shigella flexneri* 2a vaccine strain EcSfta-2. *Vaccine* 13:495-502, 1995.
313. Medina EC, Widmalm G, Weintraub PA, Levine MM, Lindberg AA. Structural studies of the O-antigenic polysaccharides of *Escherichia coli* O3 and the enteroaggregative *Escherichia coli* strain 17-2. *Eur J Biochem* 224:191-196, 1994.
314. Hone DM, Harris AM, Lim V, Levine MM. Construction and characterization of isogenic O-antigen variants of *Salmonella typhi*. *Molec Microbiol* 13:525-530, 1994.
315. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. *Bull Wld Hlth Org* 72:957-971, 1994.
316. Pickard D, Li J, Roberts M, Maskell D, Hone D, Levine M, Dougan G, Chatfield S. Characterization of defined *ompR* mutants of *Salmonella typhi*: *ompR* is involved in the regulation of Vi polysaccharide expression. *Infect Immun* 62:3984-3993, 1994.
317. Noriega FR, Wang JY, Losonsky G, Maneval DR, Hone DM, Levine MM. Construction and characterization of attenuated Δ aroA Δ virG *Shigella flexneri* 2a strain CVD 1203, a prototype live oral vaccine. *Infect Immun* 62:5168-5172, 1995.
318. Tacket CO, Losonsky G, Nataro JP, Wasserman SS, Cryz SJ, Edelman R, Levine MM. Extension of the volunteer challenge model to study South American cholera in a population of volunteers with predominantly blood group antigen O. *Trans Roy Soc Trop Med Hyg* 89:75-77, 1995.
319. Lagos R, Avendaño A, Prado V, Horwitz I, Wasserman SS, Losonsky G, Cryz SC jr., Kaper JB, Levine MM. Attenuated live oral cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. *Infect Immun* 63:707-709, 1995.
320. Levine MM, Noriega F. A review of the current status of enteric vaccines. *Papua New Guinea Medical Journal* 38:325-331, 1995.
321. Girón JA, Xu Jian-Guo, González CR, Hone DM, Kaper JB, Levine MM. Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic *Escherichia coli* by \square aroC, \square aroD *Salmonella typhi* vaccine strain CVD 908. *Vaccine* 10:939-946, 1995.

- 322. Comstock LE, Maneval D Jr, Pinagrahi P, Joseph A, Levine MM, Kaper JB, Morris JG Jr, Johnson JA. The capsule and O antigen in *Vibrio cholerae* O139 Bengal are associated with a genetic region not present in *Vibrio cholerae* O1. *Infect Immun* 63:317-323, 1995.
- 323. Nataro JP, Yikang D, Cookson C, Cravioto A, Savarino SJ, Guers LD, Levine MM, Tacket CO. Heterogeneity of enteroaggregative *Escherichia coli* virulence demonstrated in volunteers. *J Infect Dis* 171:465-468, 1995.
- 324. Colwell RR, Brayton P, Herrington D, Tall B, Huq A, Levine MM. Viable but non-culturable *Vibrio cholerae* O1 revert to a cultivable state in the human intestine. *World J Microbiol Biotechnol*, 12:28-31, 1996.
- 325. Glynn JR, Hornick RB, Levine MM, Bradley DJ. Infecting dose and severity of typhoid: analysis of volunteer data and examination of the influence of the definition of illness used. *Epidemiol Infect* 115, 23-30, 1995.
- 326. Ojeda A, Prado V, Martinez J, Arellano C, Borczyk A, Johnson W, Lior H, Levine MM. Sorbitol-negative phenotype among enterohemorrhagic *Escherichia coli* of different serotypes and sources. *J Clin Microbiol*, 33:2199-2201, 1995.
- 327. Morris JG, Losonsky GE, Johnson JA, Tacket CO, Nataro JP, Panigrahi P, Levine MM. Clinical and immunologic char
- 328. Prado V, Cordero J, Garreaud C, Olguin H, Arellano C, Nachar CL, Misraji A, Martinez J, Tous M, Rivas M, Levine MM. *Escherichia coli* enterohemorrágica en el síndrome hemolítica urémico, en niños chilenos. *Rev Med Chile* 123:13-22, 1995.
- 329. Gómez-Duarte, OG, Galen J, Chatfield SN, Rappuoli R, Eidels L, Levine MM. Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in *Salmonella typhi* CVD 908 vaccine strain. *Vaccine* 13:1596-1602, 1995.
- 330. Cryz SJ Jr, Que JU, Levine MM, Wiedermann G, Kollaritsch H. Safety and immunogenicity of a live oral bivalent typhoid fever (*Salmonella typhi*-Ty21a) cholera (*Vibrio cholerae* CVD 103-HgR) vaccine in healthy adults. *Infect Immun* 63:1336-1339, 1995.
- 331. Tacket CO, Losonsky G, Nataro JP, Comstock L, Michalski J, Edelman R, Kaper JB, Levine MM). Initial clinical studies of CVD 112 *Vibrio cholerae* O139 live oral vaccine: safety and efficacy against experimental challenge. *J Infect Dis* 172: 883-886, 1995.
- 332. Fasano A, Noriega FR, Maneval DR Jr, Chanasongcram S, Russell R, Guandalini S, Levine MM. *Shigella* enterotoxin 1: an enterotoxin of *Shigella flexneri* 2a active in rabbit small intestine in vivo and in vitro. *J Clin Invest* 95:2853-2861, 1995.
- 333. Noriega FR, Liao FM, Formal SB, Fasano A, Levine MM. Prevalence of *Shigella* enterotoxin among *Shigella* clinical isolates of diverse serotypes. *J Infect Dis* 172: 1408-1410, 1995.
- 334. Nataro JP, Seriwatana J, Fasano A, Maneval DR, Guers LD, Noriega F, Dubovsky F, Levine MM, Morris JG Jr. Identification and cloning of a novel plasmid-encoded enterotoxin in enteroinvasive *Escherichia coli* and *Shigella*. *Infect Immun*, 63:4721-4728, 1995
- 335. Sztein MB, Tanner MK, Polotsky Y, Orenstein JM, Levine MM. Cytotoxic T lymphocytes after oral immunization with attenuated strains of *Salmonella typhi* in humans. *J Immunol* 155:3987-3993, 1995.
- 336. Levine MM, Galen J, Barry E, Noriega F, Chatfield S, Dougan G, Tacket C. Attenuated *Salmonella* as live oral vaccines against typhoid fever and as live vectors. *J Biotechnology* 44:193-196, 1995.

337. Kotloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC, Formal SB, Levine MM. A modified *Shigella* volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for *Shigella* infectivity. *Vaccine* 13:1488-1494, 1995.
338. Noriega FR, Losonsky G, Wang JY, Formal SB, Levine MM. Further characterization of Δ aroA, Δ virG *Shigella flexneri* 2a strain CVD 1203 as a mucosal *Shigella* vaccine and as a live vector for delivering antigens of enterotoxigenic *Escherichia coli*. *Infect Immun* 64:23-27, 1996.
339. Losonsky GA, Yunyongying J, Lim V, Reymann M, Lim YL, Wasserman SS, Levine MM. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. *Infect Immun* 64:10-15, 1996.
340. Acheson DWK, Levine MM, Kaper JB, Keusch GT. Protective immunity to Shiga-like toxin following oral immunization with Shiga-like toxin I B subunit-producing *Vibrio cholerae* CVD 103-HgR. *Infect Immun* 64:355-357, 1996.
341. Lagos R, Horwitz I, Toro J, San Martin O, Abrego P, Bustamante C, Wasserman SS, Levine OS, Levine MM. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive *Haemophilus influenzae* type b infections. *Pediatr Infect Dis* 15:216-222, 1996.
342. Levine MM, Kaper JB. Live oral cholera vaccine: from principle to product. *Bull Inst Pasteur* 93: 243-353, 1995.
343. Lagos R, Losonsky G, Abrego P, San Martin O, Prado V, Wasserman S, Levine MM. Tolerancia, inmunogenicidad, excreción y transmisión de la vacuna anti-colera oral viva-atenuada, CVD 103-HgR, estudio pareado de doble ciego en niños Chilenos de 24 a 59 meses. *Bol Hosp Infant Mex* 53:214-220, 1996.
344. Girón JA, Viboud GL, Sperando V, Gomez-Duarte O, Maneval D, Albert MJ, Levine MM, Kaper JB. Prevalence and association of the longus pilus structural gene (*IngA*) with colonization factor antigens, enterotoxin types, and serotypes of enterotoxigenic *Escherichia coli*. *Infect Immun* 63:4195-4198, 1995.
345. Kaper JB, Morris JG Jr, Levine MM. Cholera. *Clin Microbiol Rev* 8:48-86, 1995.
346. Noriega FR, Losonsky G, Lauderebaugh C, Liao FM, Wang JY, Levine MM. Engineered Δ guaB-A Δ virG *Shigella flexneri* 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. *Infect Immun* 64:3055-3061, 1996.
347. Prado V, Basualdo W, Arellano C, Martinez J, Levine MM. Susceptibilidad in vitro de *Escherichia coli* enterohemorrágicos frente 11 antimicrobianos. Relación entre resistencia antibiótica y genotipos toxigénicos. *Rev Méd Chile* 123:1085-1090, 1995.
348. Levine MM. The legacy of Edward Jenner. *Brit Med J* 312:1177-1178, 1996
349. Kotloff K, Noriega F, Losonsky G, Sztein MB, Nataro JP, Levine MM. Safety, immunogenicity and transmissibility in humans of CVD 1203, a live oral *Shigella flexneri* 2a vaccine candidate attenuated by deletions in *aroA* and *virG*. *Infect Immun* 64:4542-4548, 1996.
350. Barry EM, Gomez-Duarte O, Chatfield S, Rappuoli R, Losonsky GA, Galen JE, Levine MM. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in *Salmonella typhi* vaccine strain CVD 908. *Infect Immun* 64:4172-4181, 1996.
351. ILSI Risk Science Institute Pathogen Risk Assessment Working Group (Levine, MM, member of Working Group). A Conceptual Framework to Assess the Risks of Human Disease Following Exposure to Pathogens. *Risk Analysis* 16:6 841-848, 1996.

352. Levine O, Lagos R, Losonsky GA, San Martin O, Abrego P, Bustamante C, Wasserman SS, Levine MM. No adverse impact on the immune response to pertussis antigens or clinical protection against pertussis from co-administration of *Haemophilus influenzae* type b conjugate and diphtheria-tetanus-pertussis vaccines in the same syringe. *J Infect Dis* 174:1341-1344, 1996.
353. Levine MM, Prado V, Lior H, Lagos R. Epidemiologic studies of diarrhea associated with enteropathogenic *Escherchia coli* (EPEC) in infants and children in Santiago, Chile. *Rev Microbiol Sao Paulo* 27 (supplement 1):40-44, 1996.
354. Ojeda A, Marinkovic K, Prado V, Ferreccio C, Levine MM. Rendimiento comparativo de diferentes esquemas de trabajo para aislamiento de enteropatógenos en coprocultivo. *Rev Chil Infectol* 13:137-144, 1996.
355. Galen JE, Gomez-Duarte O, Losonsky GA, Halpern J, Lauderbaugh CS, Kaintuck S, Reymann M, Levine MM. A murine model of intranasal immunization to assess the immunogenicity of attenuated *Salmonella typhi* live vector vaccines in stimulating serum antibody responses to foreign antigens. *Vaccine* 15:700-708, 1997.
356. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R, Galen JE, Pickard D, Dougan G, Chatfield SN, Levine MM. Safety of live oral *Salmonella typhi* vaccine strains with deletions in *htrA* and *aroC aroD* and immune response in humans. *Infect Immun* 65:452-456, 1997.
357. Levine OS, Granoff D, Fritzell B, Levine MM. Factors associated with superior antibody response to a single dose of *Haemophilus influenzae* type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age. *Vaccine* 15:325-328, 1997.
358. Cookson ST, Stamboulion D, Demonte J, Quero L, Martinez de Arquiza C, Aleman A, Lepetic A, Levine MM. Repetitive seasonal cholera in Northern Argentina: a cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high risk population. *Int J Epidemiol* 26:212-219, 1997.
359. Fasano A, Noriega FR, Liao FM, Wang W, Levine MM. Effect of *Shigella* enterotoxin 1 (ShET1) on rabbit intestine *in vitro* and *in vivo*. *GUT* 40:505-511, 1997.
360. Losonsky GA, Lim Y, Motamedi P, Comstock L, Johnson JA, Tacket CO, Kaper JB, Levine MM. Vibriocidal antibody responses following *Vibrio cholerae* O139 wild-type and vaccine exposure in North American volunteers: specificity and relevance to immunity. *Clin Diag Lab Immunol* 4:264-269, 1997.
361. Levine MM, Galen J, Barry E, Noriega F, Tacket C, Sztein M, Chatfield S, Dougan G, Losonsky G, Kotloff K. Attenuated *Salmonella typhi* and *Shigella* as live oral vaccines and as live vectors. *Behring Inst Mitt* 98:120-123, 1997.
362. Tacket CO, KL, Losonsky G, Nataro JP, Michalski J, Kaper JB, Edelman R, Levine MM. Volunteer studies investigating the safety and efficacy of live oral El Tor *Vibrio cholerae* O1 vaccine strain CVD 111. *Am J Trop Med Hyg* 56:533-537, 1997.
363. Levine MM, Levine OS. Disease burden, public perception, and other factors that influence new vaccine development, implementation and continued use. *Lancet* 350:1386-1392, 1997.
364. Tacket CO, Kelly SM, Schödel F, Losonsky G, Nataro JP, Edelman R, Levine MM, Curtiss R III. Safety and immunogenicity in humans of an attenuated *Salmonella typhi* vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal system. *Infect Immun* 65:3381-3385, 1997.
365. Ivanoff B, Levine MM. Typhoid fever: Continuing challenges from a resilient bacterial foe. *Bull Inst Pasteur* 95:129-142, 1997.

366. Marks RS, Bassis E, Bychenko A, Levine MM. Chemiluminescent optical fiber immunosensor for detecting cholera antitoxin. *Optical Engineering* 36:1-7, 1997.
367. Prado V, Martinez J, Arellano C, Levine MM. Variación temporal de genotipos y serogrupos de *E. coli* enterohemorrágicos aislados en niños chilenos con infecciones intestinales o síndrome hemolítico-urémico. *Rev Méd Chile* 125: 291-297, 1997.
368. Donnenberg MS, Tacket CO, Losonsky G, Frankel G, Nataro JP, Dougan G, Levine MM. Effect of prior experimental human enteropathogenic *Escherichia coli* infection on illness following homologous and heterologous rechallenge. *Infect Immun* 66:52-58, 1998.
369. Perry RT, Plowe CV, Koumaré B, Kotloff KL, Losonsky GA, Wasserman SS, Levine MM. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and non-infected adults in Mali. *Bull Wild Hlth Org* 76:63-71, 1998.
370. Tacket CO, Taylor RK, Losonsky G, Lim Y, Nataro JP, Kaper JB, Levine MM. Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of *Vibrio cholerae* O139 infection. *Infect Immun* 66:692-695, 1998.
371. Pang T, Levine MM, Ivanoff B, Wain J, Finaly B.B. Typhoid fever -- important issues still remain. *Trends Microbiol* 6:131-133, 1998.
372. González CR, Noriega FR, Huerta S, Santiago A, Vega M, Paniagua J, Ortiz-Navarrete V, Isibasi A, Levine MM. Immunogenicity of a *Salmonella typhi* CVD 908 candidate vaccine strain expressing the major surface protein gp63 of *Leishmania mexicana mexicana*. *Vaccine* 16:9/10 1043-1052, 1998.
373. Lagos R, Valenzuela MT, Levine OS, Losonsky GA, Erazo A, Wasserman SS, Levine MM. Economisation of vaccination against *Haemophilus influenzae* type b: a randomised trial of the immunogenicity of fractional dose and two-dose regimens. *Lancet* 351:1472-76, 1998.
374. Levine MM, Lagos R, Levine OS, Heitmann I, Enriquez N, Pinto ME, Alvarez AM, Whu E, Mayorga C, Reyes A. Epidemiology of invasive pneumococcal infections in infants and young children in metropolitan Santiago, Chile, a newly industrializing country. *Pediatr Infect Dis J* 17:287-293, 1998.
375. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. *Nature Medicine* 4:607-609, 1998.
376. Lagos R, Levine OS, Avendaño A, Horwitz I, Levine MM. The introduction of routine *Haemophilus influenzae* type b conjugate vaccine in Chile: a framework for evaluating new vaccines in newly industrializing countries. *Pediatr Infect Dis J* 17:9 Supplement S139-S148, 1998.
377. Sack DA, Tacket CO, Cohen MB, Sack RB, Losonsky GA, Shimko J, Nataro JP, Edelman R, Levine MM, Giannella RA, Schiff G, Lang D. Validation of a volunteer model of cholera with frozen bacteria as the challenge. *Infect Immun* 66:1968-1972, 1998.
378. Levine MM, Dougan G. Optimism over vaccines administered via mucosal surfaces. *Lancet* 351:1375-1376, 1998.
379. Hoppenbrouwers K, Lagos R, Swennen B, Ethevenaux C, Knops J, Levine MM, Desmyter J. Safety and immunogenicity of an *Haemophilus influenzae* type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. *Vaccine* 16:921-927, 1998.
380. Lagos R, Kotloff K, Hoffenbach A, San martin O, Abrego P, ureta AM, Pines E, Blondeau C, Bailleux F, Levine MM. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing

diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and *Haemophilus influenzae* type b conjugate antigens in two-, four- and six-month old Chilean infants. J Pediatr Infect Dis 17:294-304, 1998.

381. Prado V, Pidal P, Arellano C, Lagos R, San Martin O, Levine MM. Multirresistencia antimicrobiana en cepas de *Shigella* sp en una comuna semi rural del área norte de Santiago. Rev Méd Chile 126:1464-1471, 1998.
382. Tang C, Moxon R, Levine MM. For discussion: live attenuated vaccines against meningococcus. Vaccine 17:114-117, 1999.
383. Rios M, Prado V, Arellano C, Borie M, Fica A, Levine MM. Clonal diversity of Chilean isolates of enterohemorrhagic *Escherichia coli* from patients with hemolytic-uremic syndrome, asymptomatic subjects, animal reservoirs, and food products. J Clin Microbiol 37:778-781, 1999.
384. Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, Abrego A, Lososny G, Alegria S, Levine MM. Effect of small bowel overgrowth on the "take" of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 180:1709-1712, 1999
385. Lagos R, San Martin O, Wasserman SS, Prado V, Lososny GA, Bustamante C, Levine MM. Palatability, reactogenicity and immunogenicity of engineered single-dose live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. Pediatr Infect Dis J 18:624-630, 1999.
386. Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM. Strategy for cross-protection among *Shigella flexneri* serotypes. Infect Immun 67:782-788, 1999.
387. Orr N, Galen JE, Levine MM. Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM₁₉₇, and its fragments in *Salmonella typhi* vaccine strain CVD 908-htrA. Infect Immun 67:4290-4294, 1999.
388. Prado V, Lagos R, Nataro JP, Martin OS, Arellano C, Wang JY, Borczyk AA, Levine MM. A population-based study of the incidence of *Shigella* diarrhea and causative serotypes in Colina, a semi-rural poor community in Santiago, Chile. Pediatr Infect Dis J 18:500-5, 1999.
389. Levine MM, Ferreccio C, Abrego P, San Martin O, Ortiz E, Cryz SC. Duration of efficacy of Ty21a, attenuated *Salmonella typhi* live oral vaccine. Vaccine 17:2 Supplement S22-S27, 1999.
390. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM. Global burden of *Shigella* infections: implications for vaccine development and implementation of control strategies. Bull WHO 77:651-666, 1999.
391. Levine OS, Lagos R, Muñoz A, Villaroel J, Alvarez AM, Abrego A, Levine MM. Defining the burden of pneumonia in children preventable by vaccination against *Haemophilus influenzae* type b. Pediatr Infect Dis J, 18:1060-1064, 1999.
392. Pasetti MF, Anderson RJ, Noriega FR, Levine MM, Sztein MB. Attenuated Δ guaBA *Salmonella typhi* vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin Immun 92:76-89, 1999.
393. Taylor DN, Sanchez JL, Castro JM, Lebron C, Parrado CM, Johnson DE, Tacket CO, Lososny GA, Wasserman SS, Levine MM, Cryz SJ. Expanded safety and immunogenicity of a bivalent, oral attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama. Infect Immun 67:2030-2034, 1999.
394. Tacket CO, Cohen MB, Wasserman SS, Lososny G, Livio S, Kotloff K, Edelman R, Kaper JB, Cryz SJ, Gianella RA, Schiff G, Levine MM. Randomized, double-blind, placebo-controlled multi-centered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with *Vibrio cholerae* O1 El Tor, Inaba three months after vaccination. Infect Immun 67:6341-6345, 1999.

395. Galen JE, Nair J, Wang JY, Tanner MK, Sztein MB, Levine MM. Optimization of plasmid maintenance in the attenuated live vector vaccine *Salmonella typhi* strain CVD 908-*htrA*. *Infect Immun* 67:6424-6433, 1999.
396. Peter G, des Vignes-Kendrick M, Eickhoff TC, Fine A, Galvin V, Levine MM, Maldonado YA, Marcuse EK, Monath TP, Osborn JE, Plotkin S, Poland GA, Quinlisk MP, Smith DR, Sokol M, Soland DB, Whitley-Williams PN, Williamson DE, Breiman RF. Lessons learned from a review of the development of selected vaccines. *National Vaccine Advisory Committee. Pediatrics* 104:942-50, 1999.
397. Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Levine MM. *Shigella flexneri* 2a strain CVD 1207 with specific deletions in *virG*, *sen*, *set* and *guaBA* is highly attenuated in humans. *Infect Immun* 68:1034-39, 2000.
398. Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, Nataro JP, Edelman R, Perry J, Bedford P, Brown D, Chatfield S, Dougan G, Levine MM. Phase 2 clinical trial of attenuated *Salmonella enterica* serovar Typhi oral live vector vaccine CVD 908-*htrA* in U.S. volunteers. *Infect Immun* 68:1196-1201, 2000.
399. Pickett TE, Pasetti MF, Galen JE, Sztein MB, Levine MM. *In vivo* characterization of the murine intranasal model for assessing the immunogenicity of attenuated *Salmonella typhi* as live mucosal vaccines and as live vectors. *Infect Immun* 68:205-213, 2000.
400. Anderson RJ, Pasetti MF, Sztein MB, Levine MM, Noriega FR. Δ *guaBA* attenuated *Shigella flexneri* 2a strain CVD 1204 as a *Shigella* vaccine and as a live mucosal delivery system for fragment C of tetanus toxin. *Vaccine* 18:2193-2202, 2000.
401. Richie E, Punjabi NH, Sidharta Y, Peetosutan K, Sukandar M, Wasserman SS, Lesmana M, Wangsasaputra F, Pandam S, Levine MM, O'Hanley P, Cryz SJ, Simanjuntak CH. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. *Vaccine* 18:2399-2410, 2000.
402. Tacket CO, Galen J, Sztein MB, Losonsky G, Wyant TL, Nataro J, Wasserman SS, Edelman R, Chatfield S, Dougan G, Levine MM. Safety and immune responses to attenuated *Salmonella enterica* serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C. *Clin Immunol* 97:146-153, 2000.
403. Tacket CO, Sztein MB, Losonsky G, Abe A, Finlay BB, McNamara BP, Fantry GT, James SP, Nataro JP, Levine MM, Sonnenberg MS. The role of EspB in experimental human Enteropathogenic *Escherichia coli* (EPEC) infection. *Infect Immun* 68:3689-3695, 2000.
404. Pasetti MF, Tanner MK, Pickett TE, Levine MM, Sztein M. Mechanisms and cellular events associated with the priming of mucosal and systemic immune responses to *Salmonella enterica* serovar Typhi live vector vaccines delivered intranasally in the murine model. *Vaccine* 18:3208-3213, 2000.
405. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. *J Infect Dis* 182:302-305, 2000.
406. Cooper PJ, Chico H ME, Losonsky G, Sandoval C, Espinel I, Sridhara R, Aguilar M, Guevara A, Guderian RH, Levine MM, Griffin GE, Nutman TB. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. *J Infect Dis* 182:1199-1206, 2000.
407. Wu S, Beier M, Sztein M, Galen JE, Pickett T, Holder AA, Gómez-Duarte O, Levine MM. Construction and immunogenicity in mice of attenuated *Salmonella typhi* expressing *Plasmodium falciparum* merozoite surface protein (MSP-1) fused to tetanus toxin fragment C. *J Biotechnol*. 83:125-135, 2000.
408. Wang JY, Noriega FR, Galen JE, Barry E, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated *Salmonella enterica* serovar Typhi oral vaccine strain CVD 909. *Infect Immun* 68:4647-4652, 2000.

408. Levine MM. Immunization against bacterial diseases of the intestine. *J Pediatr Gastroenterol Nutr* 31:366-355, 2000.
409. Koprowski H II, Levine MM, Anderson RA, Losonsky G, Pizza M, Barry EM. Attenuated *Shigella flexneri* 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic *Escherichia coli*. *Infect Immun* 68:4884-92, 2000.
410. Plaisance KI, Kudaravalli S, Wasserman SS, Levine MM, Mackowiak PA. Effect of antipyretic therapy on the duration of illness in experimental influenza A, *Shigella sonnei*, and *Rickettsia rickettsii* infections. *Pharmacotherapy*. 20:1417-22, 2000.
411. Gómez-Duarte O, Pasetti M, Santiago A, Sztein MB, Hoffman SL, Levine MM. Expression, secretion and immunogenicity of the *Plasmodium falciparum* SSP-2 protein in *Salmonella* vaccine strains by a type I secretion system. *Infect Immun* 69:1192-1198, 2001.
412. Orr N, Galen JE, Levine MM. Novel use of anaerobically induced promoter, *dmsA*, for controlled expression of Fragment C of tetanus toxin in live attenuated *Salmonella enterica* serovar Typhi strain CVD 908-*htrA*. *Vaccine* 19:1694-1700, 2001.
413. Altboum Z, Barry EM, Losonsky G, Galen JE, Levine MM. Attenuated *Shigella flexneri* 2a Δ *guaBA* strain CVD 1204 expressing ETEC CS2 and CS3 fimbriae as a live mucosal vaccine against *Shigella* and enterotoxigenic *Escherichia coli* infection. *Infect Immun* 69:3150-8, 2001.
414. Wang JY, Pasetti MF, Noriega FR, Anderson RS, Wasserman SS, Galen JE, Sztein MB, Levine MM. Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated Δ *guaBA* *Salmonella enterica* serovar Typhi strain CVD 915. *Infect Immun* 69:4734-4741, 2001.
415. Galen JE, Levine MM. Can a "flawless" live vector vaccine strain be engineered? *Trends Microbiol* 9:372-376, 2001.
416. Campbell JD, Levine MM. Vaccines against enteric bacterial pathogens. *Asian J Paediatric Practice* 5:19-37, 2001.
417. Levine MM, Tacket CO, Sztein MB. Host-*Salmonella* interaction: clinical trials. *Microbes Infect* 3:1271-79, 2001.
418. Levine MM, Campbell J and Kotloff K. Overview of vaccines and immunization. *Brit Medical Bulletin*, 62:1-13, 2002.
419. Stephens I, Levine MM. Management of typhoid fever in children. *Pediatr Infect Dis J*. 21:157-8, 2002.
420. Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL.. Phase I evaluation of delta virG *Shigella sonnei* live, attenuated, oral vaccine strain WRSS1 in healthy adults. *Infect Immun* 70:2016-21, 2002.
421. Kidgell C, Pickard D, Wain J, James K, Diem Nga LT, Diep TS, Levine MM, O'Gaora P, Prentice MB, Parkhill J, Day N, Farrar J, Dougan G. Characterisation and distribution of a cryptic *Salmonella typhi* plasmid pHCM2. *Plasmid*. 47:159-71, 2002.
422. Campbell JD, Lagos R, Levine MM, Losonsky GA. Standard and alternative regimens of *Haemophilus influenzae* type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants. *Pediatr Infect Dis J* 21:822-826, 2002.
423. Lagos R, Muñoz A, Valenzuela MT, Heitmann I, Levine MM. Population-based surveillance for hospitalized and ambulatory pediatric invasive pneumococcal disease in Santiago, Chile. *Pediatr Infect Dis J* 21:1115-1123, 2002.

- 424. Pasetti, M, Levine MM, Sztein MB. Animal models paving the way for clinical trials of attenuated *Salmonella enterica* serovar Typhi live oral vaccines and live vectors. *Vaccine*. 21:401-18, 2003.
- 425. Levine MM. Can needle-free administration of vaccines become the norm in global immunization? *Nature Med* 9:99-103, 2003.
- 426. Barry EM, Altboum Z, Losonsky G, Levine MM. Immune responses elicited against multiple enterotoxigenic *Escherichia coli* fimbriae and mutant LT expressed in attenuated *Shigella* vaccine strains. *Vaccine* 21:333-340, 2003.
- 427. Pasetti MF, Barry EM, Losonsky G, Singh M, Medina-Moreno, SM, Polo JM, Robinson H, Sztein MB, Levine MM. Attenuated *Salmonella enterica* serovar Typhi and *Shigella flexneri* 2A strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. *J Virol* 77:5209-5217, 2003.
- 428. Altboum Z, Levine MM, Galen JE, Barry EM. Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic *Escherichia coli* when it is expressed in a *Shigella* live-vector strain. *Infect Immun* 71:1352-1360, 2003.
- 429. Salerno-Goncalves R, Wyant TL, Pasetti MF, Fernandez-Vina M, Tacket CO, Levine MM, Sztein MB. Concomitant Induction of CD4(+) and CD8(+) T Cell Responses in Volunteers Immunized with *Salmonella enterica* Serovar Typhi Strain CVD 908-htrA. *J Immunol* 170:2734-2741, 2003.
- 430. Lagos R, Muñoz A, Dumas R, Pichon S, Zambrano B, Levine M, Vidor E. Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies. *Vaccine* 21:3730-3733, 2003.

CHAPTERS AND BOOKS

1. DuPont HL, Levine MM, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Oral Attenuated Vaccines in the Control of Shigellosis. International Conference of the Application of Vaccines Against Viral, Rickettsial, and Bacterial Diseases of Man, December 14-18, 1970. Pan American Health Organization/World Health Organization. Scientific Publication #226, Washington, D.C., pp. 364-367, 1971.
2. Levine MM, DuPont HL, Hornick RB, Gangarosa EJ, Formal SB, Snyder MJ, Libonati JP, Vacuna de Shigella dysenteriae-1 (Shiga) in "Symposium on Shiga Dysentery in Central America." Pan American Health Organization Scientific Publication #283, Washington, D.C., 1974.
3. Levine MM. Epidemiologic and Sereoepidemiologic Methods in Evaluation of the Endemicity of Typhoid Fever in Peru (Dissertation for D.T.P.H.) Copyright University of London, 1974.
4. Levine MM, Craig JP, Pierce NF, Waterman D, Caplan ES, Libonati JP. The Immune Response to Parenteral and Oral Cholera Toxoid in Volunteers. Proceedings of the 12th Joint Conference, U.S.-Japan Cooperative Medical Science Program Cholera Panel. Sapporo, Japan, October 6-8, 1976.
5. Levine MM. Bacillary Dysentery. In: Conn H (ed.), Current Diagnosis. Philadelphia: WB Saunders, Co., 1976.
6. Levine MM, Rennels MB, Bacillary Dysentery. In: Conn, H., (ed.), *Current Therapy*, 31st Ed. Philadelphia: W.B. Saunders and Co., 1979.
7. Levine MM. Immunity to Cholera as Evaluated in Volunteers. In Nobel Symposium on Cholera and Related Diarrhoeas, 43rd Stockholm, 1978. Cholera and Related Diarrhoeas: Molecular Aspects of a Global Health Problem. Editors O Ouchterlony and J Holmgren. S Karger, Basel, 1980.
8. Levine MM, Hornick RB. Immunology of Enteric Pathogens - Salmonella, Shigella and *E. coli*. In: Nahmias A, and O'Reilly R, (Eds.), Immunology of Human Infections, Volume 11. Plenum, New York: pp. 249-290, 1981.
9. Levine MM. Shigellosis. In: Top FH, Jr, and Wehrle PF, (Eds.), Communicable and Infectious Diseases, 9th Edition. St. Louis: Mosby Co., pp. 569-576, 1981.
10. Levine MM and Cisneros L. Typhoid Fever. In: Conn FH, (Ed.), Current Therapy. Philadelphia: W.B. Saunders Co., 1981
11. Clements ML, Levine MM, *Vibrio cholerae*, *Escherichia coli*, and Related Diarrheal Infections. In: Stanford JP, and Luby JP, (Eds.), The Science and Practice of Clinical Medicine. York: Grune and Stratton, pp.282-287, 1981
12. Levine MM. Adhesion of Enterotoxigenic *Escherichia coli* in Man and Animals. In: Taylor-Robinson D, (ed.), Adhesion and Pathogenicity. Ciba Symposium: pp.142-154, 1981.
13. Clements ML, Levine MM, Black RE, Treatment of Enteric Infections and Combinations. In: Hitchings GH, (ed.), Handbook of Experimental Pharmacology. Vol. on "Sulfonamides, Trimethoprim and Combinations." Springer-Verlag, New York: Chap. 17, pp.357-378, 1982.
14. Levine MM, Clements ML, Black RE, Hughes TP, Cleaves TF, Oral Rehydration with Simple Sugar/Salt Solutions as an Alternative in Rural Areas when Glucose/Electrolyte Solutions are Unavailable. In: Holme T, Holmgren J Eds., Acute Enteric Infections in Children: New Prospects for Treatment and Prevention. Elsevier, Amsterdam: pp.325-331, 1981.
15. Levine MM, Black RE, Clements ML, Nalin DR, Cisneros L, Finkelstein RA, Volunteer Studies in Development of Vaccines Against Cholera and Enterotoxigenic *Escherichia coli*: A Review. In: Holme T, Holmgren J, Eds., Acute

Enteric Infections in Children: New Prospects for Treatment and Prevention. Elsevier, Amsterdam: pp.443-459, 1981.

16. Levine MM. Myth and Reality in the Management of Diarrhea. In: Simpson TW, Strickland GT, Mercer MA, Eds., New Developments in Tropical Medicine II. National Council for International Health, Washington, D.C., 1983.
17. Levine MM. Cholera. In: Gellis SS, Kagan GM, Eds., Current Pediatric Therapy, 11th edition. Saunders, Philadelphia: pp. 609-611, 1984.
18. Levine MM. Vaccine Against *Escherichia coli* Infections. In: Germanier R, Ed., Bacterial Vaccines, Chapter 7. New York: Academic Press, pp. 187- 235, 1984.
19. Formal SB, Levine MM, Shigellosis. In: Germanier R, Ed., Bacterial Vaccines, Chapter 6. Orlando: Academic Press, pp. 167-186, 1984.
20. Levine MM, Black R, Clements ML, Pathogenesis of Enteric Infections Caused by *Vibrio*. In: Colwell R, Ed., Vibrios in the Environment, Chapter 7. New York: Academic Press, pp. 109-122, 1984.
21. Levine MM. Immunization Against Infectious Diarrhoeas. Chapter 12, In: Gracey M, Ed., Diarrhoeal Disease and Malnutrition: A Clinical Update. London: Churchill Livingstone, pp 183-200, 1985.
22. Kaper JB, Levine MM, Lockman HA, Baldini MM, Black RE, Clements ML, Morris JG, Development and Testing of Recombinant Live Oral Cholera Vaccine. Vaccines 85. Molecular and Chemical Basis of Resistance to Parasitic, Bacterial and Viral Diseases. Cold Spring Harbor Laboratories, pp. 107- 111, 1985.
23. Morris JG, Michalski J, Wright AC, Kaper JB, Kaviti JN, Kinoti S, Mohamed AJ, Turkish J, Mhalu FS, Levine MM, Molecular Epidemiology of Antibiotic- Resistant Cholera in East Africa. In: Advances in Research on Cholera and Related Diarrhea. Vol. 4, Tokyo: KTK Scientific Publishers, in press.
24. Levine MM, Kaper JB, Black RE, Clements ML, Morris JG, Landmarks on the Road Toward a Live Oral Attenuated Cholera Vaccine. In: Proceedings of the 20th U.S.-Japan Joint Conference on Cholera, 1984. Martinus-Nijhoff Publishers, in press.
25. Levine MM, Black RE, Clements ML, Young CR, Cheney CP, Schad P, Collins H, Boedeker EC, Prevention of Enterotoxigenic *Escherichia coli* Diarrheal Infection in Man by Vaccines that Stimulate Antiadhesion (Anti-Pili) Immunity. In: Boedeker EC (ed.), Attachment of Organisms to the Gut Mucosa. Boca Raton: CRC Press, pp. 223-244, 1984.
26. Levine MM, Black RE, Ferreccio C, Clements ML, Lanata C, Rooney J, Chilean Typhoid Committee, The Efficacy of Attenuated *Salmonella typhi* Oral Vaccine Strain Ty21a Evaluated in Controlled Field Trials. In: J Holmgren, A Lindberg, R Mollby, Proceedings of the Nobel Conference on Recent Advances in Vaccines and Drugs against Diarrhoeal Diseases, Stockholm, June 3-6, 1985. Student Literatur, Gothenberg, pp. 90-101, 1986.
27. Levine MM, Morris JG, Losonsky G, Boedeker E, Rowe B, Fimbriae (pili) Adhesins as Vaccines. In: Lark D, Normak S, Brent-Uhlin E, Eds., Protein-Carbohydrate Interactions in Biological Systems. London: Academic Press, pp. 143-145, 1986.
28. Levine MM, Black RE, Ferreccio C, Clements ML, Lanata C, Sears S, Morris JG, Cisneros L, Germanier R, Chilean Typhoid Commission, Interventions to Control Endemic Typhoid Fever: Field Studies in Santiago, Chile. In: Control and Eradication of Infectious Diseases. An International Symposium. PAHO Copublication Series No. 1, Pan American Health Organization, Washington, D.C., 1986, pp.37-53.
29. Levine MM, Kaper JB, Morris JG, Herrington D, Losonsky G, Tall B, Hall R, Reactogenicity, Colonizing Capacity, and Immunogenicity of Further Attenuated, Genetically-Engineered *Vibrio cholerae* 01 Vaccine Strains. In: Proceedings of the 21st U.S.-Japan Joint Conference on Cholera, 1985. Martinus-Nijhoff Publishers, in press.

30. Levine MM, Tramont EC, Vaccines Against Enteric Infections. In: Branski D, Pinari G, Rozen P, Walker-Smith J, Eds., Pediatric Gastroenterology: Aspects of Immunology and Infections. Karger, Basel, pp. 355-369, 1986.
31. Holmgren J, Svennerholm A-M, Clemens J, Sack D, Black R, Levine M. An Oral B Subunit-Whole Cell Vaccine Against Cholera: From Concept to Successful Field Trial. In: Mesleky J., ed. Proceedings of the International Congress on Mucosal Immunology, Niagara Falls, 1986.
32. Levine MM, Black RE, Ferreccio C, Clements ML, Lanata C, Rooney J, Field Trials of Efficacy of Attenuated *Salmonella typhi* Oral Vaccine Strain Ty21a. In: Robbins JB, Ed., Proceedings of International Symposium on Bacterial Vaccines, Bethesda, 1984. New York, Praeger Press, pp. 79-89, 1987.
33. Levine MM. Typhoid Fever Vaccines. In: Vaccines. Plotkin SA, Mortimer A, Jr., eds. Philadelphia, W.B. Saunders Company, pp. 333-361, 1988.
34. Kapikan AZ, Flores J, Hoshino Y, Midthun D, Green KY, Gorziglia M, Chanock RM, Potash L, Perez-Schael I, Gonzalez M, Vesikari T, Gothefors L, Wadell G, Glass RI, Levine MM, Rennels MB, Losonsky GA, Christy C, Dolin R, Anderson EL, Belshe RB, Wright PF, Santosham M, Halsey NA, Clements ML, Sears SD, Steinhoff MC, Black RE. Rationale for the development of rotavirus vaccine for infants and young children. In: Talwar, ed. Progress in Vaccinology. Springer-Verlag, 1989:150-180.
35. Levine MM. Development of vaccines against bacteria. In: Enteric Infection. Farthing MJG, Keusch GT, eds. Chapman and Hall, London 1989, pp. 495-508.
36. Levine MM. Vaccines and Vaccination in the Historical Perspective. In: New Generation Vaccines: The Molecular Approach. Woodrow GC, Levine MM, eds. New York, Marcel Dekker, Inc. 1990, pp 3-19.
37. Levine MM, Hone D, Stocker B, Cadoz M. New and Improved Vaccines to Prevent Typhoid Fever. In: New Generation Vaccines: The Molecular Approach. Woodrow GC, Levine MM, eds. New York, Marcel Dekker, Inc., 1990, pp 269-288.
38. Levine MM. Vaccines against enterotoxigenic *Escherichia coli* infections. Vaccines based predominantly on antibacterial immunity. In: The Molecular Approach. Woodrow GC, Levine MM, eds. New York, Marcel Dekker, Inc., 1990, pp 649-660.
39. Levine MM. Typhoid fever and enteric fever. In: Current therapy in infectious diseases 3. Kass E, Platt R, eds. BC Decker, Inc, Philadelphia, 1990, pp. 143-145.
40. Levine MM, Edelman R. Future vaccines against enteric pathogens. In: Immunization of Adults I: Infectious Disease Clinics of North America. Schaffner W, ed. Saunders Co, Philadelphia, 1990, pp. 105-1217.
41. Levine MM. Vaccines against enteric infections. In: Diarrheal Diseases, Field M, ed. Elsevier, New York, 1991, Chapter 20, pp 455-484.
42. Kaper JB, Levine MM. Cholera. In: Vaccines and Immunotherapy. Cryz SJ, ed. Pergamon Press, Inc., New York, 1991, Chapter 6, pp. 73-85.
43. Levine MM. Typhoid fever. In: Vaccines and Immunotherapy. Cryz SJ, ed. Pergamon Press, Inc., New York, 1991, Chapter 5, pp. 59-73.
44. Levine MM. Shigellosis. In: Hunter's Tropical Medicine, 7th ed., Strickland GT, ed., W.B. Saunders, Philadelphia, 1991, Chapter 37, pp.340-344.
45. Levine MM. Diarrhea caused by *Escherichia coli*. In: Hunter's Tropical Medicine, 7th ed., Strickland GT, ed., W.B. Saunders, Philadelphia, 1991, Chapter 41.1, pp. 377-381.

46. Savarino S, Levine MM. Specific and non-specific treatment of diarrhea. In: Infectious Diseases. Gorbach SL, Bartlett JG, Blacklow NR, eds. WB Saunders, Philadelphia, 1992, Chapter 86, pp 638-646.
47. Levine MM, Pierce NF. Immunity and vaccine development. In: Greenough WB III & Barua D, eds. Cholera. Plenum Press, New York, 1992, Chapter 14, pp. 285-327.
48. Levine MM, Noriega F. Vaccines to prevent enteric infections. Bailliere's Clinical Gastroenterology 7:501-17, 1993.
49. Levine MM, Hone DM, Tacket CO, Sztein MB, Losonsky GA, Nataro JP, Gonzalez C, Dougan G, Chatfield S, Cryz S, Curtiss R, Kelley S. Attenuated *Salmonella typhi* as live oral vaccines to prevent typhoid fever and as carrier vaccines to express foreign antigens. In: Cabello F, Hormaeche C, Mastroeni P, Bonina L, eds. Biology of *Salmonella*, Plenum Press, New York, 1993, p. 343.
50. Levine MM, K. Shigellosis. In: Current Pediatric Therapy, 14th edition, Burg FD, Ingelfinger JR, Wald ER, eds., W.B. Saunders Co., Philadelphia, pp.574-575, 1993.
51. Levine MM. Typhoid fever. In: Current Pediatric Therapy, 14th edition, Burg FD, Ingelfinger JR, Wald ER, eds., W.B. Saunders Co., Philadelphia, pp.575-576, 1993.
52. Nataro JP, Levine MM. *Escherichia coli* infections of humans. In: Gyles C, ed. *Escherichia coli* in Animals. CAB International, Wallingford. Chapter 13, pp. 285-335, 1994.
53. Hone DM, Tacket CO, Levine MM, Hasday J, Harris AM. Induction of tumor necrosis factor secretion from U937 macrophage-like cells after infection with *Salmonella typhi*. Vaccines 93, in press.
54. Levine MM, Giron J, Noriega F. Fimbrial vaccines. In: Fimbriae: Adhesion, Biogenics, Genetics and Vaccines. Klemm P, ed., CRC Press, Boca Raton, Chapter 18, pp.255-276, 1994.
55. Levine MM, Tacket CO. Recombinant live cholera vaccines. in: *Vibrio cholerae* and Cholera. Wachsmuth IK, Blake P, Olsvik S, eds. Am Soc Microbiol, Washington, D.C., Chapter 26, pp.395-413, 1994.
56. Levine MM. Typhoid Fever Vaccines. In: Vaccines. Plotkin SA, Mortimer A, Jr., eds. Philadelphia, W.B. Saunders Company, Chapter 21, pp. 597-633, 1994.
57. Levine MM, Nataro JP. Intestinal infections. In: Mucosal Immunology, Vol.2 Mucosal Diseases. Ogra P, Mestecky J, Lamm M, Strober W, Bienenstock J, McGhee JR, eds.. Academic Press, San Diego, Chapter 41, pp 505-512, 1994.
58. Levine MM, Savarino S. The treatment of acute diarrhea. Chapter 21. In: Owen R, Surawicz C, eds., W.B. Saunders, Philadelphia, pp 519-536, 1995.
59. Fouts TR, Tacket CO, Levine MM, Lewis GK, Hone DM. Expression of human immunodeficiency virus envelope protein, recombinant gp120, in an attenuated *salmonella typhi* vector vaccine. Chapter 44. In: Recombinant and synthetic vaccines. Talwar GP, Rao KVS, Chauhan VS, eds. Narosa Publishing House, New Delhi, pp. 352-356, 1994.
60. Levine MM. Development of bacterial vaccines. In: Infections of the gastrointestinal tract. Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL, eds. Raven Press, New York, 1995, pp 1441-1470.
61. Levine MM, Tacket CO. Live oral vaccines against cholera. In: Ala'Aldeen D, Hormaeche C, eds. Molecular and clinical aspects of bacterial vaccine development. John Wiley & Sons, Chichester, 1995, pp. 233-258.
62. Levine, MM. Vaccines against typhoid fever. In: Ala'Aldeen D, Hormaeche C, eds. Molecular and clinical aspects of bacterial vaccine development. John Wiley & Sons, Chichester, 1995, pp.155-178.

63. Levine MM, Levine OS. Changes in human ecology and behaviour in relation to the emergence of diarrheal diseases, including cholera. In: Infectious diseases in an age of change. Roizman B, ed. National Academy Press, Washington, D.C., 1995, pp. 31-42.
64. Levine MM. Non-target effects of live vaccines: myth, reality and demagoguery. In: Non-target effects of live vaccines. Developments in Biological Standardization vol. 84;33-38, 1995, Karger, Basel.
65. Levine MM, Kaper JB. Cholera: pathogenesis and vaccine development. In: Drasar B, Forrest B, eds., Cholera and the Ecology of Cholera. Chapman and Hall, 1996. Chapter 5, pp. 125-186.
66. Levine MM, Noriega F. Vaccines against diarrheal disease, dysentery and enteric fever. In: Gracey M and Walker-Smith JA, Diarrheal Disease. Nestlé Nutrition Workshop Series volume 38, Lippincott-Raven, Philadelphia, 1997, pp. 139-151
67. Kotloff KK, Levine MM. *Shigella* infections. In: LaMont JT, ed., Gastrointestinal Infections. Diagnosis and Management. Chapter 9, Marcel Dekker, New York, 1997, pp. 265-291.
68. Mintz ED, Tauxe RV, Levine MM. The global resurgence of cholera, Chapter 3, in: Communicable Disease: Epidemiology and Control. Noah N and O'Mahony M, eds., John Wiley & Sons, Chichester, 1998, pp.63-104.
69. Savarino S, Levine MM. Specific and non-specific treatment of diarrhea. In: Infectious Diseases. Gorbach SL, Bartlett JG, Blacklow NR, eds. WB Saunders, Philadelphia, 1998, Chapter 83, pp 781-788.
70. Levine MM. Typhoid Fever Vaccines. In: Vaccines. Plotkin SA, Orenstein W, eds. Philadelphia, W.B. Saunders Company, 1999, Chapter 33, pp 781-814.
71. Levine MM. Immunoprophylaxis of Shiga toxin-producing *Escherichia coli* infection and disease: strengths and weaknesses of various strategies. In: *Escherichia coli* O157:H7 and other Shiga toxin-producing *E. coli* strains. Kaper JB and O'Brien AD, eds. ASM Press, Washington, DC, 1998, Chapter 40, pp.405-408.
72. Levine MM. Typhoid Fever. In: Bacterial infections of humans: epidemiology and control, Evans AS, Brachman PS, eds. Plenum Medical, New York, 1998. Chapter 42, pp 839-858.
73. Levine MM and Vial P. Typhoid Fever. In: Current Pediatric Therapy, 16th edition, Burg FD, Ingelfinger JR, Wald ER, Polin RA, eds., W.B. Saunders Co., Philadelphia, pp. 100-101, 1998.
74. Nataro JP and Levine MM. Enteric bacterial vaccines: *Salmonella*, *Shigella*, cholera, *Escherichia coli*. In: Mucosal Immunology, 2nd ed. Ogra P, Mestecky J, Lamm M, Strober W, Bienenstock J, McGhee JR, eds.. Academic Press, San Diego, Chapter 53, pp 851-866, 1999.
75. Levine MM, Barry E, Nataro JP, Kaper JB. The molecular epidemiology of 19th century cholera. In: Digging for Pathogens. Ancient Emerging Diseases B Their Evolutionary, Anthropological and Archaeological Context. Greenblatt C, ed. Balaban Publishers, Rehovot, Chapter 13, pp 265-276, 1998.
76. Levine MM. Shigellosis. In: Hunter's Tropical Medicine, 8th ed., Strickland GT, ed., W.B. Saunders, Philadelphia, 1999, Chapter 40, pp. 319-323.
77. Levine MM. Diarrhea caused by *Escherichia coli*. In: Hunter's Tropical Medicine, 8th ed., Strickland GT, ed., W.B. Saunders, Philadelphia, 1999, Chapter 42, pp. 334-338.
78. Levine MM, Gotuzzo E. Cholera. In: Tropical Infectious Diseases. Principles, Pathogens and Practice. Guerrant RL, Walker DH, Weller PF, eds. Churchill Livingstone, Philadelphia, 1999. Volume I, Chapter 26, pp. 326-335.

79. Levine MM, Sztein MB. *Shigella*, *Salmonella typhi*, *Escherichia coli*. In: Effects of Microbes of the Immune System. Cunningham MW, Fujinami RS, eds. Lippincott-Raven Publishers, Philadelphia. Chapter 12, 2000, pp. 171-194.
80. Levine MM, Galen JE, Barry E, Tacket CO, Kotloff K, Gomez-Duarte O, Pasetti MF, Sztein MB. Live vectors: have they delivered? In "Fighting Infection". Blackwell Science, London, 2000, pp. 72-86.
81. Levine MM, Levine OS. Disease burden, public perception and other factors that influence new vaccine development, implementation and continued use. In: Progress in Vaccinology. Richard Moxon, ed., Euromed Communications, Ltd., Surrey, UK, 2000, Chapter 3, pp. 27-45.
82. Levine MM, Svennerholm AM. Enteric Vaccines: Present and Future. In: The Textbook of Travel Medicine and Health, 2nd ed. DuPont HL, Steffen R., eds. B.C. Decker, Inc., Hamilton, Ontario, 2001. Chapter 22.3, pp. 252-263.
83. Levine MM, Gotuzzo E. Cholera. In: Essentials of Tropical Infectious Diseases. Guerrant RL, Walker DH, Weller PF, eds. Churchill Livingstone, Philadelphia, Pennsylvania, 2001. Chapter 19, pp. 163-167.
84. Levine MM. Bacterial Enteric Vaccines. In: Infections of the gastrointestinal Tract, 2nd ed. Blaser MB, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL. Eds. Lippincott, Williams & Wilkins, Philadelphia 2002. Chapter 80, pp. 1251-1271.
85. Levine MM, Galen JE, Barry E, Pasetti MF, Tacket, CO, Sztein MB. Attenuated *Salmonella* and *Shigella* Live Vectors. In: Vaccine Delivery Strategies. Dietrich G, Goebel W eds. Horizon Scientific Press, Norfolk, UK 2002. Chapter 8, pp 185-210.
86. Levine MM, Donnenberg MS. *Escherichia coli* vaccines. In: New Bacterial Vaccines. Ellis RW, Brodeur BR eds. Landes Bioscience, Georgetown, Texas 2003. Chapter 8. In press.
87. Levine MM, Lagos R. Vaccines and vaccination in the historical perspective. In: New Generation Vaccines, 3rd edition. Levine MM, Kaper JB, Rappuoli R, Liu MA & Good MF, eds. Marcel Dekker, New York, 2004, Chapter 1, in press.
88. Levine MM, Campbell JD. Mucosal immunization and needle-free injection devices. In: New Generation Vaccines, 3rd edition. Levine MM, Kaper JB, Rappuoli R, Liu MA & Good MF, eds. Marcel Dekker, New York, 2004, Chapter 33, in press.
89. Levine MM, Galen JE, Tacket CO, Barry E, Pasetti M, Sztein MB. Attenuated strains of *Salmonella enterica* serovar Typhi as live oral vaccines against typhoid fever. . In: New Generation Vaccines, 3rd edition. Levine MM, Kaper JB, Rappuoli R, Liu MA & Good MF, eds. Marcel Dekker, New York, 2004, Chapter 41, in press.
90. Barry E, Levine MM. Multivalent *Shigella*/enterotoxigenic *Escherichia coli* vaccine. In: New Generation Vaccines, 3rd edition. Levine MM, Kaper JB, Rappuoli R, Liu MA & Good MF, eds. Marcel Dekker, New York, 2004, Chapter 61, in press.